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iAbstract
Glut4 is the principal glucose transporter expressed in the peripheral tissues. In response 
to insulin, Glut4 moves from an intracellular compartment to the plasma membrane in a 
process called translocation. Once at the cell surface, Glut4 transports glucose across the 
plasma membrane into the cell and thus regulates whole body glucose homeostasis. At 
the molecular level we tagged Glut4 with Green Fluorescent Protein (GFP) in order to 
glean further insight into the translocation process. The native fluorescence of GFP then 
allowed us to analyse the trafficking of GFP-tagged Glut4 chimeras in real time using 
confocal microscopy. Glut4-GFP expressed in 3T3-L1 fibroblasts or fully differentiated 
adipocytes, displayed an intracellular distribution that only partially overlapped with the 
early endosomal compartment. However, Glut4-GFP constructs that carried mutations 
in N- and C- terminus targeting motifs were localised to the plasma mebrane. Time 
lapse confocal analysis revealed the dynamic nature of GlutT-GFP-containing vesicles 
in the basal state. When Glut4-GFP-expressing adipocytes were treated with insulin, 
Glut4-GFP translocated to the plasma membrane. Translocation was rapid, analogous to 
endogenous Glut4 translocation in 3T3-L1 adipocytes. However, upon insulin removal, 
Glut4-GFP failed to reinternalise. We suggest that this failure to reinternalise, while 
recycling noimally in the basal state, reflects a Glut4~specific reintemalisation 
mechanism following insulin-stimulated translocation. Glut4-GFP exhibited a similar 
intracellular distribution when expressed in L6 muscle cells. Nitric oxide (NO) donors 
stimulate glucose uptake into L6 muscle cells. Using inhibitors of the nitric-oxide 
signalling pathway and Glut4-GFP we investigated the mechanism by which NO-donors 
increase glucose transport into L6 cells. Recent research has also implicated ADP- 
Ribosylation Factors (ARFs) in insulin-stimulated Glut4 trasnlcoation. ARFs are small 
molecular weight GTPases. By site-directed mutagenesis we endeavoured to change the 
specificity of the ARF5 and ARF6 isofonns from GTP to XTP. These mutations would 
allow us to control ARF5/6 frmction in stable 3T3-L1 cell lines. Our goal is then to 
analyse the contribution of ARF5 and ARF6 to insulin stimulated Glut4-GFP 
translocation.
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Chapter 1
1,0.0 Introduction
3
1.1.0 Physiological background
Energy balance is of critical importance to all organisms. Ingested food in the fonn of 
.carbohydrate, protein or fat is broken down into a usable form for metabolism or is
stored for future use. Clearly any imbalance in the organism’s ability to control its :
energy reserves would be detrimental to survival. Therefore sophisticated methods have 
evolved to fine tune the availability of energy-bearing molecules within the 
bloodstream.
Carbohydrate forms the bulk of the human diet. Enzymes in the gastro-intestinal 
tract, amylase and maltase, break down ingested carbohydrate into their constitutive 
monosaccharides; glucose, fructose and galactose [1]. These sugars are then transported 
by a distinct class of proteins from the gastro-intestinal tract into the bloodstream. The 
principal sugar used by multi-cellular organisms to caiTy chemical energy throughout 
the body is glucose. Other sugars are metabolised through the glucose pathways. Once 
glucose is available in the bloodstream the initial step of glucose metabolism is the 
transport of the liexose across the cell membrane down a normally large concentration 
gradient from the extracellular fluid into the cell cytoplasm. This process is called 
facilitated diffusion and is carried out by a family of at least five glucose transport
'proteins. However, this apparently straight-forward mechanism must fulfill a range of 
criteria to achieve effective glucose homeostasis.
Basal plasma glucose levels must be held steady at an average concentration of
4.5 mM, typically with a range of 3.4 to 6.5 mM [2]. The brain has an absolute 
requirement for glucose. If glucose concentrations fall much below these values, central 
nervous system fimction is impaired and death may ensue. However, the pool of 
circulating blood glucose is only sufficient to maintain brain oxidation for three hours, 
even if all other glucose use ceased [2]. Therefore, in the fasting state the body requires 
its glucose homestatic mechanisms to mobilise glucose stored as glycogen principally in 
the liver and skeletal muscle. The whole body control of blood glucose levels is 
facilitated by coordinated secretion of the pancreatic island hormones insulin and 
glucagon.
a
I
ïTogether, insulin and glucagon play a crucial role in the control of metabolic processes. Secretion of glucagon is coordinated to control the availability of metabolic 
substrate molecules; free fatty acids, amino acids, glucose, when required for exercise. 
The dominant effect of glucagon is in the liver. Glucagon binds to its cognate receptor 
in the plasma membrane of hepatic cells and signal transduction is via a stimulatory G- 
protein, adenyl cyclase and cAMP as a second messenger. cAMP-activated protein 
kinase A initiates a cascade of phosphorylations that activates glycogenolysis to release 
glucose into the bloodstream from glycogen stores. Furthermore, glucagon also 
activates gluconeogenesis to stimulate glucose synthesis by the hepatic extraction of 
amino acids [31.
Conversely, insulin coordinates the storage of post-prandial nutrients for future 
metabolic requirements and in almost all respects the actions of insulin are exactly 
opposite to those of glucagon [3]. However, insulin does not only antagonise the action 
of glucagon by promoting glycogen synthesis and inhibiting gluconeogenesis. Insulin 
also has an effect on glucose disposal into the peripheral tissues, adipose tissue and 
skeletal muscle. Furthennore, in the long term insulin acts as a growth factor and 
anabolic agent.
Historically, insulin has long been a biomolecule of interest to research 
scientists. Insulin was the first honnone isolated from an animal source in a pure enough 
fonn to be administered therapeutically, the first protein to be sequenced at the amino 
acid level and the first protein to have its three dimensional structure solved. It was also 
the first peptide honnone for which a mechanism of action at the cell membrane was 
demonstrated and the first protein measured by radioimmunoassay [3]. Finally, and 
perhaps most importantly, insulin was the first peptide hormone whose biosynthesis was 
achieved by recombinant DNA technology [4]. The precise mechanism by which insulin 
exerts its effects on target tissues is currently the area of intense research area around 
the world by both academic and phaimaceutical laboratories.
There is already a wealth of literatur e that describes the known actions of insulin 
in the context of glucose homeostasis [5-7]. The insulin-secreting p cells of the pancreas 
have their own glucose sensing mechanism that controls the secretion of insulin into the 
bloodstream. In simple terms, glucose is transported into tire islet cell by facilitative 
diffusion whereupon glucose is phosphorylated by glucokinase to form glucose-6- 
phosphate. Metabolism of glucose-6-phosphate raises ATP and NAD(P)H levels that in
turn cause potassium channels to close and calcium channels to open. The influx of 
calcium into the cell then triggers the exocytosis of insulin granules [8], Once released 
into the circulation, insulin travels to its target tissues.
1.2.0 The Glut family o f glucose transporters
As already mentioned, insulin has a profound effect on glucose utilisation by the 
peripheral tissues as well as the liver. The principal means by which insulin lowers 
blood glucose is by stimulating glucose uptake into muscle and fat tissue. It has been 
established that there are at least 5 distinct glucose transporter isoforms representing a 
family of facilitative glucose transporters expressed by distinct genes. The members of 
the glucose transporter family, termed the Gluts, have unique patterns of tissue 
distribution and substrate binding properties (Table 1) that define their role in whole 
body glucose homeostasis. Glutl (the erythrocyte-type glucose transporter) was the first 
glucose transporter to be purified [9]. The isolation of this protein from red blood cell 
membranes enabled the study of its kinetic parameters and the generation of antibody 
probes [10-13]. These antibodies together with the partial amino acid sequence of the 
transporter allowed for the cloning of Glutl cDNA [14, 15].
The cloning of the Glutl cDNA was the breaktlirough that allowed the 
identification of the other members of the Glut family. Using low stringency Glutl 
cDNA probes Thorens et al. were able to isolate Glut2 cDNA from a hepatocyte library 
[16]. Expression of this transporter isofonn in Xenopus oocytes allowed further studies 
of its kinetic properties [17]. Gould et a i showed that Glut2 exhibited a 
supraphysiologicai for glucose, an observation that fits well with Glut2’s 
physiological requirement to transport glucose out of the hepatocyte following 
gluconeogenesis.
In an attempt to clone a novel glucose transporter cDNA from skeletal muscle, 
Kayano et a l screened a human foetal muscle library using the low-stringency 
hybridisation approach [18]. A unique transporter was successfully cloned and called 
Gluts. However, Northern blot analysis revealed that barely any GlutS mRNA was 
detectable in adult skeletal muscle. Instead, Glut3 was very highly expressed in the 
brain and nerve tissues. Colville at al expressed GlutS in Xenopus oocytes and found 
that Gluts has a much lower Km for glucose than either Glutl or Glut2. These properties 
of Gluts suggest that the brain is able to transport glucose across its plasma membrane
under hypoglycaemic conditions when blood glucose is at a relatively low value and 
thereby satisfying the brain’s high demand for glucose [19].
Following the successes of cloning Glut2 and GlutS using the low-stringency 
hybridisation approach, it was hoped that another novel glucose transporter may account 
for the unique insulin-regulatable transport activity observed in muscle and adipose 
tissues. The cDNA sequence of Glut4 was soon forthcoming [20-24] and this new 
isofonn was found to be expressed in the muscle, adipose and heart [25]. Insulin 
stimulation of rat adipose tissue results in an approximate 20-30 fold increase in glucose 
transport [26]. Furthermore, kinetic analysis reveals that an elevation in the Vmaxfor the 
glucose transport rate is responsible for this increase [27] with no significant effect on 
the substrate affinity constant K^. The now widely accepted model by which insulin 
elicits this effect on glucose tiansport is by increasing the number of Glut4 molecules at 
the plasma membrane [28, 29]. Unlike the other glucose transporter isoforms, Glut4 has 
an intracellular distribution. However, upon insulin binding to its cognate receptor on 
the plasma membrane, a signalling cascade is triggered within the cell that results in the 
movement of Glut4 from its basal intracellular location to the plasma membrane, in 
process called Translocation’ [30]. Glut4 displays a relatively low Km value for glucose 
and therefore once recruited to the plasma membrane works near its maximal rate to 
transport blood glucose into the peripheral tissues [27]. Subsequent to blood glucose 
normalisation and insulin withdrawl, Glut4 is reinteraalised [31-33].
Hexose transport in the small intestine is evidently a prerequisite to glucose 
availability in the bloodstream. The transport of glucose from the lumen of the gastro­
intestinal tract into the epithelial cells is mediated predominantly by the unrelated NaK 
dependent glucose transporter [34]. However, another facilitative glucose transporter, 
Gluts was cloned from human small intestine [18]. This apparent anomaly in the normal 
boundary separating glucose transporter expression between the small intestine and the 
other tissues was explained when Burant et al demonstrated that Glut5 is in fact a 
dedicated fructose transporter [35]. Northern blot analysis has since revealed that GlutS 
is expressed in a range of tissue, including muscle, adipose and brain [36]. This 
observation suggests that GlutS serves to transport dietary fructose across the 
gastrointestinal tract epithelium and furthennore allows peripheral tissues to metabolise 
blood fructose.
:.... .
An outline of the Glut family tissue distribution and kinetic properties is shown 
in the table below [37].
Isoform Tissues Kra (mM) for the non-metabolisabie 
glucose analogue 2-deoxyglucose
Glutl Placenta; brain; blood-tissue barrier; adipose and muscle tissue 
(low levels); tissue culture cells; Uansfromed cells
6.9±L5
Glul2 Liver; pancreatic p-cell; kidney proximal tubule 11.2+1.1
Gluts Brain and nerve cells 1.4+0.06
Glut4 Muscle, heart and adipose tissue 4.6±0,3
Gluts Small intestine; brain, muscle and adipose tissue at low levels Not Applicable
Table 1 Tissue distribution o f the Glut isoforms
1.2.1 Glucose transporter structure
Based on their amino acid sequence, all members of the Glut family are predicted to 
contain twelve membrane spanning amphiphatic helical domains (figure 1.0) [37]. The 
glucose transporter essentially consists of two ‘‘halves”, encompassing helices 1-6 and 
7-12, a conformation that may have evolved following an ancestral gene duplication 
event [38]. The two halves are linked by a large intracellular loop. Another large loop is 
present on the extracellular domain of the transporter between helices 1 and 2 and 
contains an N-linked glycosylation site. Both the N~ and C- terminals of the Gluts are 
positioned on the cytoplasmic side of the membrane. The intracellular location of the N- 
and C- termini has been confirmed using antibodies raised against the extreme ends of 
the Glutl that react only when the inner surface of the plasma membrane is exposed 
[39]. The question of which areas or specific amino acids endow particular glucose 
transporters with their unique properties has been addressed in a number of studies. 
Injection of glucose transporter mRNA into Xenopus oocytes and subsequent kinetic 
analysis has revealed the importance of a conserved QLS motif in transmembrane helix 
7 for substrate specificity [40]. A similar study identified an asparagine residue in helix 
VIII of Gluts important for the efficient transport of glucose [41]
Figure 1.1 Hypothetical model for the structure of the glucose transporters
The protein is predicted to contain 12 transmembrane helices (1-12), with both the N- and C-termini 
intracellularly disposed. N-linked glycosylation can occur in the extracellular loop between helices 1 and 
2 as shown. Conserved amino acids are indicated by the appropriate single-letter code; filled circles 
indicate conservative substitutions. Note that not all conserved amino acids are shown. (Figure taken with 
permission from Review Gould, G. W , and Holman, G. D. 1993).
Ligand binding and labeling studies suggest that the glucose transporters have separate 
internal and external substrate binding sites. For example the photolabel ATB-BMPA is 
specific for the exofacial site [42] whereas cytochalasin B is specific for the internal 
binding site [43]. These observations suggest that the glucose transporter is capable of a 
conformational change in order to transfer a glucose molecule across the membrane. 
Indeed, a C- terminal truncation of Glutl when expressed in Chinese Hamster Ovary 
(CHO) cells locks the transporter into an inward-facing form without transport activity 
[44]. Similarly, substitution of tyrosine 293 locks Glutl into an outward-facing
conformation when analysed in CHO cells, as indicated by a reduction in cytochalasin B 
affinity [45]. These studies emphasise the importance of understanding glucose 
transporters as dynamic molecules rather than merely simple pores to allow the passage 
of glucose. As with other membrane proteins, this area of Glut research is hampered by 
the absence of any 3D crystal. Nevertheless, the detailed and careful studies described
shed much light on the nature of facillatative glucose transport.
1.3.0 Signalling pathways leading to glucose uptake I1.3.1 Insulin signalling
As mentioned previously, insulin stimulates fat and muscle cells to increase their rate of 
glucose transport principally by recruiting Glut4 to the plasma membrane. Therefore, 
some mechanism must carry the signal from the insulin receptor to the intracellular 
Glut4 compartment. The insulin receptor itself is a tetrameric protein composed of two 
a-subunits and two ft-subunits [46, 47]. Furthermore, the insulin receptor is also a 
tyrosine kinase [48]. Insulin binding to the a-subunit induces a conformational change 
that stimulates the Idnase activity of the (3-subunit [49]. The j3-subunit in turn catalyses 
the transfer of a phosphate group onto tyrosine residues within the insulin receptor itself 
and intracellular substrate proteins [50]. Substrate phosphorylation by the insulin 
receptor tyrosine kinase appears to involve the binding of phosphorylated receptor 
tyrosine 960 to phosphotyrosine-binding (PTB) domains of substrate proteins [51]. The 
substrate proteins of insulin receptor tyrosine kinase include members of the Insulin 
Receptor Substrate (1RS) family [51]. Phosphorylation of 1RS enables the recruitment of 
signalling proteins through their Src homology 2 (SH2) or PTB domains to 
phosphotyrosine sites on the insulin receptor/ERSl complex. These signalling proteins 
include the pi 10 subunit of phosphatidyl-inositol 3-kinase (PI3K) that is recruited to the 
complex via the SH-2 domain of the p85 PI3K regulatory subunit [52]. They also 
include the phosphotyrosine phosphatase SHPTP2 that has the potential to 
dephosphorylate 1RS and the insulin receptor thus turning off the insulin signal [53]. 
Also, GRB2 an adaptor protein that links insulin signalling into the Ras pathway [54] 
and Rho-associated protein serine/thieonine kinase ROKa [55] that may alter processes 
under the control of the small GTPase Rho such as actin assembly and mitogenisis. 
Clearly with such a complicated array of signalling proteins associated with the insulin
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receptor and 1RS, there is considerable scope for cross talk between signalling 
pathways. This complexity makes it difficult to predict the final out come of inhibition 
of any one of the individual signalling elements. A simplified view of the insulin 
receptor, 1RS and some of the potential downstream effector molecules is shown in the 
figure below.
Insulin
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ROKa
Glut4
vesicle
SHPTP2
APKK
Glut4A y 
vesicle I - p pp pp
Microsomal membranes i #
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Figure 1.2 Signalling elements downstream of p21"^ and phosphatidyl-inositol 3-kinase products 
regulated by insulin
SOS, Son Of Sevenless (the Ras guanine nucleotide exchange factor); GAP, Ras GTPase activating 
protein; MAPK, mitogen activated protein kinase; MAPKK, mitogen activated protein kinase kinase; 
PDK, kinase responsible for phosphorylating Thr308 o f  PKB; PKB, protein kinase B.
As shown in the figure above, clearly two of the major signalling pathways activated by 
insulin are the PI3-K and the p21*^ ® cascades. Furthermore, recent research is starting to
i"j-
establish a link between PI3-K activation and membrane fusion events. Some of these 
regulators of membrane fusion include ADP-Ribosylation Factors (ARF) [56], the 
early-endosomal autoantigen (EEAl) [57] and the ARF binding site opener (ARNO) 
[58] and will be discussed in greater depth later in this chapter.
A great deal of effort has been expended in establishing which particular signalling 
elements are responsible for tire acute phase of the insulin response and Glut4
translocation. Expression of the Raf-1 protein kinase in 3X3-LI adipocytes has no effect 
on insulin-stimulated glucose uptake whereas basal uptake is increases 40-fold [59]. In 
addition, microinjection of oncogenic p2P^ ® into 3T3-LI adipocytes has no effect on 
insulin-stimulated Glut4 translocation but does induce c-Fos protein expression, a 
dovrastream component of the MAPK mitogenic pathway [60]. These data suggest that 
the p21^^  pathway communicates the long-term mitogenic signal from insulin to 
ti anscription factors within the nucleus of the cell.
However, a large amount of data now indicates that PI3-K plays a crucial role in acute 
phase insulin signalling and Glut4 trabslocation [52], Specific inhibitors of PI3-K, such 
as wortmannin and LY29004, completely abrogate the short term actions of insulin [31, 
61], as does expression of dominant inliibitory constructs of the p85 regulatory subunit 
of PI3-K [62]. An analogous experiment whereby a constitutively active form of the 
catalytic pi 10 subunit of PI3-K is injected into 3T3-L1 adipocytes demonstrates that 
expression of pi 10 is sufficient to cause translocation of Glut4 to the plasma membrane 
[63]. All of these studies support the hypothesis that tlie PI3»K rather than the p21^® 
pathway mediates insulin-stimulated Glut4 translocation. However, more recent data 
suggests that a further insulin-specific signalling pathway in conjunction with PI3-K 
activity is necessary to communicate the biological effects of insulin. Jiang et a l 
synthesised a cell-penneable analogue of the PI3-K product PI(3,4 ,5)P3 that was unable 
on its own to cause Glut4 tianslocation in 3T3-L1 adipocytes [64]. However, the PIP3 
analogue was capable of rescuing insulin-stimulated hexose transport into adipocytes 
pretreated with wortmannin. Such data argues that PI3-K activation is indeed necessary 
but not sufficient for short-term insulin action. The nature of this additional PI3-K- 
independent signalling event that contributes to insulin-stimulated glucose uptake in the
presence of wortmannin remains unknown.
I
muscle preparations [72]. However, practical limitations arise when trying to study the
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1.3.2 Exercise stimulated glucose H'ansport
Of course glucose uptake into peripheral tissues does not only occur in the post-prandial 
state. During exercise skeletal muscle requires an increased level of glucose transport 
influx to fuel the metabolic processes required for ATP generation and muscle 
contraction. However, it is now known that there are distinct intracellular signalling 
mechanisms that lead to exercise- and insulin-stimulated glucose tiansport in skeletal 
muscle [65]. In skeletal muscle tissue the effects of contraction and insulin on glucose 
transport are additive, yet only the effect of the latter is blocked by wortmamiin [66]. 
Similarly, insulin but not contraction stimulates the activity PI3-K and the downstream 
serine/threonine kinases PDK and PKB (figure 1.2) [67].
During exercise, ATP levels decrease within the muscle cell whereas AMP levels 
increase. The muscle cell uses this high AMP signal to stimulate more glucose uptake 
via the 5'-AMP-activated protein kinase (AMPK). Rat hind limb contraction but not 
insulin has been shown to stimulate AMPK activity [68]. The cell pemieable 5'-AMP 
analogue 5-aminoimidazole-4-carboximide ribonucleoside furthermore mimics the 
effects of contraction by stimulating glucose uptake into skeletal muscle in a 
wortmannin-insensitive manner [68, 69]. These data indicate that like PI3-K in insulin- 
stimulated glucose uptake, AMPK may be the key molecular switch mediating exercise- 
stimulated hexose transport.
The effects of the nitric oxide (NO) signalling pathway on glucose transport in muscle
I
V'jhcells has also been keenly investigated over recent years. Nitric oxide stimulates 
guanylate cyclase to produce cGMP that has three known possible fates within the cell. 
The cGMP may be broken down by phosphodiesterases, although cGMP is also known 
to inhibit cAMP-dependent phosphodiesterases, or open a cyclic nucleotide-gated ion 
channel [70], or stimulate cGMP-dependent protein kinase G (PKG) [71] (figure 1.3).
Contraction-stimulation is known to increase levels of NO from incubated skeletal
effects of muscle contractions and endogenous NO production on cells grown in culture.
'Therefore NO-donors, such as sodium nitroprusside (SNP), have been widely used to
study the effects of an exogenous source of NO on various biological effects [73]. In 
skeletal muscle SNP is known to stimulate glucose transport and raise intracellular 
cGMP levels [74]. In agreement with these studies, the nitric oxide synthase inhibitor L-
f■;sS'
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NAME blocks exercise-stimulated glucose transport in rat skeletal muscle but has no 
effect on insulin-stimulated glucose transport [75].
Clearly, like AMPK, NO appears to play a crucial part in exercise-stimulated glucose 
transport separate and removed from the effects of insulin. An intriguing hypothesis is
that AMPK and NO are in fact two halves of the same puzzle. One may conjecture that 
.as AMP levels rise within the cell during exercise, AMPK is stimulated, which in turn 
phosphorylates and activates nitric oxide synthase (NOS), leading to increased cGMP 
levels and elevated glucose transport through an as yet undefined downstream signalling
■■Ipathway (figure 1.3). Evidence in support of this hypotliesis is provided by a recent 
study showing that AMPK can phosphorylate and activate cardiac endothelial NO 
synthase (eNOS) in vitro [76].
1.3.3 G~Protein~coupled signalling pathways and glucose transport 
Adrenergic receptor agonists are also known to have a stimulatory effect on glucose 
uptake. From a physiological point of view this would make sense since skeletal muscle 
requires an enhanced supply of glucose to energise a “fight or flight” response. 
Adrenergic receptor agonists couple to glucose transport via heterotrimeric G-proteins 
[77], adenylate cyclase activation [78], cAMP production and stimulation of protein 
kinase A (PKA) activity [79]. The |3-adrenergic agonist noradrenaline in both skeletal 
muscle [80] and 3T3-L1 adipocytes [81] has been shown to increase glucose transport. 
Furthermore, the effects of insulin and noradrenaline on glucose uptake are additive 
[82]. This result infers that noradrenaline and insulin stimulate different signalling 
pathways. In support of this hypothesis the effects of noradrenaline are not inhibited by 
wortmannin [82]. Clearly, glucose transport is mediated by a number of stimuli
providing great potential for cross talk control between different intracellular signalling 
mechanisms. For example the reported effect of adenosine to potentiate the stimulation
by insulin of glucose uptake in brown fat cells from 15- to 30-fold [83]. This evidence 
does indeed suggest that the G protein-coupled signal triggered by adenosine can 
regulate the insulin-stimulated pathway. ?
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Figure 1.3 Outline of the muscle contraction-, nitric oxide- (NO) and G protein-linked receptor 
agonist-stimulated glucose transport pathways
AMPK, 5'-AMP-activated protein kinase; PDE, phosphodiesterase; PKG, protein kinase G; PKA, protein 
kinase A, CNG channel, cyclic nucleotide-gated ion channel.
1.4.0 Glut4 trafficking
1.4.1 Glut4 subcellular distribution
Almost twenty years have passed since glucose transporter translocation was proposed 
as the mechanism by which insulin mediates enhanced glucose transport into muscle 
and adipose tissue [30, 84]. Since then the precise mechanism by which the glucose 
transporter trafficks to the plasma membrane has proven elusive to researchers. Glut4 is 
considered to be the key glucose transporter isoform that mediates glucose uptake in
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peripheral tissues and is highly expressed in adipose tissue and striated muscle [85], 
whereas Glutl is expressed at significantly lower levels in the same tissue [85]. In both 
the basal and insulin-stimulated state [29, 32, 86] Glut4 slowly recycles between the 
plasma membrane and one or more intracellular compartments. However, the
13
overwhelming majority of Glut4 resides within intracellular vesicles in the basal state, 
making the distribution of Glut4 unique amongst the glucose transporter isoforms. 
Kinetic analysis of Glut4 trafficking has revealed that the increase in Glut4 observed at 
the plasma membrane in response to insulin is primarily the result of a large increase in 
the rate of Glut4 vesicle exocytosis and a smaller decrease in the rate of internalisation 
by endocytosis [86, 87]. PI3-K appears to play a crucial part in Glut4 translocation since 
treatment of cells with low nanomolar concentrations of wortmannin completely 
abolishes the recruitment of Glut4 to the cell surface [88, 89]. Furthermore, insulin 
mediates the targeting of IRS/PI3-K complexes to microsomes with a concomitant rise 
in PI3-P, PI 3,4-P2 and PI 3,4,5-P] levels within the vesicle membrane. These data are 
consistent with the hypothesis that that PI3-K is involved in the insulin-regulated 
movement of Glut4 to the plasma membrane.
The elements downstieam of PI3-K in the insulin-stimulated signalling 
pathways regulating Glut4 translocation are poorly understood, tlowever, the 
involvement of serine/thronine kinases is suggested by the ability of inhibitors of serine 
phosphatases to stimulate Glut4 translocation in the presence of wortmannin [88]. This 
result is supported by the claim that insulin also causes the recruitment of PKB to 
GIut4“Containing vesicles [90] in a wortmannin-dependent manner. In concert with this
result, constitutively active PKB results in up-regulation of glucose transport and 
redistribution of Glut4 to the plasma membrane [91]. To further complicate matters, 
stable transfection of the protein kinase C isoform PKC-<^  into 3T3-L1 adipocytes also 
leads to Glut4 translocation [92]. Whether such studies truly reflect a complicated 
serine/threonine kinase cascade downstream of PI3-K in vivo, or merely represent an 
artifact of kinase overexpression remains to be seen.
It is well established that integral membrane proteins traffic to and from the 
plasma membrane through an endosomal recycling membrane system [93]. 
Immunoelectron microscopy has revealed that Glut4 is distributed to a number of 
different classes of intracellular vesicles. To date the consensus of research suggests that 
the majority of intracellular Glut4 protein is localised to small vesicles and
II
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tubulovesicular structures throughout the cytosol, with relatively smaller amounts 
associated with the endosomal system and the trans Golgi network (TGN) [94-96], 
Each of these intracellular organelles represent complex, discontinuous membrane 
structures. Therefore, differentiating between these structures even at the resolution 
afforded by the electron microscope is difficult. Nevertheless, several observations 
suggest that a large fraction of the Glut4 population resides within a unique Glut4 
storage compartment separate from the other elements of the constitutive recycling 
pathway. For example, internalisation of transferrin conjugated to horse-radish
peroxidase in adipocytes and its subsequent ablation using diamino benzidine chemistry
has shown that endosomal recycling proteins such as the transferrin receptor and Glutl
can be specifically ablated whereas a large fraction of Glut4 cannot in 3T3-L1
adipocytes [97, 98].
.Using immunofluorescence and immunoelectron microscopy, Ralston et aL 
examined the distribution of Glut4 in skeletal myotubes [99]. In this study the 
researchers used a panel of antibodies as markers of the Golgi complex, of the TGN, 
and of early and late endosomes to define the position of these subcellular 
compartments relative to Glut4. They observed segregation of Glut4 and TfR both by 
immunofluorescence and by immimogold electron microscopy. By immunofluorescence 
alone Glut4 was found primarily around the nuclei, in a pattern suggesting an 
association with the Golgi complex. Similarly, immunoelectron microscopy showed that 
most of the Glut4 was associated with Golgi complexes. To test that GIut4 was indeed 
localised to the TGN the researchers treated the cells with the fungal metabolite 
Brefeldin A (BfA) that causes the Golgi complex, the endosomes and the TGN to 
disperse. However, in Bfa-treated cells Glut4 no longer colocalised with the TGN 
marker TGN38. Therefore, they were forced to conclude that if Glut4 is stored in the 
TGN in muscle myotubes, it must be a subcompartment that does not contain TGN38. 
Alternatively, the Glut4 storage compartment represents a population of vesicles 
geographically close to yet separate from the TGN. This latter suggestion is supported 
by immunofluorescence analysis of 3T3-L1 adipocytes where no colocalisation between 
Glut4 and TGN38 is observed [100]. Moreover, in the same study, no TGN38 was 
detected in immunoabsorbed Glut4-containing vesicles when immunoblotted with a 
TGN-38 specific antiserum. In the analogous experiment with immunoabsorbed TGN-
38-containing vesicles, only 5-10% of the total low-density membrane Glut4 
colocalised with TGN-38,
Together, these data paint a complex picture of Glut4 distribution with 
subpopulations of Glut4 colocalising with various markers of the endosomal system or 
TGN to greater or lesser extents. However, none of the subcellular markers described 
previously fully mimic the distribution of the intracellular Glut4 pool. Nevertheless, 
there appears to be other proteins that do share a considerable degree of colocalisation 
with Glut4. Unlike the transferrin receptor endosomal marker or TGN38 the TGN 
marker, the v-SNARE Vesicle Associated Membrane Protein 2 (VAMP2) colocalises 
with Glut4 [97]. Another protein, the aminopeptidase vpl65 (IRAP) has also been found 
to colocaiise identically with Glut4 in adipocytes and cardiomyocytes [101]. Although 
the exact biological function of vpl65 is as yet unknown, injection of 3T3-L1 
adipocytes with a GST-IRAP or a fusion protein containing only 28 amino acids from 
IRAP was as effective as 100 nM insulin in increasing cell surface Glut4 when analysed 
by immunofluorescence [102]. These observations therefore suggest the presence of a 
distinct vesicle population enriched in VAMP2 and Glut4. This unique compartment 
may account for the ability of insulin to stimulate 2-4-fold plasma membrane increases 
of recycling proteins, for example Glutl and transfenin receptor, whereas plasma 
membrane Glut4 content can increase 10-20 fold [86].
1.4.2 Glut4 trafficking and the SNARE hypothesis
From studies in the mammalian synapse, it has been revealed that the membrane 
proteins referred to as v-SNAREs, located in transport vesicles, bind to t-SNAREs 
located in the target membrane [103]. The high affinity and specificity of this 
interaction ensures that transport vesicles dock and fuse with their connect target 
membrane. The SNARE hypothesis thereby proposes that for all membrane trafficking 
events, a high-affmity match between a ligand in a transport/secretory vesicle (v- 
SNARE) and a receptor in the target membrane (t-SNARE) would be required to 
complete a docking and fusion reaction [93].
The v-SNARE Vesicle-Associated Membrane Protein 2 (VAMP2) is expressed 
in adipocytes [104]. This was a significant finding because like the mammalian synapse, 
adipocytes also possess a regulated secretory system that translocates Glut4 to the 
plasma membrane. Unlike the transferrin receptor endosomal marker or TGN38 the 
TGN marker, VAMP2 colocalises with Glut4 and translocates to the plasma membrane 
in response to insulin [97]. It was subsequently shown that adipocytes also express an 
additional v-SNARE called cellubrevin that, based on subcellular fractionation, also
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Iappears to colocaiise with Glut4 in adipocytes [105]. However, the use of the 
transferrin-conjugated horseradish peroxidase endosome ablation technique proposed a 
more specific role for VAMP2 in Glut4 trafficking than cellubrevin [97]. Whereas the |
majority of cellubrevin was targeted to endosomes, a large fraction of VAMP2 was 
targeted to the Glut4 storage compartment [97].
■S'More recently several other studies have implicated a role for VAMP2 in Glut4 
translocation. Vaccinia virus-mediated expression of the cytoplasmic domain of
VAMP2 in adipocytes or the introduction of VAMP2-GST fusion proteins into 
permabilised adipocytes results in the inhibition of insulin-stimulated Glut4 |
translocation [106, 107]. Likewise, introduction of the cytoplasmic domain of syntaxin 
4, the VAMP2 t-SNARE, also resulted in an inhibition of insulin-stimulated Gliit4 but 
not Glutl translocation to the plasma membrane [106]. Finally, microinjection of 
tetanus toxin and botulinum D toxin which cleave members of the VAMP family block 
insulin-stimulated Glut4 translocation in 3T3-L1 adipocytes [108]. In combination these |
data suggest a model whereby VAMP2 is a constituent of Glut4-containing vesicles and 
regulates the insulin-induced fusion of these vesicles to the plasma membrane during 
translocation. On the other hand, cellubrevin, classified as an endosomal v-SNARE in 
previous studies [109], only colocalises vrith the fraction of Glut4 that is distributed to 
the recycling endosomes, and mediates the constitutive endosomal trafficking of Glut4 
[110].
We have already mentioned that Syntaxin 4 is a likely t-SNARE for VAMP2 
[106]. Using the technique of Far Western blotting, membrane fractions from 3T3-L1 
adipocytes have been probed with the cytosolic portion of VAMP2 fused to GST [111].
Two plasma membrane-enriched proteins were specifically labeled with this probe, 
identified as Syntaxin 4 and Syndet, a murine homologue of a previously described t-
Ï
SNARE SNAP-25, These proteins were further shown to fonn an SDS resistant ternary 
complex and microinjection of anti-Syndet antibodies into 3T3-L1 adipocytes inhibited |
insulin-stimulated Glut4 translocation by 40% [111]. A model now begins to take shape 
in which Syntaxin 4/Syndet form the t-SNARE for VAMP2 that provides the specificity 
for insulin-induced fusion of Glut4-containing vesicles with the plasma membrane.
However, until recently the accessory molecules that presumably must be required to 
control this fusion event remained unidentified.
In the case of synaptic transmission there are several modulators of v- and t- 
SN ARE interactions, in particular the MunclS proteins [112]. The MunclSa isofonn is
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predominantly expressed in neurons where it inhibits the association of v-SNARES
To continue the analogy between synaptic vesicles, the role of MunclSc in 
insulin-stimulated Glut4 translocation in 3T3-L1 adipocytes was examined [112]. Using
iIII-
VAMPl and SNAP25 with the t-SNARE syntaxin 1 [113]. However, Tellman et al.
successfully isolated three distinct MunclS isoforms from a 3T3-L1 adipocytes cDNA
library by screening with a rat brain MunclS DNA probe [114]. MunclSa, previously ■
identified in neuronal tissue, and two novel isoforms, MunclSb and MunclSc were 
cloned from the adipocytes cDNA library.
yeast two-hybrid analyses, MunclSc was shown to specifically compete for VAMP2
binding to syntaxin 4 and plasma membrane lawn assays revealed that over expression 
of FLAG epitope tagged MunclSc in 3T3-L1 adipocytes inhibited insulin-stimulated 
translocation of Glut4 [112]. Furthermore, MunclSc was transfected into Chinese 
Hamster Ovary (CHO) cells to examine its function as a regulatory target of insulin 
signal transduction [112]. Although CHO cells are not a bonafide insulin-responsive cell 
line, they were used in this experiment since these cells contain very low endogenous 
levels of MunclS. Immunoprécipitation of endogenous syntaxin 4 demonstrated the co- 
immunoprecipitation of the expressed FLAG-MunclSc protein. However, insulin 
stimulation resulted in a decreased amount of FLAG-MunclSc that was co- 
immunoprecipitated with syntaxin 4. Flence, this data suggests that MunclS inhibits the 
interaction between VAMP2 and syntaxin 4 in the basal state by binding tightly to the 
latter protein at the plasma membrane. Insulin then relieves this inhibition by inducing 
the dissociation of MunclSc fi'om syntaxin 4.
In addition to v-SNAREs and t-SNAREs, multiple membrane fusion events 
involving the Golgi, endoplasmic reticulum and plasma membrane depend on the N- 
ethylmaleimide-sensitive factor (NSF) [115]. Although NSF is widely recognised as an 
essential factor in multiple transport events this protein's exact function is still 
unknown. However, membrane association of NSF does require the accessory proteins 
termed a - ,  |3-, and y-SNAPs (soluble NSF attachment proteins) [93]. In vitro 
biochemical studies have demonstrated that NSF, SNAPs and SNAREs form a 20 S 
complex that is proposed to fimction in vesicle fusion [103]. However, to form a stable
20 S par ticle, a nonhydrolysable analogue of ATP, for example ATPyS is required. NSF 
has an intrinsic ATPase activity that in the presence of ATP results in the disassembly 
of the 20 S complex into its constitutive parts [103]. Interpretation of this finding is
S '
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.difficult, however it seems likely that the hydrolysis of ATP by NSF causes a 
conformational change in the SNARE proteins that plays some part in the vesicle fusion fi
sequence of events. Furthermore, such in vitro studies using recombinant proteins may 
force interactions not that are not replicated in vivo. More recent studies have in fact 
placed the function of NSF earlier in the sequence of vesicle fusion events before 
vesicle docking [115-117], If this scenario proves the same in Glut4-containing vesicles, 
then NSF and a-SNAP would function to prime v- and t-SNAREs into a docking 
competent state (figure 1.4).
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Figure 1.4 Sequence of events involving the SNARE proteins that function in Glut4 trafficking
19
1,4.3 The role o f small molecular weight GTPases in Glut4 trafficking
yThe Rab family of small GTP-binding proteins is also known to play an important role 
in vesicle trafficking. To date more than 30 different Rab proteins have been identified 
with each one specialised towards a particular membrane fusion event [118], By 
analogy with research examining the trafficking of membrane proteins to the yeast 
vacuole, Rab proteins are thought to catalyse the membrane fusion event subsequent to 
SNARE priming by NSF and a-SNAP [117], Rab 4 was proposed to play a specific 
role in insulin sensitive cells when it was discovered that Rab 4 colocalises with the 
Glut4-enriched membrane fraction and with vesicles immunopurified with an anti-Glut4 
antibody in 3T3-L1 adipocytes [119]. After insulin treatment, a 50% decrease in the 
Rab4 content of the low density microsomal fraction was observed, concomitantly with 
a departure of Glut4 to the plasma membrane. Insulin redistributed Rab4 to the cytosol 
and its movement was reversed by insulin withdrawl. It therefore appears that Rab4 
cycles between the cytosol and Glut4-containing vesicles depending upon the presence 
or absence of insulin respectively. In a more recent study, a synthetic peptide 
corresponding to the Rab 4 hypervariable carboxyl-terminal domain was successfully 
transferred into rat adipocytes by electroporation and inhibited insulin-stimulated 
glucose transport by 50% without affecting the basal transport activity [120]. The 
researchers also showed that the exocytotic recmitment of Glut4 by insulin to the 
plasma membrane was inhibited by the Rab4 peptide. Another study by Shibata et al 
showed that insulin stimulated the binding of a radiolabeled non-hydrolysable GTP 
analogue [^^S]GTPyS to Rab4 in a wortmannin-dependent manner [121]. Furthermore, 
dissociation of Rab4 from microsomes to the cytosol was also inhibited by wortmannin.
This result suggests that insulin stimulates the guanine nucleotide exchange on Rab4 via 
a PI3-K-dependent signalling pathway. The accepted interpretation of this data is that 
Rab4 is therefore an essential component of the translocation machinery (figure 1.5).
1.4.4 The possible role o f ‘'velcro factors” and guanine nucleotide exchange proteins in 
Glut4 vesicle fusion
The pieces of the molecular jigsaw that link signalling via PI3-K and membrane fusion 
events mediated by SNAREs were discovered only recently. The PI3-K product PI(3)P 
binds the early-endosomal autoantigen (EEAl) through a FYVE finger domain within
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the protein, in tiie context of the early endosomal membrane [57]. Tliis interaction is 
inhibited by wortmannin such that endosome fusion no longer can take place [57]. 
Crucially, this interaction is stabilised by the presence of GTP-bound Rab5 since EEAl 
contains two GTP-Rab5 binding sites, at the N- and C- termini [57]. Therefore, EEAl is 
hypothesised to function as a ‘velcro factor’ in the initial docking between endosomal 
membranes, by virtue of the dual interaction of its C-terminus with PI3P and Rab5 and 
of its N-tenninus with Rab 5. EEAl may also dimerize owing to an extensive coiled- 
coil domain [93]. This dimerization would allow interaction with PI(3)P at both 
membranes and perhaps also allow an interaction with SNARE molecules, based on the 
ability of EEAl to promote membrane fusion events [57]. To date, other than EEAl, the 
FYVE finger domain has been identified in the yeast Sec Ip family of proteins that 
interact with SNAREs [93]. It would be of great interest to know if any variants of the 
FYVE finger domain proteins capable of binding PI(3,4,5)3 are expressed in insulin- 
responsive cells.
EEAl is not the only identified ‘velcro factor’. Another, Rabaptin-5 that also 
interacts with Rab5 was identified using a yeast two-hybrid screen [122]. In addition, 
rabaptin-5 is complexed with Rabex-5 that acts as a rab5 GTP nucleotide-exchange 
factor (GEF) [123]. But intriguingly, while Rabaptin-5 can interact with Rab5 at its C- 
terminus, it can also interact with GTP-bound rab4 at a distinct N-terminal site [124]. 
This presents the tantalising possibility that Rabaptin-5 could act as a molecular linker 
between rab4, rab5 and a FYVE finger domain protein, possibly mediating an 
interaction between Glut-4 containing vesicles (Rab4) and the plasma membrane (Rab5) 
[125] in response to insulin. This, as yet imtested link, is outlined in the figure below.
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Figure 1.5 Putative transient docking step in the fusion of Glut4-containing vesicles with the plasma 
membrane
Subsequent to priming by NSF, SNAP, ATP and stimulation o f P13-K activity by insulin, a putative 
FYVE finger domain-containing protein binds PI(3,4,5)P3 in the membranes. We hypothesise that a 
FYVE finger protein (for example a yeast Sec Ip homologue) could then recruit rabaptin-5 to the complex 
and acts as an adaptor between Rab4 and Rab5 containing membranes. Rabaptin-5 is also associated with 
a guanine nucleotide exchange factor (GEF), that catalyses the exchange o f  GDP for GTP on Rab 
proteins. The GTP-bound Rabs then stabilise the interactions between PI(3,4,5)P), the FYVE finger 
protein, rabaptin-5 and the SNAREs long enough for membrane fusion to occur.
Another class of GEFs that includes GRPl [126], ARNO [127] and cytohesin-1 
[128] contain a pleckstrin homology domain (PH) that has the ability to bind PI(3,4,5)P3 
with high affinity. Furthermore, these GEFs also contains a Sec7 domain that catalyses 
the exchange of GDP for GTP on ADP-Ribosylation Factors (ARFs). The relationship 
between ARF proteins, small GTPases known to modulate membrane transport events, 
and Glut4 trafficking is discussed in detail in Chapter 4. However, it is clear that this 
further class of GEFs that binds directly to PI3-kinase products and regulates guanine 
nucleotide exchange on ARFs represents another rich vein for prospectors investigating 
signalling and membrane trafficking.
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1.4.5 Glut4 endocytosis
So far in this chapter we have only discussed trafficking events that lead to Glut4
exocytosis. The exocytotic arm of Glut4 trafficking is emphasised because kinetic
analysis has indicated that insulin increases tlie rate of Glut4 exocytosis 10-20 fold with_only a 2-3-fold decrease in the rate of endocytosis [129], Whereas PÎ3-K activity is 
necessary to increase the rate of Glut4 exocytosis, wortmannin has no effect on the rate 
of Glut4 endocytosis [130]. Instead, Glut4 endocytosis is mediated by clathrin-coated 
pits [131]. Electron microscopy of plasma membrane fragments indicates that in the 
non-stimulated state Glut4 is primarily localised to clathrin lattices. Following insulin 
treatment, Glut4 labeling of clathrin lattices is only slightly increased, whereas the 
labeling of uncoated regions is markedly increased [131]. This suggests that Glut4 
recycles from the plasma membrane both in the presence and absence of insulin. This 
interpretation of the data is confiimed by the finding that disruption of clathrin lattices 
by potassium depletion increases levels of cell surface Glut4 in the basal state [132].
The clathrin-coated vesicles comprise of a clathrin coat linked to the endocytosed 
membrane protein via a heterotetrameric adaptin complex (AP-2) [93]. A tyrosine-based 
targeting motif at the N-terminus of Glut4 is suggested to interact with AP-2 [133], 
providing further evidence that Glut4 recycles from the plasma membrane via clathrin- 
coated vesicles (CCVs). The initial localisation of AP-2 to the plasma membrane is
thought to be provided by interaction with the membrane receptor synaptotagmin 1
,[134]. However, the CCVs that bud from the plasma membrane are distinct from those
which bud from the TON and incorporate a different adaptor complex (AP-1) [93].
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Figure 1.6 The internalisation of Glut4 is thought to occur through a dynamin-dependent 
mechanism
Subsequent to insulin-stimulated Glut4 translocation, Glut4 accumulates in clathrin-coated invaginations 
o f  the plasma membrane. Endocytosis is mediated by interactions between AP-2, synaptotagmin, 
amphiphysin and the N-terminus o f  Glut4. Dynamin is recruited to the clathrin-coated vesicle via an 
interaction with the SH-3 domain o f  amphiphysin. Insulin may modulate the interaction between dynamin 
and amphiphysin, thereby inhibiting clathrin-coated vesicle formation and reducing the rate o f Glut4 
endocytosis from the plasma membrane. Once internalised the vesicles lose their clathrin coat and are 
then stored at an intracellular site or undergo another round o f  translocation.
One other essential molecule implicated in CCV formation is the GTPase dynamin
[135]. In addition to a GTPase domain, dynamin also contains a pleckstrin homology 
domain that can interact with inositol phospholipids [136], and a proline rich domain 
that binds a specific subset of SH3 domain-containing proteins, for example 
amphiphysin [137]. Furthermore, insulin induces the tyrosine phosphorylation of 
dynamin [138], providing a possible mechanism whereby insulin causes a two fold 
reduction in the rate of Glut4 endocytosis [129]. In support of a role for dynamin in 
endocytosis Al-Hasani et a i showed that expression of a GTPase-negative mutant in rat 
adipose cells increased the amount of cell surface HA-tagged Glut4 in both the basal 
and insulin-stimulated states. In contrast overexpression of dynamin wild type
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decreased the amount of cell surface HA-GIut4 in both the basal and insulin-stimulated 
states. In addition, microinjection of a dynamin peptide encompassing the ampliiphysin 
binding sites prevents Glut4 endocytosis and results in Glut4 accumulation at the 
plasma membrane [139]. Amphiphysin is also known to interact with AP-2 [137, 140]. 
Therefore we can hypothesise that insulin-induced phosphorylation of dynamin may 
inliibit the interaction between ampliiphysin, dynamin and AP-2 hence reducing the rate 
of Glut4 endocytosis (figure 1.6).
1.5,0 Tramgenic/Knockout mice as new investigative tools
The emerging field of genetic engineering has allowed researchers to examine the 
function of individual genes in the context of the whole animal. By introducing null 
mutations into a particular gene we can then observe the phenotypic consequences. 
Furthermore, a knockout mouse may expose a molecular redundancy that allows an 
engineered animal to compensate for the disruption of a particular gene.
Homologous recombination is the most commonly used technique for generating a 
knockout animal. Following sequence analysis of the gene of interest a targeting vector 
is designed. Tliis vector contains a selection gene, for example the neomycin 
phosphotransferase gene {neo) flanked by sequence corresponding to the gene of 
interest. An embryonic stem cell suspension is then microinjected or electroporated with 
the targeting vector. Once within the nucleus of the stem cells, the targeting vector is 
designed to take advantage of homologous recombination between the chromosomes 
during mitosis. With luck, the neo gene is then inserted into an exon of the gene to be 
disrupted. After 5-7 days, the G418-resistant clones are isolated and subjected to 
screening for homologous recombination by PCR. Clones in which the gene of interest 
has been successfully targeted are then implanted into the host animal. The phenotypes 
of the viable embryos are then analysed after birth [141]. The same strategy of 
homologous recombination can also be used to overexpress the product of a gene. In 
transgenic mice, a transgene construct with its own promoter will normally be expressed 
in all tissues where the gene is noimally expressed, while it can be targeted to selected 
tissues by the choice of an appropriate promoter. [141].
A brief outline of the effects of manipulating insulin signalling or Glut4 trafficking in 
knockout mice is given in the table below.
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G ene K nockou t V iable D iabetes Pheno type R eference
Insulin N o Yes Growth retardation [142]
Insulin Receptor No Yes Growth retai'dation [143]
IRS-1 Yes No G iow th retardation and mild 
insulin resistance
[144]
IRS-2 Yes Yes Growth retardation and 
hyperinsulinaemia
[145]
Glut4 Yes No G rowth retardation and 
hyperinsulinaemia
[146]
PI3-K (p85a) Yes No Hypoglycaemia [147]
T able 2 G ene knockouts an d  th e ir  physiological consequence in mice
Perhaps not surprisingly insulin or insulin receptor knockout mice are not viable. 
Homozygous insulin receptor knockouts were viable for less than a week, [143] and in 
that time display marked hyperglycaemia that led to hyperinsulinaemia. The absence of 
insulin signalling in the liver and adipose tissue also resulted in reduced hepatic 
glycogen content and decreased fat cell content respectively. This data highlights the 
crucial nature of insulin in regulating whole body glucose homeostasis and therefore the 
survival of the animal itself.
A more recent muscle-specific IR gene knockout was achieved using the Cre/loxP 
system [148]. The resultant muscle-specific IR gene knockout mice displayed a 95% 
reduction in IR expression in skeletal muscle. These animals remained phenotypically 
normal despite having greatly impaired insulin-stimulated glucose uptake into skeletal 
muscle. This was a surprising finding since skeletal muscle is generally considered to be 
the principal tissue of insulin-stimulated glucose disposal. This result may signify that 
compensatory measures exist in mice to maintain glucose homeostasis.
Another good example of functional redundancy and compensatory measures in 
insulin signalling is provided by the IRS-1 gene knockout. Four members of the 1RS 
family have now been identified (IRS-1, 2, 3, and 4) [52]. IRS-1 and IRS-2 are widely 
distributed, although the relative expression levels are different between tissues. Unlike 
the IR mutants IRS-1 homozygous null mutants do not present with any major 
metabolic abnormalities [144], although a mild degree of insulin resistance was 
obseived. This result suggested that another mechanism was substituting for IRS-1
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deletion. To address this possibility, insulin signalling and action were further studied in 
muscle from IRS-1 knockout mice. A 144% increase in IRS-2-associated PI3~K activity 
compared to controls was found in muscle form IRS-1 mice [149]. This data thus 
provided evidence for an 1RS» 1-independent pathway of insulin signalling.
In turn IRS-2 was inactivated in knockout mice and the phenotype observed markedly 
different from the IRS-T^" mouse [145]. As the animals grew older, mild insulin 
resistance had developed into severe diabetes by 10 weeks. The IRS-2 deficiency was 
found to contribute not only to peripheral insulin resistance, similar to an IRS-1 
deficiency, but also prevented adequate pancreatic [3-cell compensation. Both of these 
abnormalities are found in human type 2 diabetic patients [150]. In contrast with the 
significant enhancement of insulin-stimulated PB-kinase associated with IRS-2 seen in 
the 1RS-1'^'mice, insulin stimulated PB-kinase activity associated with IRS-1 in muscle 
was reduced by more than 50%. Therefore, IRS-1 cannot compensate for an IRS-2 
deficiency in the same way that IRS-2 can compensate for an IRS-1 deficiency. This 
may explain the more severe diabetic phenotype observed in IRS-2‘^ 'mice.
Studies using inhibitors suggest that PB-K is a crucial enzyme in insulin signalling 
[31, 89], This obseivation was tested further in mice homozygous for a targeted 
disruption in the p85a regulatory subunit of PB-kinase [147]. In this mutant expression 
of the full-length p85a gene is blocked while the ability to express a truncated 
p85a splice variant is retained. These mice are viable, indicating that the other PB- 
kinase adaptor/regulatory subunits may compensate for the loss of p85a. These animals 
are in fact hyper-responsive to insulin and present with hypoglycaemia. This 
observation is explained by upregulation of the p50a alternative splicing isoform that 
overcompensates for the loss of p85a in insulin-sensitive tissues.
We have already discussed the structure, function and trafficking of Glut4 in some 
detail. Glut4 is the principal glucose transporter isoform responsible for glucose 
disposal into insulin-responsive tissues [151, 152]. Therefore one might expect that 
disruption of Glut4 would result in insulin resistance. Application of the gene-targeting 
approach to the Glut4 gene has produced mice canying a null mutation in this gene 
[146]. The targeted disruption was achieved by inserting a neo cassette into exon 10 of 
the Glut4 gene. Surprisingly, homozygous Glut4 null mice did not show an overtly 
diabetic phenotype. However, Giut4'^‘ mice were insulin resistant, indicated by a 5-6- 
fold higher postprandial hyperinsulinaemia. A compensatory increase of Glut2 and
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Due to the redundancy between elements of the insulin signalling pathway it is
Glutl were detected in the liver and heart respectively. Nevertheless, increased 
expression of other glucose isofonns was not detected in skeletal muscle. This finding 
brought speculation that as yet unidentified glucose transporter isoform may be 
expressed in skeletal muscle that can compensate for null mutation in the Glut4 gene.
The phenotype of the Glut4 null mouse is even more surprising when compared to 
transgenic mice that have elevated levels of Glut4 expression [153]. Liu et aL found that 
increased expression of the human Glut4 gene in vivo results in a constitutively high 
level of cell surface Glut4 protein expression and more efficient control over 
fluctuations in plasma glucose concentrations. Clearly there is a dichotomy between 
tliese two observations, where Glut4 null mice have essentially normal blood glucose 
control whereas mice that overexpress Glut4 show enhanced glucose control.
In light of the data from the Glut4 null mouse, a Glut2 null mouse may also be 
expected to show evidence of a mechanism to compensate for Glut2 ablation. Targeted 
disruption of the Glut2 gene has been achieved in mice by replacing exons 5, 6, and 7 
by a neo cassette [154]. However, in contrast to Glut4 null mice, Glut2 null mice were 
diabetic and died within 2-3 weeks of birth. We speculate that the unexpectedly mild 
phenotype of the Glut4 null mice may be a result of the method used to disrupt the 
Glut4 gene. Disruption of the Glut4 gene was achieved by targeting exon 10 only, 
whereas in the Glut2 null mouse 3 exons were dismpted. A situation may therefore arise ■4
where a partially disrupted Glut4 protein may still be capable of transporting glucose in 
response to insulin, hence maintaining a reasonable degree of blood glucose control.
Furthermore, a partially mutated Glut4 protein may not necessarily be evident on a
!Western blot from Glut4" tissues due to altered electrophoretic properties.
difficult to make firm conclusions from null mutations in the context of the whole
'unimal. Such studies do however highlight the complexity of insulin signalling and 
Glut4 trafficking. In addition targeted gene disruptions shed some light on the 
pathogenesis of diabetes.
Diabetes itself is a major health problem being responsible for a great deal of 
morbidity and mortality in the western world [6, 150]. The disease is also becoming 
more widespread throughout Asia as more cultures develop a taste for a western 
lifestyle and high fat foods. The majority of diabetic patients suffer from non-insulin- 
dependent diabetes mellitus (NIDDM), characterised by hyperglycaemia in the presence
of nonnal or elevated levels of circulating insulin. This insulin resistance could in
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theory arise from any defect in the insulin signalling and Glut trafficking pathways 
distal to the binding of the hormone to its plasma membrane receptor. Research in 
humans with NIDDM has tried to address whether there are any genetic predispositions 
towards this disease.
Mutations found in patients with genetic forms of extreme insulin resistance confinn 
that the tyrosine kinase activity of the insulin receptor plays a crucial role in insulin 
signalling [155]. However, mutations in the insulin receptor gene are not responsible for 
the majority of cases of NIDDM. Similarly, mutations in the insulin gene itself, or the 
glucokinase gene (glucose is phosphorylated by glucokinase to fonn glucose 6- 
phosphate as the initial step in glucose metabolism) are rarely foimd in cases of NIDDM 
[156, 157]. Several polymorphisms have been identified in the amino acid sequence of 
human IRS-1 and studies have reported that some of the variant sequences are increased 
in prevelance among patients with NIDDM [158, 159]. However, when mutant forms of 
IRS-1 were expressed in COS-7 cells, the mutations did not alter the level of expression 
or the extent of insulin receptor-mediated tyrosine phosphorylation of recombinant IRS- 
1 [160]. Nor did the mutations disrupt the association of recombinant IRS-1 with PI3-K. 
Therefore, this biochemical study does not lend support to the hypothesis that mutations 
in IRS-1 contribute to NIDDM. Perhaps this is not suiprising since mouse IRS-1 
deletion mutants only present with mild diabetes [144].
Knockout studies in mice suggest that IRS-2 may play a more significant role in 
insulin signalling [145] Therefore mutations in IRS-2 may be more likely to contribute 
to an NIDDM predisposition. Bektas et aL investigated whether variability at the IRS-2 
locus plays a role in the etiology of early-onset autosomal dominant type 2 diabetes 
[161]. They evaluated the genetic linkage between diabetes and two polymorphic 
markers located in the region of the IRS-2 gene in 29 families with early-onset 
mitosomai dominant type 2 diabetes. However, no mutations segi'egating with diabetes 
could be found in these families, indicating that IRS-2 is not a major gene in this 
disease. Mutations in the p85a subunit of PI3-kinase that contribute to insulin resistance 
have also been identified in some small populations [162, 163], but no biochemical 
characterisation of these p85 variants has yet been perfoimed.
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41.6.0 The role o f GliitA in Non-Insulin Dependent Diabetes Mellitus 
Clearly there is a lack of convincing evidence that mutations in elements of the insulin 
signalling cascade as we understand it contribute to the development of NIDDM. Since 
the translocation of Glut4 in response to insulin in peripheral tissues is considered the 
key event in maintaining glycaemic control, perhaps mutations in the Glut4 gene would 
more readily account for the development of NIDDM. Point mutations in Glut4 have 
been noted, however these too occur in too small a proportion of cases to be considered 
an important aetiological factor in insulin resistance [164, 165].
Again, gene defects cannot account for the functional impairment of insulin- 
stimulated glucose transport in NIDDM. Instead, a functional impairment is the most 
likely cause of insulin resistance. The principal types of functional defects that may 
arise can be divided into two groups. Firstly, insulin resistance may arise due to
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inadequate expression of glucose transporters in peripheral tissues, and secondly, Glut4 
may be expressed at sufficiently high levels but does not translocate efficiently to the 
plasma membrane.
Pretranslational suppression of Glut4 protein is documented as causing insulin
resistance in adipocytes from patients with NIDDM and obesity [166], Hence, lower
than normal levels of Giut4 raRNA are detected in adipocytes from these subjects.
Glut4 translocation has also been shown to be defective in adipocytes obtained from
obese and type 2 diabetic patients [167], Similarly, transgenic mice expressing the
human Glut4 gene specifically in adipose tissue display a marked increase in basal
glucose disposal and insulin-sensitive glucose uptake [168].
_In skeletal muscle the situation has proven to be different. Most studies have 
shown no change in muscle cellular Glut4 expression in insulin resistant patients [169, 
170]. However, plasma membrane-associated levels of Glut4 were lower, suggesting an 
inipaimient of translocation in response to insulin. Therefore, the defect causing insulin 
resistance in skeletal muscle may lie on the pathway of insulin signalling or transporter 
translocation. Nevertheless, the phannacological manipulation of Glut4 expression may 
be a useful strategy to alleviate insulin resistance. This notion is supported by research 
in transgenic mice. Leturque et aL created transgenic mice that had a 3-fold increase in 
Glut4 glucose transporter level in skeletal muscle and heart [171]. This increase was 
sufficient to significantly improve insulin action and to reduce basal glucose levels in 
transgenic streptozotocin-induced diabetic mice.
-ft-
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The molecular basis for regulation of Glut4 gene expression in states of relative
insulin deficiency in vivo has been difficult to solve. However it is well established that
_physical exercise has an up-regulatory effect on muscle Glut4 content [172], This
Î
increase in Glut4 expression explains the improvement in insulin sensitivity observed in 
exercise trained subjects [173].
hi a more recent study, a perfectly conserved myocyte enhancer factor 2 
(MEF2)-binding domain was identified in the promoter regulatory region of the Glut4 
gene [174]. This domain was necessary, but not sufficient, to support tissue-specific 
expression of a chloramphenicol acetyltransferase (CAT) reporter gene in heart, skeletal 
muscle and brown adipose tissue of transgenic mice. Gel shift assays of nuclear extracts 
from the major Glut4-expressing tissues had significant MEF2 binding activity. In 
addition, MEF2 DNA binding activity was substantially reduced in nuclear extracts
isolated from the skeletal muscle of diabetic mice, which correlated with decreased 
transcription of the GIut4 gene. However, this decrease was fully restored by insulin 
treatment. This observation is analogous to the established view that in states of insulin 
deficiency there is marked reduction in Glut4 expression due to a decrease in Glut4 
gene transcription which can be restored upon insulin treatment [175]. Taken together 
these data support a role for MEF2 in the regulation of Glut4 expression in the principal 
tissues of glucose disposal, therefore agents with the potential to upregulate MEF2 
expression or activity may prove effective antidiabetic agents.
Clearly a better understanding of Glut4 expression and in particular Glut4 
translocation may open the doorway to designing more effective treatments for insulin 
resistance. It was with this background in mind that a strategy to study Glut4 
translocation using green fluorescent protein was proposed.
II. "ii1.7.0 Green Fluorescent Protein
Green fluorescent protein (GFP) was discovered by Shimomura et al as a companion 
protein to aequorin, a chemihuninescent protein from Aequorea jellyfish [176]. The
,same group then published the emission spectrum of GFP which peaked at 508 nm 
[177]. However, the emission spectrum of purified aequorin was blue and peaked near 
470 nm, the approximate value of one of the excitation peaks of GFP. These data 
implied that the GFP converted the blue light emitted from aequorin into green 
fluorescence in intact cells. The GFP chromophore was later identified by Shimomura et
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al as 4-(^"hydroxybenzylidene)imidazolidin-5”One attached to the peptide backbone of 
GFP [178]. The GFP gene was cloned by Prasher et al. [179] and subsequently shown 
to retain its fluorescent properties when expressed in other organisms [180]. Therefore, 
the gene alone contains all the information necessary for the posttranslational synthesis 
of the chromophore, and no jellyfish-specific enzymes are required. This research 
heralded the application of GFP to cellular biology.
In due course, the tliree dimensional structure of GFP was solved in 1996 [181]. GFP 
is an 11-stranded p-bairel threaded by an a-helix running up the axis of the cylinder. 
The chromophore is attached to the a-helix and situated in the center of the p-barrel 
[181] (figure 1.7).
The GFP protein used in our study of Glut4 trafficking was a triple mutant 
(GFP3) (a gift from Dr. J. Pines, Wellcome/CRC Institute, Cambridge, U.K.). The first 
is a benign mutation, Q80R, common in most cDNA constructs derived from the 
original sequence and is probably the result of a PCR error [182]. The second mutation, 
V I63A, is proposed to improve 37°C-folding, reduce aggiegation at high concentrations 
and increase the diffusibility of the protein inside cells [183]. The third mutation S65T 
improves the brightness of GFP and shifts the excitation peak of GFP slightly from 470 
to 489 mn [184].
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Figure 1.7 Three-dimensional structure o f GFP. Image taken from Tsien et al. 1998 [182]
The cell biological applications of GFP fall into two main groups. GFP can be used as 
a reporter gene, or alternatively, as a molecular tag. When used as a reporter gene, GFP 
expression reflects the strength of the promoter to which the GFP cDNA is linked [180]. 
In tagging studies however, GFP fluorescence reflects levels of gene expression or 
subcellular localisations caused by targeting domains or host proteins to which GFP is 
fused. The application of this technique to research in cellular biology are numerous 
including, GFP-tagged TGN38 to study membrane traffic pathways, [185], visualisation 
of protein transport along the secretory pathway, [186] and real time visualisation of 
internalisation of the thyrotropin-releasing hormone receptor [187].
The use of GFP to tag proteins at the molecular level has several advantages 
over conventional fluorescent techniques. Principally, GFP fluorescence can be 
observed in living rather than chemically-fixed cells, and consequently allows the real 
time visualisation of GFP-tagged proteins. In this study we hoped to make use of these 
advantages to improve our understanding of Glut4 trafficking.
1.8.0 Summary o f our work
We begin Chapter 2 of this thesis by describing general materials and methods 
molecular biology behind the construction of the Glut4-GFP cDNAs. These constructs 
were then transfected into 3T3-L1 fibroblasts. Chapter 3, in order to investigate wild
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type and mutant Glutd-GFP distribution in a fibroblastic background. The localisation 
of Glut4"GFP was also compared to Texas Red Transferrin, an early endosomal marker. 
Finally we examined the effects of cytoskeleton-disrupting agents in Glut4-GFP~ 
transfected cells. Comparisons between our own results and those of other groups using 
conventional immunofluorescence techniques to examine Glut4 distribution are made in 
the discussion.
In Chapter 4 we examined wild type and Glut4~GFP distribution and translocation in 
3T3-L1 adipocytes, an insulin-responsive cell line. Again we compared Glut4-GFP and 
endosomal marker distribution. Furthermore, we investigated the movement of Glut4- 
GFP to the cell surface in response to insulin and describe what we believe to be a 
Glut4-specific reinternalisation mechanism following insulin-induced translocation. The 
implications of this Glut4-specific recycling mechanism are later discussed within the 
context of known Glut4 trafficking parameters.
Chapter 5 describes the molecular biology and biochemistiy used to construct and 
analyse ADP Ribosylation Factor (ARF) XTPases. Following recent research that 
suggests a role for ARFs 5 and 6 in insulin-induced Glut4 translocation we endeavored 
to make XTP-specific ARF5/6 in order to control ARF function in permeabilised 
adipocytes [56]. Site directed mutagenisis was used to convert the nucleotide specificity 
of ARFs 5 and 6 from GTP to XTP. Successfully mutated and epitope tagged ARF 
cDNA constructs were then expressed in HEK293 cells and analysed by 
immimoblotting. The long term goal of the ARF XTPases remains to examine the role 
ARFs 5 and 6 may play in Glut4-GFP translocation.
Finally, in Chapter 6 we move on from insulin-induced Glut4-GFP translocation to 
study Nitric Oxide-induced glucose uptake and translocation in L6 muscle cells. We 
examine the effects of nitric oxide donors and inliibitors of the nitric oxide signalling 
pathway on deoxyglucose uptake and cGMP levels within the cell. We suggest that 
nitric oxide-induced cGMP levels are closely linked to the rate of deoxyglucose uptake 
in L6 cells. However, we observed no effects of a nitric oxide donor on GFP-Glut4 
translocation.
In closing, we propose that GFP-tagged Glut4 provides a novel means to study Glut4 
trafficking in real time. Visualisation of Glut4-GFP in live cells gives us an insight into 
the dynamics of Glut4 movement not possible using conventional techniques. The 
ability to examine the subcellular distribution of Glut4 in live cells and in real time 
therefore represents a step forward in our understanding of Glut4 trafficking.
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2.0.0 General Materials and Methods
PIO and P l i  oligonucleotide sequences 
Sense Primer P 10
5 ' T T T T G G A T C C A G T A A A G G A G A A G A A 3 '■4----------- :----------  — --—-----------   :---- —>
BamH I GFP3 coding sequence 
Anti-Sense Primer PI 1
S ^ T T T T T C T A G A T C A C T T C A G G T C C T C C T C C G A G A T C A G
C T T C T G C T C C A T T T T G T A T A G T T C A T C S ^
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Chapter 2
2.1.0 Materials.
Nocodazole, Cytochalasin D, Chloroquine and Wortmannin were from Sigma, U.K.
Texas red transfenin and Lysotracker-Red® were from Molecular Probes (Leiden, The 
Netherlands). LY294002 was generously provided by Dr Simon Cook (BBSRC 
Babraham Institute, Cambridge, UK).
2.2.0 Molecular sub-cloning o f GFP3 by Polymerase Chain Reaction (PCR)
Two oligonucleotide primers (PIO and P l l )  were designed corresponding respectively 
to the 5' and 3' ends of the GFP3 cDNA. Primers were synthesised and supplied by 
Genosys, The PIO primer removed the start codon from GFP3 and introduced in its 
place a BamH I restriction site, whereas the PI 1 primer introduced an Xba I restriction 
site and a ‘myc’ epitope tag.
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Stop Xba I
The GFP3 cDNA was then amplified by PCR using Tag DNA polymerase and 
subcloned into an expression vector using the Eukaryotic TA Cloning® kit from 
Invitrogen. Taq polymerase has a nontemplate-dependent activity which adds a single 
deoxy-adenosine (A) to the 3 ' ends of duplex molecules. The linearised vector supplied 
with the Invitrogen kit has single 3' deoxythymidine (T) residues. This allows PCR 
inserts to ligate efficiently with the vector.
2.2.1 Insertion ofTaq-amplifiedPCR products into pCR3.1 vector 
The pCR3.1 vector DNA is T-tailed to allow for efficient ligation to the Tb^-amplified 
and A-tailed PCR product. However, the pCR3.1 vector also carries a eukaryotic 
cytomegalovirus promoter that allows for expression in a cellular background of any 
suitable cDNA subcloned into the multiple cloning site of pCR3.1.
\  ce lu i  P m n iu lc r
5' Vec tor
Figure 2.1 A-tailed PCR products generated by Taq DNA polymerase were ligated into the T-tailed 
eukaryotic expression vector pCR3.1
2.2.2 GFP cDNA PCR Protocol
1.0 pi of GFP3/pcDNA3 template DNA (50 ng/ pi)
2.5 pi PIO primer (50 pM)
2.5 pi PI 1 primer (50 pM)
5.0 pi lOx PCR Buffer 
0.5 pi lOOmM dNTPs
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37.5 pi sterile H2O
1.0 pi Taq DNA polymerase
PCR cycle parameters 
10 minutes 94°C 
1 minute 94°C “X 
1 minute 55°C ] 30 cycles
3 minutes 72°C 
10 minutes 72®C
2.2.3 Agarose gel analysis o f GFP cDNA PCR product
Following completion of the PCR, the DNA was purified with the Wizard PCR clean-up 
kit and re-suspended in 50 pi TE buffer (pH 7.6) (10 mM Tris.Cl, 1 mM EDTA). 5 pi of 
the resultant DNA (lane A, figure) solution was then checked by gel electrophoresis 
[188] on a 1% agarose TBE (0.09 M Tris Borate, 0.002 M EDTA) gel to verify the 
DNA product size against a Lambda DNA-BstE II Digest molecular weight standard 
(lane B, figure 2.2). The GFP3 cDNA migrated through the gel at a rate corresponding 
to its predicted molecular size of 700 base pairs.
[DNA size (base pairs)
Figure 2.2 The GFP3 cDNA PCR product was analysed by TBE agarose gel electrophoresis
The distance migrated by the GFP3 cDNA (Lane A) was then compared to a Lambda DNA-.85Æ II 
Digest molecular weight standard (Lane B).
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Where “X” ng is the amount of PCR product of “Y” base pairs to be ligated for a 1:1
Control Ligation GFP3/pCR3.1 Ligation
1 pi lOx ligation buffer 1 pi of 14 ng/pl GFP3 PCR DNA
5 pi sterile H2O 
Ligation reactions were incubated overnight at 14°C
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The DNA was then quantified by measuring its absorbance in TE solution at 260mn 
[188]. The GFP3 DNA A-tailed PCR product was then ligated into the Invitrogen 
pCR3.1 expression vector.
2.2.4 Ligation o f GFP cDNA into pCRS.l vector
To estimate the amount of PCR product needed to ligate with 60 ng of pCR3.1 vector.
the formula shown below was used.
Xng PCR product = (Y bp PCR product: 6001(60 ng pCR3.1 vector)
(size in bp of the pCR3.1 vector: 5044)
(vector:insei1) molar ratio. However, it is recommended that a 1:2 (vector:insert) ratio 
be used, so “X” was multiplied by 2 to calculate the amount needed for ligation.
2 pi pCR3.1 vector (30 ng/pl) 1 pi of lOx ligation buffer
2 pi pCR3.1 vector (30 ng/pl) 2 pi pCR3.1 vector (30 ng/pl)
: ;6 pi sterile H2O 2 pi pCR3,1 vector (30 ng/pl)
2.2.5 Bacterial Transformation
Subsequently, 2 pi of each ligation reaction was transformed into One Shot^^ TOPI OF'
competent cells as described in the Invitrogen TA Cloning Kit. Transformed cells were
spread onto agar plates containing 50 pg/pl ampicillin and grown overnight at 37°C.
Colonies were then picked from the GFP3/pCR3.1 agar plate and grown overnight in 3 
.ml LB medium containing 50 pg/pl ampicillin at 37°C in a rotary shaking incubator at 
225 rpm. Putative GFP3/pCR3.1 DNA was extracted from the resultant cultures by the 
alkaline lysis method of small-scale preparations of plasmid DNA [188].
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enzymes with the rationale that these enzymes would cut at the newly created BamH I
GFP3/pCR3.1 clones:
2.2.6 Restriction enzyme analysis o f putative GFP3/pCR3.1 clones
DNA from the putative GFP3/pCR3.1 clones was cut with BamH I and Xba I restriction
f‘ÿ;and Xba I restriction sites if the GFP3 PCR product had been successfully sub-cloned
into the pCR3.1 vector. 4
The following restriction digest was performed for each of the 18 putative
5.0 Hi putative GFP3/pCR3.1 DNA
j iS1.0 pi lOx multi-core buffer V
4.0 pi sterile H^O
'i0.5 pi BamH I f0.5 pi Xba I
I
Each of the digests was incubated for 2 hours in a 37°C water bath and then analysed by 
gel electophoresis on a 1 % agarose TBE gel.
Two of the eighteen putative clones yielded a DNA fragment, estimated at 700 
base pairs in length when compared to the DNA molecular weight marker, 
corresponding to the GFP3 cDNA positioned between the BamH I and Xba I restriction ’’Sisites. The bacterial cultures corresponding to GFP3/pCR3.1 clones 1 and 2 were frozen 
at -80°C (600 pi culture volume: 800 pi sterile 50% glycerol) so that cultures could be 
regrown and fresh DNA extracted at a later date.
However, the directionality of the GFP3 insert within these two clones remained
to be established. The nature of the TA Cloning Kit allows for the DNA PCR product to 
insert into the pCRS.l vector in either the sense or antisense orientation. Therefore, a 
single BamH I digest run alongside a BamH I, Xba I double digest, was performed to 
establish the orientation of the insert. DNA restriction digests were carried out as 
described above.
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Figure 2.3 The two possible alignments of the GFP3 cDNA within the pCR3.1 vector and the 
relative positions of restriction sites used to determine GFP3 cDNA orientation within clones
Following analysis on a 1% agarose TBE gel (figure 2.4) it was established that one of 
the two clones. Clone 1, contained the GFP3 insert in the correct orientation. The DNA 
sequence of this construct, GFP3/pCR3.1 was then verified by automated sequencing 
and found to contain no random mutations.
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Figure 2.4 Orientation analysis of the GFP3 cDNA PCR product within the pCR3.1 vector
Orientation was analysed by restriction digests with BamH 1 and BamH 1/Xba 1, followed by agarose gel 
electrophoresis. GFP3/pCR3.1 clones in which the GFP3 cDNA was correctly inserted into the vector 
backbone yielded no visible band when digested with BamH 1 (Lane A) and a 750 bp band when digested 
with BamH I/Xba 1 (Lane B). Resultant DNA bands were compared to a cDNA molecular weight marker 
(Lane E). Clones in which the GFP3 cDNA was incorrectly inserted into the vector backbone yielded 750 
bp bands when digested with Bam HI (Lane C) or BamH 1/Xba 1 (Lane D).
2.2.7 PCR amplification and sub-cloning o f wild type and mutant Glut4 into
cDNA in plasmid vectors for wild type rat Glut4 and each of the four Glut4 mutants 
used in this study (FAG, SAG, DAG and LAG) were supplied by Dr. D. James, 
University of Queensland. Two single stranded oligonucleotide DNA primers, PI and 
P9, corresponding to the 5 ' and 3 ' ends respectively of the Glut4 cDNA were designed. 
Primers were synthesised and supplied by Genosys. The PI primer introduced a Hind III 
restriction site immediately upstream of the Glut4 start site, whereas the P9 primer 
introduced a BamH I site in place of the Glut4 ‘stop’ codon. This BamH I site 
corresponds to the BamH I site introduced into the 5' end of the GFP3 cDN A by PCR 
and therefore allows an ‘in-frame’ fusion of the Glut4 and GFP3 cDNA to be 
constructed.
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PI and P9 oligonucleotide sequences 
Sense Primer PI
Start
5 ' T T T T A A G C T T G A C G A G A T G C C G T C G 3-4 »4 " » -4-Hind III
Antisense Primer P9
Kozak Glut4 coding 
sequence
5 T T T T G G A T C C G T C G T T C T C A T C T G G 3
P9 Sense
5 C C A G A T G A G A A C G A C G G A T C C A A A A 3----------------------------------------------------^4----------------►Glut4 c-terminus coding sequence 
minus ‘stop’ codon
BamH I
Schematic diagram of Glut4 and GFP3 cDNA fusion 
Hind III BamH I
Glut4
Xbal
I ’ l o n i o t o i \  c c t u i
Hind III BamH I
Figure 2.5 Overview of Giut4 cDNA ligation into the Hind III and BamH I sites of GFP3/pCR3.1.
The cDNA corresponding to wild type and mutant Glut4 was amplified by PCR using 
the PI and P9 primers under the conditions and parameters already described for the 
PCR amplification of the GFP3 cDNA. Similarly, the wild type and mutant Glut4 PCR
42
amplified cDNA fragments were A-tail subcloned into the Invitrogen pCRS.l vector as
previously described. Following mini-prep DNA extraction, the putative Glut4/pCR3.1
DNA clones were double digested with BamH I and Xba I restriction enzymes. Putative
.Glut4/pCR3.1 clones containing the correct insert yielded a DNA band corresponding to 
the Giut4 or Glut4 mutant cDNA upon a BamH I/Hind III double digest and agarose gel 
electrophoresis.
The wild type and mutant Glut4 cDNAs that yielded an insert upon restriction 
digests with BamH I and Hind III were sequenced as previously described and the 
corresponding bacterial cultures made into glycerol stocks and stored at -80°C. Once the 
sequence of the wild-type and mutant Glut4/pCR3.1 and tlie GFP3/pCR3.1 cDNAs had 
been verified, the corresponding glycerol stocks were thawed and used to inoculate 100 
ml LB (+ 50 pg/ml ampicillin). These bacterial cultures were grown overnight in an 
orbital shaker (225 rpm) incubator at 37°C. Plasmid DNA was then extracted from the 
bacterial cultures using the ‘Qiagen’ Maxi-Prep kit which works by the same alkaline 
lysis principal as that described for the ‘mini-preps’. The plasmid DNA thus obtained 
was quantified by measuring its optical density at 260 mn.
I
■j
,a:
2.3.0 Sub-cloning o f wild type and mutant Glut4 cDNA into the GFP3/pCR3.1 vector 
First the GFP3/pCR3.1, wild type Glut4/pCR3.1 and Glut4 mutant/pCR3.1 plasmid 
vectors were cut with the BamH I and Hind III restriction enzymes as shown:
8 pi (5 pg) GFP3/pCR3.1 5 pi (5 pg) wt Glut4/pCR3.1
4 pi lOx Multi-Core buffer or
24 pi H2O 5 pi (5 pg) mutant Glut4/pCR3.1
2 pi Hind III 2 pi lOx Multi-Core buffer
2 u l BamH I 11 plHzO
40 pi total 1 pi Hind III
20 pi total
Reaction mixes incubated at 37°C for 2 hours.
The 40 pi total volume of the GFP3/pCR3.1 reaction mix was then treated with calf 
intestinal phosphatase (CIP). CIP treatment removes the exposed 5' phosphate gi'oup
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from the plasmid vector DNA molecule, thus reducing the likelihood that the DNA 
vector will religate with itself rather than the chosen DNA insert;
40 pi GFP3/pCR3.1 reaction mix
20 pi lOx CIP buffer
130 pi H2O
10 ul CIP enzvme
200 pi total volume
Tube incubated at 37°C for 2 hours.
The 200 pi CIP-treated DNA solution was then phenol/chloroform extracted [188] to 
remove enzyme proteins and ethanol precipitated to remove the buffer, before 
resuspension in 10 pi T.E.
2.3.1 Agarose gel purification o f linearised, CIP-treated GFP3/pCR3.1 vector and wild- 
type/mutant Glut4 cDNA fragments
Each of the DNA samples was loaded onto a 1% agarose TAE gel and separated by 
electrophoresis. The appropriate DNA bands were cut from the gel with a clean razor 
blade and the DNA purified using the Wizard PCR Preps DNA Purification System. 
The samples were then resuspended in 50 pi H2O and 5 pi quantitated visually on 
another 1% TAE agarose gel.
2.3.2 Ligation o f wild-type and mutant Glut4 cDNA into GFP3/pCR3.1
Each of the wild type and mutant Glut4 cDNA fragments were ligated into the 
GFP3/pCR3.1 vector and transformed into One Shot™ TOPI OF' competent cells by 
means of the protocols previously described. Similarly, DNA was ‘mini-prep’ extracted 
from putative bacterial clones and restriction digested as shown before with BamH I and 
Hind III. DNA clones in which the Glut4 cDNA had successfrilly ligated into the 
GFP3/pCR3.1 vector yielded a 1500 base pair fragment, corresponding to the wild type 
or mutant Glut4 cDNA.
The plasmid DNA from the wild type or mutant Glut4-GFP3/pCR3.1 clones was 
sequenced as previously described to check for random mutations. Frozen glycerol 
stocks of the bacterial clones expressing the wild tjqie or mutant Glut4-GFP3/pCR3.1
4 4
■i'âconstruct were made as before and used to inoculate LB culture media prior to large 
scale ‘Maxi-Prep’ extraction of plasmid DNA.
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2.4.0 Sub-cloning ofGFP-Glul4 cDNA intopNOT.NOT 
A plasmid vector expressing GFP3-Glut4 was supplied by Dr. C. Livingstone, |
GFP3G4/pcDNAl. The following subcloning strategy was designed to transfer the 
GFP3G4 cDNA from pcDNAl (Invitrogen) into the pOP13.aP2 expression vector, via 
the pNOT.NOT shunt vector: The pOP13.aP2 expresion vector was chosen because the 
aP2 element represents a fat-specific promoter. Therefore, our GFP-Glut4 construct
when subcloned into pOP13.aP2 would be under the control of the aP2 element and /Atherefore only expressed in fully differentiated 3T3-L1 adipocytes. It was hoped that «
limiting the expression of GFP-Glut4 to an adipocyte background would overcome any 
potential problems arising from GFP-Glut4 expression while the cells remained 
preadipocytes.
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Hind III
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GFP3G4/pCR3.1 
9200 bp
"  Ssp I
Restriction digest 
w ith Ssp I
Ssp I
Hind III
Ssp I
4342 bp
Restriction digest w ith 
H ind IIISsp I
Hind III
Ssp IGliil4
2766 bp
Hind III
Ciiiitd
GFP3G4/pNOT.NOT 
5700 bp
Gel purified and subcloned 
into the pNOT.NOT shunt 
vector Ssp FSma I 
/  .Not I
Subcloned into the N ot I sites o f  
the pOP13 expression vector
Not I Hind III Ssp I
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Figure 2.6 Outline o f the process used to subcloiie GFP-GIut4 DNA into the shunt vector 
pNOT.NOT. and thereafter into the fat specific expression vector pOP13.aP2.
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Once the subcloning steps were complete, the nucleotide sequence of 
pOP13GFP3G4.aP2 was checked by automated sequencing, and the plasmid amplified 
using the Qiagen Maxi-Prep kit. The pOP13GFP3G4.aP2 was then transfected into 3T3- 
L1 fibroblasts as described below and stable cell lines selected.
2.5.0 Tissue culture
3T3-L1 fibroblasts were grown on polylysine-coated glass coverslips, with one 
coverslip in each well of a six-well tissue culture plate. Coverslips were dipped in 
polylysine solution for 10 minutes, dried off in a drying oven, then rinsed with distilled 
water and autoclaved before being placed in 6-well plates. Cells were then seeded into 
the tissue culture plates and maintained in Dulbecco’s modified Eagle’s medium high 
glucose supplemented with 10% calf serum and 1% penicillin/streptomycin, at 37 °C 
and 10 CO2.
Fibroblasts which were later to be differentiated into adipocytes were grown on 
collagen-coated coverslips. Collagen solution (Sigma, Type I Collagen) was applied to 
each well, swirled and then removed. The plates were dried with the lid off in the cell 
culture hood under an ultraviolet lamp and then washed with serum-free Dulbecco’s 
modified Eagle’s medium. Once the 3T3-L1 fibroblasts were four days post-confluency, 
differentiation into adipocytes was initiated. Throughout the differentiation process the 
same type of medium was used as that used to giow the fibroblasts, but with the calf 
serum replaced by 10% foetal calf serum. On the first day of the differentiation process 
the medium was supplemented with isobutylmethylxanthine (500 pM), dexamethasone 
(25 pM), and insulin (4 pg/ml). After 2 days the medium was replaced, supplemented 
with insulin (4 pg/ml) only. 2 days later and every 2 days thereafter, medium containing 
no supplements was used to feed the cells.
2.5.1 Stable cell line selection
The pOP13GFP3G4.aP2 DNA plasmid contains a neo R gene. Therefore, following 
transfection, any cell that stably incorporates the pOP 13 GFP3 G4. aP2 DNA into its own 
chromosomal DNA will also express the neo resistance gene and become resistant to the 
drug G418. The pOP 13GFP3G4. aP2 plasmid was transfected into 3T3-L1 fibroblasts 
grown to 30% confluency in 10 cm tissue culture plates. The following day, transfected 
cells, and untransfected control cells were treated with 500 pg/ml G418 to kill any cells
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not carrying the neo R gene. After 7 days of G418 treatment all the untransfected 
control cells were dead, and G418 resistant colonies, that had incorporated the
pOP13GFP3G4.aP2 plasmid into tlieir genome, were visible on the plates with I 
.transfected cells. These colonies were selected by placing cloning rings sealed with 
sterile Vaseline onto the base of the base of aspirated tissue culture plates and adding 
200 pi ti-ypsin to each ring. Tiypsinised cells from each individual cloning ring were 
then grown in separate 25 cm^ tissue culture flasks in medium supplemented with 300 
pg/ml G418,and then split into 5x 75 cm^ flasks. Once the clonal cells grown in 75 cm  ^
flasks approached confluency, they were frozen down [188] and stored in liquid 
nitrogen.
2.6.0 Cell microinjection
3T3-L1 adipocytes were grown on glass coverslips and injected at days 7 to 10 post­
differentiation using an Eppendorf microinjector system fitted on a Zeiss Axiovert 
microscope. A heated stage was adjusted to provide a temperature of 3TC  in the 
bathing medium (DMEM supplemented with 10% foetal bovine serum, 
penicillin/streptomycin and 20 mM Hepes pH 7.4) which was pre-equilibrated in a CO2 
incubator prior to use. Prior to injection, plasmid DNA diluted to a concentration of 
-200pg/ml in either dH20 or TE buffer was microfuged for 15 minutes to separate out 
any particulate matter and the supernatant DNA solution transferred to a fresh tube. For 
each coverslip, around 100 cells were injected into the nucleus with plasmid DNA at a 
pressure of ~ 20 hpa. Following injection, cells were washed twice with DMEM 
containing 10% foetal bovine serum and incubated in DMEM/foetal bovine serum 
overnight in a CO2 incubator at 37‘^ C.
2.7.0 Confocal microscopy
All of the GFP images described in this work were taken by confocal microscopy. We 
used this method rather than conventional fluorescent microscopy because confocal 
microscopy produces blur-free, crisp images of cells at various depths. Confocal 
imaging rejects the out-of-focus information by placing a pinhole in front of the 
detector, so that only the region of the specimen that is in focus is detected. Confocal 
imaging can only be performed by pointwise illumination and detection, hence a laser is 
used as a light souice in laser scanning microscopy.
I:
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Figure 2.7 Optical design of a confocal microscope
Light at a wavelength o f  488nm is emitted from laser (A) and passes through a small pinhole (B) and 
expands to fill the entrance pupil o f  the microscope objective lens. The objective lens focuses the light to 
a small spot on the specimen, green oblong, at the focal plane o f  the objective lens. Light reflected back 
from the illuminated spot on the cell is partially reflected by a beamsplitter (D) and directed at a pinhole 
(E) placed in front o f  the detector (F). The position o f  this pinhole (F) is what gives the system its 
confocal property, by blocking light that did not originate from the focal plane o f  the microscope 
objective. The ability to reject light from above or below the focal plane enables the confocal microscope 
to detect light emitting from just one depth within the specimen cell. A true 3D image can be processed 
by taking a series o f  confocal images at successive planes into the specimen and assembling them in 
computer memory.
This description shows how the confocal microscope detects light from one point in 
the cell, corresponding to one pixel in the image. The brightness of the pixel depends on 
the intensity of the light measured from that point in the cell. In order to collect an 
image of the whole area of interest the laser beam is moved with scanning mirrors to 
move the focused spot through the cell. The image is assembled pixel by pixel as the 
scan proceeds.
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Figure 2.8 The confocal microscope obtains an image in a different way from a conventional 
microscope
Most confocal microscopes scan a diffraction-limited spot over a cell in order to 
generate a confocal image. However, figure 2.8, illustrates how a wide-field microscope 
obtains an image all at once by illuminating the entire cell. This form of imaging is 
inherently an analogue process and requires the use of a CCD camera to convert it to a 
digital image. Scanning beam confocal microscopy on the other hand is a digital process 
as shown in figure 2.8. Therefore, by illuminating one point at a time, the scanning 
microscope gains a tremendous increase in light intensity when compared to a wide- 
field microscope.
2.7.1 Image capture and analysis
Cover-slips of injected cells were imaged using a Zeiss 4 Laser Scanning Confocal 
microscope operating in confocal mode using either 40X, 63X or lOOX Plan- 
APOCHROMAT 1.4 NA oil-immersion objectives, with samples on a heated stage 
adjusted so as to provide a temperature of 37°C in the bathing medium. Images were 
collected using either (or both) of 488 nm or 543 nm lasers with appropriate filter sets 
for collection of the GFP signal (band-pass 505-520 nm) or ‘red’ signals (long-pass 590 
nm). Data files were saved in .TIP format and analysed using MetaMorph software 
(Universal Imaging, CA). In order to quantitate the extent of GFP-GIut4 translocation to 
the plasma membrane, we employed MetaMorph software to isolate a region of interest 
which corresponded to a defined area just above and just below the plane of the plasma
50
51
membrane in a given confocal image. Fluorescence intensity in this area was expressed 
as a percentage of the total cellular GFP”Glut4 fluorescence. Such analysis corrects for 
variations in cell morphology and for expression level of GFP-Glut4 within individual 
cells and between separate experiments
2,7.2 3-Dimensional reconstructions and time-lapse movies
Z-sections of Glut4-GFP-transfected cells were made by taking confocal slices at 0.5 
pm intervals through the body of the cell. On average 25-30 such sections were taken 
through each cell, corresponding to an approximate cell height of 12-15 pm. Three- 
dimensional reconstructions of z-sections through Glut4-GFP-transfected cells were 
then built in computer memoiy using Metamorph software. Time-lapse movies were 
made by taking a confocal slice through the same section of a Glut4-GFP-transfected 
cell once every 30 seconds. On average, the time-lapse movies contain 30 frames, 
corresponding to 15 minutes of real time. The 3-d reconstructions and time-lapse 
movies were saved in TIF format and then converted into Quicktime files for writing to 
CD-ROM. For best results we recommend copying 3-d reconstruction and time lapse 
files from the CD-ROM onto a computer hard drive before viewing.
Î
2.8.0 Use offluorescently labelled markers for intracellular organelles.
3T3-L1 fibroblasts or adipocytes expressing GFP-Glut4 were incubated with Texas Red 
Transferrin (20pg/ml) or Lysotracker-Red® (50 nM) for 30 minutes at 37°C in serum- 
free DMEM in the incubator. Thereafter, cells were washed in KRP/glucose, transferred 
to the heated microscope stage at 37°C and images collected as outlined above.
2.9.0 2-Deoxyglucose uptake assay
All uptake assays were performed in tiiplicate on fully differentiated adipocytes grown 
in 6-well tissue culture plates. Following the approprate treatment, cells were washed 
once with 2 ml of Krebs Ringer Phosphate (KRP) buffer pH.7.4, then incubated for 20 
minutes in radioactive 50 pM 2-deoxyglucose (14C 2-deoxyglucose 0.1 pCi/ml). 
Uptake was stopped by three washes with ice cold phosphate buffered saline (PBS) pH. 
7.4 and the plates left to air dry. Thereafter, cells were then solubilized by incubation in 
1% Triton X-100 on an orbital shaker and the radioactivity associated with the cells 
determined by scintillation counting. Uptake values were corrected for the non-specific
I
association of sugars with the cells by substracting the uptake in the presence of 10 pM 
cytochalasin B, a potent inhibitor of transport.
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Chapter 3
3.0,0 Distribution of wild-type and mutant Glut4-GFP in a 3T3-L1 fibroblast 
background
3.1.0 Introduction
Fat and muscle are insulin-responsive tissues that redistribute Glut4 from an 
intracellular location to the plasma membrane upon insulin binding to its cell surface 
receptor [30, 189]. In the absence of insulin, when fat and muscle cells are analysed by
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,immunoelectron microscopy, Glut4 is found to reside within small intracellular vesicles 
[95] [96]. Similarly, when transfected into Chinese Hamster Ovary (CHO) cells or
■fibroblasts, Glut4 is distributed to punctate structures in the cell interior [190] [191] 
identified by immunoelectron microscopy as small vesicles [192]. Regardless of cell 
background, Glutl [193,194], Glut2 [195] and Glut3 [196] are targeted preferentially to 
the plasma membrane. These observations suggest that of all the glucose transporter 
isoforms, only Glut4 is targeted to an intracellular compartment in a number of different 
cell types. In adipocytes and skeletal muscle, distribution of Glut4 to this unique 
compartment may provide the basis for its specialised function as the insulin-regulatable 
glucose transporter.
Upon further examination in CHO cells, intracellular Glut4 was located within
endocytic structures distinct from early recycling endosomes defined by the presence of 
the transferrin receptor (TfR) [190]. In the same study, another marker TGN38 which 
labels the trans-Golgi network, also did not significantly colocalise with Glut4- 
containing vesicles. A similar study in the neuroendocrine cell line PC 12 also found 
little overlap between Glut4 and TfR [197]. Furthermore, Herman et al. saw little 
colocalisation between Glut4 and the unique synaptic-vesicle-specific protein 
synaptophysin, and the polymeric immunoglobulin receptor (plgR), a marker of 
transcytotic and endocytotic pathways when Glut4 was expressed in PC 12 cells. Taken 
together, these data indicate that following transfection of non-insulin responsive cells, 
a distinct subpopulation of Glut4 storage vesicle is observed. The function of this 
compartment within cells not normally associated with post-prandial glucose disposal 
may reflect a widespread ability of various cell types to modulate the cellular 
distribution of certain plasma membrane proteins.
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Targeting motifs within the N- and C- termini confer upon Glut4 its discrete 
intracellular location [191, 192, 198-200]. Piper et a l showed that an aromatic-based 
motif found in the N-terminus of Glut4 (FQQl) is crucial for the intracellular location of 
Glut4 in CHO cells. The mutation F5A resulted in the redistribution of Glut4 to the cell 
surface. Moreover, Verhey et a l observed that mutation of a dileucine motif in the C- 
tenninus of Glut4 is sufficient to alter the subcellular sorting of the transporter from its 
normal intracellular location to the cell surface in N1H3T3 cells. A dileucine pair has
also been implicated in the internalisation and lysosomal sorting of other plasma
.membrane proteins that include the T cell surface antigen CD4 [201] and the Mannose- 
6-Phosphate receptor [202]. Interestingly, the dileucine motif lies adjacent to the 
principal phosphorylation site in Glut4, serine 488 [203]. This serine residue is 
phosphorylated by cAMP-dependent protein kinase [203], Mutation of this residue 
impairs the internalisation of Glut4 when expressed in CHO cells [199] and therefore 
serine 488 phosphorylation may also play a significant part in the subcellular 
distribution of Glut4. All of the observed targeting motifs and phosphorylation states of 
Glut4 may in combination explain some of the unique properties of the insulin- 
regulatable glucose transporter.
Chloroquine is an acidotrophic drug that accumulates within acidic vesicles 
neutralising the pH. [204]. In insulin signalling, termination of signal transduction is 
achieved by endosomal insulin degradation following dissociation of insulin from its 
receptor as the intralumenal environment of the endosome acidifies [205]. Thus Bevan 
at a l showed that treatment of rats with chloroquine extends the lifetime of the 
activated insulin receptor complex in endosomes thereby enhancing the positive effects 
of insulin on glucose transport and glycogen synthesis. Presumably by the same 
mechanism in a clinical context, chloroquine has been shown to reduce insulin 
resistance in type 11 diabetes [206]. If a portion of the intracellular pool of Glut4 resides 
within acidic endosomes, chloroquine treatment may also be expected to have an effect 
on the normal subcellular distribution of Glut4.
Over the years our understanding of the cyto skeleton and the part it plays in cell 
function has changed from a position whereby the cytoskeleton plays merely a structural 
role. More recent studies have led to the realisation that elements of the cytoskeleton 
play a crucial role in cell movement, signalling and intracellular tafficking [207]. Both 
microtubules and actin filaments are implicated in the postendocytotic trafficking of the 
polymeric immunoglobulin receptor in MDCK cells [208]. Therefore microtubules and «
54
II
actin filaments may also be expected to play a role in the efficient trafficking of other 
plasma membrane proteins that recycle through endosomes, for example TfR and 
glucose transporters. Indeed, Jin et a l foimd that nocodazole, a microtubule 
depolymerising agent, does affect TfR recycling from the cell surface to endosomes in 
cultured human leukemia cells [209], Furthermore, Tsakiridis et a l showed that in L6 
muscle cells disruption of the actin cytoskeleton using Cytochalasin D, a widely used 
inhibitor of actin filament formation [210], prevented the recruitment of glucose 
transporters to the plasma membrane and inhibited the insulin-dependent stimulation of 
glucose transport [211]. In a similar study in 3T3-L1 adipocytes, Wang et a l implicated 
actin-dependent phosphatidylinositol 3-kinase (P13-K) relocalisation to glucose
• .transporter storage vesicles as a prerequisite to insulin-stimulated glucose transport
[212]. Although Clark et a l also put forward a role for actin in P13K localisation in 
adipocytes they failed, along with another study [213], to show any effect on insulin 
action of agents known to disrupt the cytoskeleton. Clearly, there are giminds for further 
research to explore the relationship between cytoskeletal elements and components of 
the insulin-stimulated glucose transport machinery.
In the work described in this chapter we used GFP-tagged Glut4 to resolve in a 
fibroblast background some of the questions outlined above. There are several 
advantages of using GFP-tagged protein chimeras to study aspects of Glut4 targeting 
distribution. Firstly, the native fluorescence of GFP allows visualisation of GFP-tagged 
molecules in living cells, eliminating any artifacts encountered in traditional 
immunofluorescence studies produced by the fixation process. Furthermore, since GFP 
allows us to visualise proteins in living cells, we can follow the trafficking of GFP- 
tagged molecules in real time. Using confocal microscopy we looked at the basal 
distribution of GFP-tagged wild type Glut4 in the 3T3-L1 fibroblasts. Then, we 
examined the relative importance of known targeting motifs within Glut4. Using 
molecular techniques GFP-tagged Glut4 mutants were made and their cellular 
distribution compared to wild type. Furthermore, colocalisation studies showed the 
degree of overlap between wild type or mutant Glut4-GFP and Texas-Red Transferrin, a 
marker for the endosomal recycling compartment. Finally, using the cytoskeleton- 
disrupting agents nocodazole and cytochalasin D we examined the relative contributions 
of microtubules and actin respectively on basal Glut4-GFP distribution.
We propose that even in a non-physiological background, Glut4-GFP displays a
distinct pattern of distribution similar to that of native Glut4 in muscle and fat cells. In
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addition, we suggest that the localisation of Glut4-GFP is intimately tied to the 
microtubule network of fibroblast cells.
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3.2.0 Materials and Methods
3.2.3 Image capture and analysis o f actin and microtubules
Actin and microtubules were labeled as described above and visualised under 
fluorescent light on a Zeiss inverted microscope using a 40X Plan-APOCHROMAT 1.4 
NA oil-immersion objective. Images were collected using a Charged Coupled Device 
(CCD) camera and data files saved in .TIP fom at and analysed using MetaMorph 
software (Universal Imaging, CA) on a desktop PC.
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3.2.1 Phallotoxin/Rhodamine staining o f actin filaments
3T3-L1 fibroblasts were grown to 80 % confluency on poly lysine-coated coverslips and 
given any appropriate drug treatment. Cells were then washed 3 times with PBS pH. 7.4 
at 37°C and fixed in 3.7% fonnaldehyde in PBS for 10 minutes at room temperature. 
Next the cells were washed 3 times with warm PBS and then pemieabilised in PBS + 
0.1% Triton X-100 for 5 minutes. Following another 3 washes with PBS, non-specific 
binding sites were blocked by incubating the cells in PBS + 1% Bovine Serum Albiunin 
(BSA) for 30 minutes. The cells were then incubated in room temperature in 
phallotoxin/rhodamine, diluted 1:40 in PBS + 1% BSA, and kept covered to prevent 
evaporation and photodegradation. Finally, cells were washed 3 times with PBS and the 
coverslips mounted on microscope slides with Tmmu-mount’ (Shandon)
3.2.2 Immunofluorescence staining o f microtubules
3T3-LI fibroblasts grown to 80% confluency on glass coverslips were washed 3 times 
with PBS pH.7.4 at 37°C and then fixed with 3.7% formaldehyde in PBS for 10 minutes 
at room temperature. The cells were then washed 3 times with PBS and permeabilised 
in PBS + 0.1% Triton X-100 for 5 minutes. Next, the cells were washed 3 more times in 
PBS before incubation in PBS + 1% BSA for 60 minutes to block non-specific binding 
sites. Mouse anti-tubulin primary antibody diluted 1:3200 in PBS + 1% BSA was added 
to the cells and incubated for 2 hours at room temperature. Subsequently, cells were 
washed 5 times in PBS before incubation with anti-mouse Texas-Red conjugated 
secondaiy antibody, diluted 1:200 in PBS + 1 %  BSA, for 2 hours. Cells were then 
washed 3 times in PBS and the coverslips mounted on microscope slides with Immu- 
mount.
■I
3.3.0 Results
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3.3.1 Transient expression o f Glut4~GFP chmeras in 3T3-L1 fibroblasts
A eukaryotic expression vector containing the cDNA that encodes Enlianced Green
Fluorescent Protein (EGFP) was purchased from Clontech. This plasmid was used as a
control when investigating the cellular distribution of Glut4-GFP chimeras in 3T3-L1
fibroblasts. At the molecular level, GFP cDNA was tagged to the N-teiininus (GFP-
Glut4/pcDNAl) or the C-terminus (Glut4~GFP/pCR3.1) of Glut4 in a suitable
eukaryotic expression vector. These GFP-tagged Glut4 DNA constructs were then
transfected into 3T3-L1 fibroblasts and their cellular localisation examined by LSM as
described. The GFP-Glut4 and the Glut4-GFP chimeras were found to have a similar 
.pattern of distribution within the cell. Regardless of whether Glut 4 was tagged with 
GFP at the N- or C- termini, the pattern of green fluorescence associated with Glut4 
within the cell was the same. Both GFP-Glut4 and Glut4-GFP were distributed to a 
perinuclear compartment and discrete punctate structures spread throughout the 
cytoplasm when transiently expressed in 3T3-L1 fibrobalsts (figure 3.2.2). However, 
when the EGFP control plasmid was transfected into fibroblasts, green fluorescence 
from EGFP was seen evenly dispersed throughout the cytoplasm and nucleus (figure
3.2.1). This suggests that the pattern of distribution seen when the Glut4-GFP chimeras 
are expressed in cells is a function of Glut4 targeting.
.3.3.2 Transient expression of GFP-tagged Glut4 mutants in 3T3-L1 fibroblasts 
Previous studies have shown that targeting motifs at both the N- and C- termini of Glut4 
are important for normal Glut4 targeting within the cell. The FAG, SAG, DAG and 
LAG Glut4 mutants that carry mutations within these targeting motifs were tagged with 
GFP at the C-terminus using molecular methods and subcloned into the eukaryotic
expression vector pCRS.l. Following transfection into 3T3-L1 fibroblasts, the cellular
.distribution of the GFP-tagged Glut4 mutants was examined by LSM and compared to 
that of GFP-tagged wild type Glut4 (figure 3.2.2).
.!3.3.3 FAGGFP distribution in 3T3-L1 fibroblasts
The Glut4 ‘FAG’ mutant carries a phenylalanine to alanine mutation at position 5 of a 
putative phenylalanine targeting motif in the N-terminus of Glut4. Following transient
■3
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expression of GFP-tagged FAG in 3T3-L1 fibroblasts, the distribution of green 
fluorescence associated with the FAGGFP chimera was noticeably different to that seen 
when GFP-tagged wild type Glut4 was transfected into the same cell type (figure 3.2.2). 
Whereas almost all wild type Glut4-GFP fluorescence was intracellular, the FAGGFP 
chimera was predominantly located at the plasma membrane. Fuithermore, the 
perinuclear compartment visible in wild type Glut4-GFP-transfected cells was less 
noticeable in cells expressing FAGGFP. This suggests that the phenylalanine residue at 
position 5 may be important for the intracellular retention of Glut4 in a fibroblast 
background.
ft.
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3.3.4 Distribution ofSAGGFP andDAGGFP in 3T3-L1 fibroblasts 
The C-terminus of Glut4 contains a serine phosphorylation site at position 488. We 
speculated that this phosphorylation site adajacent to a dileucine motif at positions 
489/490 may be important in Glut4 trafficking. Therefore two mutant Glut4 GFP 
chimeras were constructed that carry a mutation at this phosphorylation site. SAGGFP 
contains a serine 488 to alanine mutation, while DAGGFP carries a serine 488 to 
aspartate mutation. With the DAG mutant we hoped to simulate a phosphorylated serine 
488 by substitution with a negatively charged aspartate residue. However, when 
SAGGFP/pCR3.1 and DAGGFP/pCR3.1 were transiently expressed in 3T3-L1 
fibroblasts the subcellular organisation of green fluoresence seen under LSM was not 
noticeably different to that seen in cells transfected with wild type GFP-tagged Glut4 
(figure 3.2.2). This was illustrated by a perinuclear and punctate pattern of distribution 
within the cell. This leads us to conclude that the serine phosphorylation site at position 
488 of Glut 4 is not crucial to the intracellular distribution of wild type Glut4 when 
expressed in 3T3-L1 fibroblasts.
3.3.5 Transient expression ofLAGGFP in 3T3-LI fibroblasts
Glut4 cDNA encoding leucine to alanine mutations within the C-terminal dileucine 
motif of Glut4 (LAG) was ligated into the GFP3/pCR3.1 expression vector and 
transfected into 3T3-L1 fibroblasts. When visualised by LSM, the subcellular 
distribution ofLAGGFP appeared to alter depending on the level of chimera expression. 
In cells that appeared to express a high level of LAGGFP, judged by the total amount of 
fluorescence seen in the cell by LSM, a significant amount of LAGGFP was located at 
the plasma membrane (figure 3.2.2). However, in cells that showed a lesser degree of
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expression, the LAGGFP fusion protein did not appear to accumulate at the cell surface 
(figure 3,5). These results suggest that when expressed at high levels, LAGGFP may 
saturate a component the cell’s recycling mechanism and therefore accumulates at the 
plasma membrane. This observation therefore implies that the C-terminal dileucine 
motif is important in mediating the distribution of wild type Glut4 in a fibroblast 
background. Î
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3.3.6 Colocalisation studies o f Glut:4-GFP and Texas Red Transferrin 
Texas Red Transferrin is a commonly used cellular marker for the early endosomal 
recycling compartment. In order to establish whether our wild type Glut4-GFP and 
mutant Glut4-GFP species were occupying this endosomal compartment in 3T3-L1 
fibroblasts, Texas Red Transferrin (TRT) was added to Glut4-GFP-transfected cells in 
culture. The degree of colocalisation between the green and red channels, corresponding 
to GFP and Texas Red respectively, was examined by dual wavelength confocal 
microscopy. In areas where the colocalisation between the green and the red channels is 
complete the colours merge to yellow.
Figure 3.3A shows the colocalisation between GFP-Glut4 and TRT, whereas figure 
3.3B shows the overlap between Glut4-GFP and TRT in 3T3-L1 fibroblasts. The yellow 
areas in both of the merged images from figures 3.4A and 3.4B suggest that at least a 
portion of the GFP-tagged Glut4 resides in an endosomal compartment. However, there 
are also areas within the cell where the green and red channels do not overlap, 
indicating that there is another GFP-Glut4 pool out with the early endosomal recycling 
compartment.
GFP and TRT colocalisation experiments were also performed using the mutant 
Glut4-GFP constructs. SAGGFP (figure 3.4A) and DAGGFP (figure 3.4B) showed a 
degree of overlap with TRT similar to that seen when using wild type Glut4-GFP, 
suggesting that the serine 488 phosphorylation site is not involved in Glut4 
sequestration from the endosomal recycling compartment in 3T3-L1 fibroblasts.
However, the extent of colocalisation between TRT and FAGGFP (figure 3.5A) did 
appear different when compared to wild type Glut4-GFP and TRT. Most of the 
FAGGFP containing regions seen in figure 3.5A have direct Texas Red Transferrin 
counterparts, hence the large degree of yellow overlap seen in the merged images.
Therefore substitution of the phenylalanine residue at position 5 may cause the majority 
of Glut4-GFP to become trapped in endosomal recycling compartment and accumulate
at the plasma membrane. Furthermore, the overlap obsei*ved between LAGFP and TRT 
(figure 3.5B) was also somewhat different to that seen with wild type Glut4. A large
.Lr:.Àportion of the LAGGFP chimera was located within the perinuclear compartment of 
3T3-L1 fibroblasts, with few corresponding areas seen in cells labeled with TRT. This 
suggests that the dileucine motif in the C-terminal portion of Glut4 may be important 
for Glut 4 entry into the recycling endosomal compartment. Therefore, LAGGFP is 
restricted to a non-endosomal pool in 3T3-L1 fibroblasts and will accumulate at the 
plasma membrane if expressed at high levels.
3.3.7 Effect o f disruption o f the cell cytoskeleton on Glut4-GFP distribution 
Nocodazole is a known inhibitor of microtubule polymerisation, whereas cytochalasin 
D disrupts the fonnation of actin filaments. To test the effectiveness of nocodazole in 
3T3-L1 fibroblasts, cells were incubated with 10 jug/inl nocodazole for 60 minutes, 
fixed in 3.7% fonnaldehyde and the microtubules immunolabeled as described. 
Untreated cells displayed a reticular network of microtubules that was particularly dense 
around one side of the nucleus (figure 3.6A). This dense area of microtubules was taken 
to be the microtubule organising center (MTOC). The MTOC in 3T3-L1 fibroblasts 
broadly matched in terms of size and localisation the perinuclear compartment seen in 
Glut4“GFP transfected cell. However, in nocodazole-treated cells the microtubules were 
disorganised and the MTOC dispersed (figure 3.6B).
iTo investigate whether disruption of microtubules could alter the distribution of Glut4-GFP in 3T3-L1 fibroblasts, transfected cells were incubated at 37°C in the 
presence of nocodazole. Live cells were then visualised by confocal microscopy (figure 
3.7). In Glut4-GFP-tiansfected cells treated with nocodazole, the perinuclear 
compartment seen in untreated cells had dispersed. Furthermore, the discrete, punctate 
vesicles visible in the cytoplasm of untreated Glut4-GFP-transfected cells were more 
poorly defined. Incubation with nocodazole caused a similar pattern of GFP 
fluorescence in cells transfected with GFP-Glut4 or Glut4 mutant GFP species. These 
data are taken to imply that in a fibroblast background Glut4-GFP distribution is 
dependent upon an intact microtubule network, particularly in the region of the MTOC.
The ability of cytochalsin D to disrupt actin filaments in 3T3-L1 fibroblasts was 
verified by incubating cells in the presence of 25 pg/ml cytochalsin for 30 minutes and
1
immuno-staining with phalloidin-rhodamine. Fluorescence microscopy of untreated
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function by treatment with chloroquine leads to the accumulation of GFP-Glut4 at the
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cells showed linear actin filaments stretched across the body of the cell (figure 3.6C).
However, in cytochalasin D treated cells the characteristically straight actin filaments
were absent (figure 3.6D). Fibroblasts transfected with Glut4-GFP were also treated
with 25 qg/ml cytochalasin D and the live cells analysed by confocal microscopy. In
contrast to nocodazole-treated cells, the Glut4-GFP-transfected cells incubated with an 
.effective concentration of 25 pg/ml cytochalasin D looked no different to untreated cells 
(figure 3.8). Hence, an intact actin cytoskeleton does not appear to be a prerequisite for 
the distinctive distribution pattern of Glut4-GFP in transfected 3T3-L1 fibroblasts.
I3.3.8 Chloroquine treatment o f  Glut4-GFP-transfected 3T3-L1 fibroblasts Chloroquine is known to increase the pH. of endosomes when added to cells in culture 
and to inhibit recycling through the early endosomal compartment. The images from our 
colocalisation studies suggest that at least a portion of the GFP-Glut4 population in 
transfected 3T3-L1 fibroblasts is located within the early endosomes. Therefore, we 
treated GFP-Glut4-transfected cells growing in normal medium with 200 pM 
chloroquine for 2 hours and examined the pattern of GFP-associated fluorescence by
LSM. Transfected cells treated with chloroquine displayed a portion of GFP-Glut4 at
the plasma membrane and another L'action of GFP-Glut4 residing within abnormally
large cytoplasmic endosomes (figure 3.9). This data lends further weight to the
argument that part of the GFP-Glut4 population in transfected 3T3-L1 fibroblasts 
.resides within the endosomal compartment. Moreover, inhibition of normal endosomal
I
plasma membrane of transfected cells.
3.3.9 GFP-Glut4~expressing 3T3-LÎ stable cell lines 
Stable cells lines that express GFP-Glut4 in a differentiation-dependent manner were 
transfected and selected as described in materials and methods. However, upon analysis 
by confocal microscopy, none of the clonal G418-resistant 3T3-L1 cells lines displayed 
any green fluorescence associated with GFP-Glut4 expression. A few cells amongst a 
mixed population of G418-resistant 3T3-Ll’s showed some green fluorescence when 
examined at day 6 of the differentiation process (figure 3.1). However, even that small
population of fluorescent cells disappeared as differentiation continued. Following 
imsuccessful attempts to make stable cell lines with GFP-Glut4 expression under the
■ 't-i
control of either a constitutive or ‘fat dependent’ (ap2) promoter, no further efforts in 
the pursuit of this goal were made.
Figure 3.1 GFP-Glut4 is not amenable to the creation of a stable adipocyte cell line.
A selection o f  cells stably expressing GFP-Glut4 from a mixed population o f  3T3-L1 adipocytes at day 6 
post-differentiation.
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Figure 3.2.1 Comparison of EGFP and GIut4-GFP expression in 3T3-L1 fibroblasts
The control plasmid pEGFP (Clontech) was transfected into 3T3-L1 fibrobalsts (A) 
and the pattern of GFP-associated fluorescence compared with Glut4-GFP (B). Glut4-GFP was 
distributed to discrete intracellular vesicles, whereas EGFP was evenly dispersed throughout the cytoplasm.
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Figure 3.2.2 Basal distribution o f w ild-type amd mutant Glut4-GFP chim eras in 3T3-L1 fibroblasts
3T3-L1 fib rob lasts  w ere  grow n to 50%  con fluency  on po ly-L ysine-coated  coverslip s and then  transfected  w ith 
wild type or mutant Glut4 cDNAs tagged with GFP. The cells were then analysed by confocal m icroscopy 24 hours after transfection.
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Figure 3.3 C olocalisation between Glut4-GFP and the endosomal marker Texas Red Transferrin
Glut4 tagged with GFP at either the N- or C- terminus (figures A and B respectively) were transfected 
into 3T 3-L lfib rob lasts and their subcellular distributions compared with the early endosom al marker 
Texas Red Transferrin (TRT). The green left hand panel represents GFP-associated fluorescence, while 
the red centre panel shows the TRT marker. The merged right hand panel shows the overlap between GFP 
and TRT in the same cell. Regions where the colocalisation between GFP and TRT are greatest show as yellow on the merged image.
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Figure 3.4 Colocalisation o f SAG- and DAG GFP with Texas Red Transferrin in 3T3-L1 fibroblasts
SA G G FP (A ) and D A G G FP (B ) w ere transfected  into 3T3-L1 fibroblasts and their subcellu lar d istributions com pared 
with the early  endosom al m arker Texas R ed Transferrin  (TRT). The green left hand panel represents G F P-associated  fluorescence, 
w hile  the red  centre panel show s the TRT marker. The m erged right hand panel show s the overlap  betw een G FP and TRT in the 
sam e cell. Regions w here the colocalisation  betw een G F P and TRT are greatest show  as yellow  on the m erged im age.
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Figure 3.5 Colocalisation o f FAG- and LAG GFP with Texas Red Transferrin in 3T3-L1 fibroblasts
FAGGFP (A) and LA GG FP (B) w ere transfected into 3T3-L1 fibroblasts and their subcellular distributions com pared 
with the early endosom al m arker Texas Red Transferrin (TRT). The green left hand panel represents GFP-associated fluorescence, 
while the red centre panel shows the TRT marker. The m erged right hand panel shows the overlap between GFP and TRT in the 
sam e cell. Regions where the colocalisation between GFP and TRT are greatest ahow  as yellow  on the m erged image.
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Figure 3.6 Effect o f the drugs nocodazole and cytochalasin D on the m icrotubules and actin filam ents respectively in 
3T3-L1 fibroblasts
3T 3-L 1 fib ro b la s ts  w ere  tre a te d  w ith  10 p g /m l n o c o d a z o le  fo r 60 m in u tes  (B ), o r 25 pg /m l c y to c h a la s in  D 
for 30 minutes (D), or left untreated (A and C). Cells were then fixed and the microtubules stained, (A and B) or the 
actin filaments stained (C and D), as described in materials and methods. Images were captured using a CCD camera and saved onto a PC.
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F i g u r e  3 . 7  W i l d - t y p e  a n d  m u t a n t  G i u t 4 - G F P  d i s t r i b u t i o n  i n  n o c o d a z o l e - t r e a t e d  c e l l s
3T3-L1 fibroblasts were transfected with wild type or mutant GFP-tagged Glut4 and then treated for 60 minutes with 
10 pg/ml nocodazole, an agent that inhibits microtubule formation. The cells were then analysed by confocal microscopy. 
Changes in the distribution of Glut4-GFP and mutant Glut4-GFP in the presence of nocodazole are evident when compared to untreated cells (figure3.2.2).
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Figure 3.8 D istribution of GFP-G lut4 in cytochalasin D-treated 3T3-L1 fibroblasts
GFP-Glut4-transfected cells were treated for 30 minutes with 25 pg/m l cytochalasin D 
(A, B and C), an inhibitor o f  actin filament formation. The distribution o f  GFP-Glut4 was then anaysed by 
confocal microscopy and compared to GFP-Glut4 localisation in untreated cells (figure 3.2.2).
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F i g u r e  3 . 9  D i s t r i b u t i o n  o f  G F P - G l u t 4  in c h l o r o q u i n e - t r e a t e d  3 T 3 - L 1  f i b r o b l a s t s
GFP-Glut4-transfected 3T3-L1 fibroblasts were treated with 200 pM of the acidotrophic agent chloroquine (A and B). 
Following a two hour incubation with chloroquine,the distribution of GFP-Glut4 was analysed by confocal microscopy. 
C hloroquine was observed to  cause the sw elling  o f  G F -PG lut4-contain ing vesicles and to 
re d is tr ib u te  som e o f  the G F P -G lu t4  p o p u la tio n  to the  plasm a m em brane (se e  a rrow s).
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3.4.0 Discussion
3.4.1 G/wW-GÆP
Using molecular techniques we made GFP-tagged wild type Glut4 cDNAs. The Glut4- 
GFP cDNAs were then subcloned into eukaryotic expression vectors and transfected 
into 3T3-L1 fibroblasts. Following transient expression of the plasmid vectors, Glut4 
associated GFP fluorescence was analysed by confocal microscopy. We found that 
GFP-tagged Glut4, with GFP present at either the N- or C- terminal of Glut4, occupied 
two distinct locations within the cell. One location represented a large perinuclear 
compartment, within which the majority of the Glut4-GFP fluorescence resided. The 
other compartment comprised the many punctate Glut4-GFP vesicles present 
throughout the cytoplasm of the cell. At this level of resolution there were no 
differences in the pattern of distribution between Glut4 chimeras tagged at either the N- 
or C-terminus.
Texas-Red Transferrin is an early endosomal marker that we used in conjunction 
with Glut4-GFP to establish the compartment within which Glut4-GFP resides when 
transfected into 3T3-L1 fibroblasts. The unmerged red images of fibroblasts incubated 
with TRT show that the early endosomal system within these cells comprises punctate 
vesicles spread throughout the cytoplasm. Figure shows that when expressed in 3T3-L1 
fibroblasts, at least some of the total wild type Glut4-GFP population is present in the 
early endosomal system, identified by the yellow overlap signal seen in the merged 
images. However, clearly there are populations of Glut4-GFP, around the perinuclear 
compartment and within cytoplasmic vesicles that do not colocalise with Texas-Red 
transferrin. Again, within the limits of our image resolution, there were no apparent 
differences in the degree of over lap between either C- or N- terminus tagged Glut4~ 
GFP and TRT.
This pattern of Glut4 distribution in a fibroblast background broadly matches the 
findings of other researchers [192, 193]. We therefore conclude that our GFP-tagged 
Glut4 chimeras localise to an intracellular compartment that is at least morphologically 
similar to that occupied by untagged Glut4 when expressed in fibroblasts. This further 
implies that the large unwieldy GFP molecule tacked on to either the N- or C- terminus 
of Glut4 does not appear to interfere with Glut4 trafficking and distribution in fibroblast 
cells. The nature of this Glut4-GFP positive, Texas Red Transferrin negative
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Acompartment within 3T3-L1 fibroblasts remains to be elucidated. This compartment 
may represent a unique organelle within 3T3-L1 fibroblasts, the formation of which is 
stimulated by the expression of Glut4. If this were true, expression of endogenous Glut4 
during 3T3-L1 adipocyte differentiation would allow for the fomation of a unique 
organelle around which the cellular translocation machinery could be organised as 
differentiation progressed. However, we cannot exclude the possibility that the 
intracellular Glut4-GFP-containing vesicles correspond to a sub-compartment of an 
organelle such as the trans-Qolgi reticulum (TGN). Fibroblasts transfected with Glut4- 
GFP showed no discernable translocation of Glut4-GFP in response to insulin (data not 
shown), despite evidence that 3T3-L1 fibroblasts do express insulin receptors [214].
Therefore, we suggest that factors in addition to Glut4 expression within a discrete 
intracellular compartment and the presence of cell surface insulin receptors are required 
for Glut4 translocation.
The pattern of overlap observed between Glut4-GFP and Texas Red Transferrin 
in 3T3-L1 fibroblasts is in agreement to reports by other groups performing similar 
imiminofluorescent studies in CHO and PC 12 cells [190, 197]. Wei et al distinguished 
between Glut4 and transferrin containing compartments in CHO cells by double- 
labeling immunofluorescence assays. In these experiments Wei et a l showed that Glut4 
and TfR did appear to be colocalised to some extent in the perinuclear region. However, 
in the periphery of the cell, many structures enriched for Glut4 but not for the TfR were 
apparent. Similarly, work by Herman et al in the neuroendocrine cell line PC 12 showed 
that Glut4 immunoreactivity was detected in punctate structures throughout the 
cytoplasm and enriched in the perinuclear region. Furthermore, Hennan et a l found the 
majority of Glut4 did not codistribute with TfR, although a small amount of overlap was 
observed primarily in the perinuclear region.
In addition our colocalisation data is similar to results obtained in fully 
differentiated 3T3-L1 adipocytes [98]. Livingstone et a l showed that endosomal 
compartment ablation only caused a 40 % reduction in Glut4 translocation to the cell 
surface in response to insulin, suggesting that there is also a non-endosomal pool of 
insulin-responsive Glut4 within 3T3-L1 adipocytes. However, it is unlikely that a 
similar non-endosomal pool of Glut4 in 3T3-L1 fibroblasts would move to the cell 
surface in response to insulin as essential components of the translocation machinery, 
for example VAMP2 [107] may not be expressed in 3T3-L1 cells until differentiation 
into adipocytes is complete. Indeed, El-Jack et al have recently shown that expression
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of the transcription factors CCA AT/enhancer-binding protein a  (C/EBPa) and
peroxisome proliferator-activated receptor y (PPARy) are prerequisites for adipogenesis
and the establishment of insulin-sensitive glucose transport in a variety of murine
fibroblast cell lines [215].
To review, we transfected GFP-tagged Glut4 into 3T3-L1 fibroblasts and saw no
difference in the pattern of distribution of Glut4 with the GFP attached to either the N- 
.or C- terminus. When expressed in fibroblasts, Glut4-GFP was localised to a perinuclear
compartment and discrete punctate vesicles thioughout the cytoplasm. Colocalisation 
.studies with the endosomal marker Texas Red Transferrin showed only a partial overlap 
with Glut4-GFP. This data, in terms of Glut4 distribution and overlap with the 
endosomal marker TRT is largely in agreement with other work performed in a variety 
of both insulin-responsive and non-insulin responsive cell lines. This suggests that 
Glut4 is targeted to a class of vesicle present in a wide range of cell types. Herman et a l 
proposed that this may be a distinct organelle involved in transient cell surface 
modification without de novo synthesis of membrane protein. Based on our data we 
propose that GFP represents a novel means by which to study in real time Glut4 
trafficking through this distinct class of vesicles.
A
3.4.2 Distribution o f Glut4~GFP mutants in 3TB-LÎ fibroblasts 
In addition to wild type, Glut4 cDNA carrying mutations in either an N-terminal 
phenylalanine motif (FAG), a C-terminal dileucine motif (LAG) or a serine 
phosphorylation site (SAG or DAG) were linked to GFP and transiently expressed in 
3T3-L1 fibroblasts. In common with the findings of Piper et al 1993, FAGGFP was 
found to distribute predominantly to the plasma membrane, with an apparent 
concomitant decrease in the amount of GFP fluorescence emanating from the 
perinuclear compartment. This suggests that the phenylalanine residue at position 5 of 
Glut4 is important for Glut4 recycling between the interior of the cell and the plasma 
membrane. Similarly, in agreement with other studies [191, 216], we also found that 
when expressed at high levels, LAGGFP accumulated at the plasma membrane (Figure
3.2.2). However, unlike FAGGFP, LAGGFP displayed a particularly well defined 
perinuclear compartment. Serine 488 is the principal phosphorylation site in Glut4 and 
there is some evidence that this residue plays a part in Glut4 distribution in CHO cells 
[199]. Two mutant Glut4-GFP constructs were made; SAGGFP carried a serine 488 to
i
alanine mutation, whereas DAGGFP carried a serine 488 to aspartate residue to mimic a 
charged phosphate gimip. We found no difference in the intracellular distribution of 
SAG and DAG compared to wild type Glut4 when tagged with GFP and transiently 
expressed in 3T3-L1 fibroblasts (figure 3.2.2).
That mutation of a phenylalanine or dileucine motif should result in the aberrant 
targeting of Glut4-GFP is perhaps not surprising. Within the secretory pathway of 
mammalian cells, selected membrane proteins are sorted from the TGN through the 
endosomal pathway to the major hydrolytic compartment, the lysosomes [217]. This 
sorting process is directed by tyrosine-based and dileucine-based targeting signals 
[218]. These targeting motifs can interact with clathrin adaptors 1 and 2 (AP-1 and AP- 
2) [133, 218]. AP-1 and AP-2 co-assemble with clathrin into a coat that drives vesicle 
budding at the TGN and plasma membrane respectively prior to trafficking through the 
endosomal system [133, 218]. Therefore any plasma membrane protein bearing a 
mutation in these tyrosine or dileucine-based targeting motifs (FAG/LAG) may not be 
correctly sorted from the TGN or plasma membrane. Such a mechanism could explain 
the accumulation of FAGGFP at the cell surface if the mutation of phenylalanine to 
alanine prevented GIut4 interaction with AP-2. Similarly, a dileucine motif mutation 
may hinder the interaction between Glut4 and AP-1 at the TGN, and AP-2 at the plasma 
membrane, thereby causing an accumulation of LAGGFP at a perinuclear TGN 
compartment and at the cell surface.
Regarding the significance of serine 488 in Glut4 targeting, our results are 
somewhat different to those described in the literature. Garripa et a l characterised the 
trafficking motifs contained in the carboxyl terminus of Glut4 by constructing a chimera 
in which the carboxyl-terminal 30 amino acids of Glut4 were substituted for the amino- 
teiminal cytoplasmic domain of the transfeirin receptor. The distribution of this chimera 
was then analysed in CHO cells. In agreement with our results, the distribution of 
Glut4/TfR chimeras in which the dileucine motif of the carboxyl domain of Glut4 was 
mutated to a di-alanine sequence was shifted towards the cell suiface. However, Garripa 
et al also found a similar shift to the cell surface when the serine 488 phosphoiylation 
site of the Glut4 carboxyl tenninus was mutated to alanine or aspartate. We suggest that 
the fibroblast cell background in our experiments may explain the difference between 
our own results concerning the importance of the Glut4 serine phosphorylation site at 
position 488 and those of Garippa et a l Furthermore, it is not unreasonable to suppose 
that the serine phosphorylation site may work in conjunction with another targeting
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element within the structure of Glut4, for example the intracellular loop between helixes
V6 & 7. Therefore, when studying the C-terminal tail of Glut4 in isolation from the rest of 
the transporter as Garripa et ah have done, subtleties in targeting based upon 
intramolecular interactions may be overlooked.
Furthermore, we transiently expressed mutant Glut4-GFP constructs in 3T3-L1 
fibroblasts and colocalised with Texas-Red Transferrin. The degree of overlap between 
the serine 488 mutants (SAGGFP and DAGGFP) and TRT was similar to the extent of
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colocalisation between wild type Glut4-GFP and TRT (figure 3.4). This suggests that |
phosphorylation of serine 488 in Glut4-GFP is not essential for sorting between an early
endosomal and a non-endosomal compartment in 3T3-L1 fibroblasts. However 
LAGGFP, carrying mutations in the dileucine motif of Glut4 did appear to show 
somewhat less overlap with TRT (figiue 3.5B), particularly in the perinuclear region.
This may represent an accumulation of LAGGFP within the TGN or a unique non- 
endosomal Glut4 pool due to a compromised interaction between the mutant Glut4 
transporter and AP-L Notwithstanding, FAGGFP showed a more complete pattern of 
overlap with TRT when compared with wild type Glut4-GFP and TRT (figure 3.5A), 
suggesting that a large proportion of FAGGFP is trapped within the early endosomal ■%system of the cell as well as at the plasma membrane (figure 3.2.2). This result is in 
agreement with studies in 3T3-L1 adipocytes [219]. Using endosomal ablation Melvin
::A:et a l showed that in a 3T3-L1 adipocyte cell line stably expressing an F5A (FAG) AGlut4 mutant, the majority of the FAG was localised to the recycling endosomal |
pathway. In combination, these results suggest that the amino terminal FQQI motif 
functions in trafficking Glut4 from early endosomes.
In conclusion, we made mutant Glut4-GFP cDNA chimeras and transfected them into 
3T3-L1 fibroblasts. Mutants containing a phenylalanine to alanine substitution at 
position 5 (FAG) were predominantly located at the cell surface. Similarly, cells that 
expressed high levels of Glut4-GFP with leucine to alanine mutations at positions 489 
and 490 (LAG), also displayed Glut4 associated GFP fluorescence at the plasma 
membrane. In contrast, when Glut4-GFP chimeras carrying a serine to alanine mutation 
at position 488 of the transporter (SAG and DAG) were transfected into fibroblast cells, 
the pattern of mutant Glut4-GFP fluorescence appeared no different to wild type. |
Furthermore, we examined the degree of overlap between our mutant Glut4-GFP 
chimeras and the endosomal marker TRT. The extent of colocalisation between 
FAGGFP and TRT was substantial when compared to wild type, suggesting that the
majority of intracellular FAGGFP was located within the endosomal system. In contrast 
there appeared to be very little of the LAGGFP mutant distributed to the endosomal 
system. These data imply that phenylalanine 5 is crucial to the coiTect intracellular 
distribution of Glut4-GFP and the effective trafficking of Glut4 from the endosomal 
system to a discrete intracellular Glut4 pool in a fibroblast background. Furthermore, 
when expressed at high levels the dileucine motif of Glut4 also becomes important for 
the correct intracellular distribution of Glut4. The colocalisation data indicates that the 
C-terminal dileucine may also be involved in the trafficking of Glut4 away from a 
unique intracellular vesicle back into the endosomal system. In addition, we found that 
serine 488 appears to play no part in the extent of distribution of Glut4-GFP into the 
endosomal system of 3T3-L1 fibroblasts. In common with the results obtained 
expressing wild type Glut4-GFP, we found that mutant Glut4-GFP when transfected 
into 3T3-L1 fibroblasts behaves in a similar manner to that seen when expressed in 
other cell types. This suggests that the cellular machinery required for the typical pattern 
of wild type or mutant Glut4 distribution is a common feature of many cell types. The 
components of this cellular machinery that guide Glut4 distribution remain to be 
identified. Nevertheless, GFP-tagged Glut4 transporters would allow us to study in real 
time the downstream effects on trafficking of disruption of any one of these 
components.
3.4.3 Effect o f the acidotrophic agent chloroquine on Glut4-GFF distribution in 3T3-L1 
fibroblasts
The acidotrophic agent chloroquine neutralises the pH. of acidic endosomes when 
applied to cultured cells. In figure 3.9 we show that chloroquine disrupts the normal 
pattern of Glut4-GFP distribution in 3T3-L1 fibroblasts with the fonnation of large 
intracellular vesicles and Glut4-GFP accumulation at the plasma membrane. This result 
also lends weight to the suggestion that a portion of the total Glut4-GFP population in 
3T3-L1 fibroblasts resides within the acidic endosomal system. On the basis of this 
result we also speculate on the lowering of blood glucose seen in response to 
chloroquine in a clinical context [206]. In addition to the prolonged activated insulin 
receptor complex described by Bevan et al, chloroquine treatment may further improve 
glucose transport into the cell by impainnent of the endosomal recycling pathway and 
hence cause an increase in glucose transporter levels at the plasma membrane.
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3.4.4 Role o f the cytoskeleton in Glut4-GFP distribution in 3T3-L1 fibroblasts 
The role of the cytoskeleton in Glut4-GFP localisation in 3T3-L1 fibroblasts was 
examined using cytochalasin D, an inhibitor of actin filament assembly [210], and 
nocodazole [209] to depolymerise microtubules. In figure 3.6 we showed that 
cytochalasin D and nocodazole are effective at the concentrations used throughout the 
study. Figure 3.7 shows that incubation of Glut4-GFP-transfected 3T3-L1 fibroblasts in 
10 pg/ml nocodazole prior to visualisation causes disruption of the perinuclear 
compartment in cells expressing either wild type or mutant Glut4-GFP. We therefore 
conclude that microtubules are needed to maintain the integrity of the perinuclear 
compartment seen when Glut4-GFP is expressed in 3T3-L1 fibroblasts. Furthermore, 
there is no longer any evidence of FAGGFP accumulation at the plasma membrane in 
nocodazole-treated cells, suggesting that microtubules also play a part in FAGGFP
displacement to the plasma membrane or to retain the mutant transporter at the cell
surface.
3.4.5 Summary
To summarise, in this chapter we have shown that Glut4-GFP chimeras are efficiently 
expressed in 3T3-L1 fibroblasts and display a distinctive pattern of distribution within 
the cell. The importance of N- and C- terminal targeting motifs to Glut4-GFP 
localisation and their contribution to sorting within the endosomal system was 
established. Furthermore, we show conclusive evidence from cells imaged in real time 
that there are at least two pools of Glut4-GFP within 3T3-L1 fibroblasts; a TRT-positive 
endosomal pool, and a TRT-negative non-endosomal pool. Finally, we showed that 
microtubules play an intimate part between Glut4-GFP and its discrete pattern of 
distribution within the cell. In the next chapter we used the now established power of 
GFP-based studies to explore Giut4 trafficking in an insulin-responsive cell line.
I
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Chapter 4
4.0.0 Trafficking of GFP-Glut4 in adipocytes.
4.1.0 Introduction.
Insulin stimulates glucose transport in skeletal muscle and adipose tissue by virtue of 
the expression of the Glut4 glucose transporter isofoiin [151, 152], In the absence of 
insulin, this transporter is predominantly localised to intracellular membranes associated 
with the endosomal system, the trans Golgi network (TGN) and within tubular 
vesicular elements throughout the cytosol [94, 95, 220, 221]. In response to insulin, 
there is a rapid redistribution of Glut4 from these locations to the plasma membrane
'Vresulting in a dramatic increase in the rate of glucose transport into the cell [94, 95,220,
221]. Studies using transporter-specific photolabels have shown that Glut4 undergoes 
continuous recycling between the plasma membrane and intracellular membrane 
compartments in both the presence and absence of insulin [26, 29, 32, 86, 87].
Green Fluorescent Protein (GFP) [179, 222] from the jellyfish Aequoria victoria has 
revolutionised cell biology, being widely used to ‘tag’ proteins of interest and study the 
dynamics of their subcellular trafficking in living cells in real time [222]. Many 
membrane/membrane associated proteins have been studied using this method, 
including TGN38 [185], G protein-coupled receptors [187, 223] and proteins which 
utilise the secretory pathway [186]. As such, GFP fusions allow detailed analysis of the 
dynamics of the behaviour of membrane proteins in a variety of different experimental 
circumstances. To that end, we have used a range of GFP-Glut4 chimeras to further 
study the trafficking of Glut4 in adipocytes.
Using these Glut4-GFP chimeras we aimed to study a number of aspects of 
Glut4 trafficking. Firstly, we wanted to establish that the distribution and response to 
insulin of our Glut4-GFP chimeras was the same as described for endogenous Glut4.
Once satisfied that the distribution of Glut4-GFP miiTored that of native Glut4 we 
sought to characterise in real time wild type and mutant Glut4-GFP distribution and 
movement. Thirdly, we wanted to further characterise the intracellular Glut4 
compartment by comparing the distribution of Glut4-GFP with markers for the 
endosomal, lysosomal system. Finally, we aimed to study the relationship between the 
Glut4-GFP-containing compaitment and the cell cytoskeleton using agents that disrupt 
microtubule formation.
.'■3
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1IîWe show that two chimeras of GFP-Glut4 (GFP at either the N- or C- terminus)
localise to intracellular membranes within 3T3-L1 adipocytes and exhibit insulin-
dependent translocation to the plasma membrane with kinetics similar to that of the
endogenous protein. These chimeras exhibit limited overlap with TfR, appear to recycle
.between the plasma membrane and intracellular compartment(s) in the absence of 
insulin, and are localised to compartments distinct from both late endosomes and 
lysosomes. In contrast to native Glut4, removal of the insulin stimulus or treatment of 
insulin-stimulated cells with PI3K inhibitors did not result in re-intemalisation of either 
chimera from the plasma membrane, suggesting that the recycling properties of GFP- 
tagged Glut4 differs from the native Glut4 molecule. We suggest that the recycling 
pathway utilised by GFP~Glut4 in the absence of insulin is distinct from that used to 
internalise GFP-Glut4 from the plasma membrane after withdrawal of the insulin 
stimulus, which may in turn represent distinct pathways for internalisation of 
endogenous Glut4 in adipocytes.
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4.2.0 Materials and Methods.
4.2.1 Construction o f Glut4-GFP chimeras 
The Glut4“GFP constructs used in this study were the same as those described in 
Chapter 3.
Î4.2.2 Insulin-stimulation experiments.Prior to experiments, coverslips of microinjected cells were incubated in serum-free 
DMEM in a COa-incubator for 2h. After this time, either insulin (100 nM) or vehicle 
were added to duplicate plates and the incubation continued for times between 2 and 30 
minutes in the incubator. Thereafter, cells were rapidly washed into KRP (130 mM 
NaCl, 5 mM KCl, 1.2 mM MgS04 , 1.2 mM CaCb, 20 mM Hepes, 1.2 mM Na2HP04 , 
pH 7.4) containing 10 mM glucose at 37°C and viewed on a Zeiss Axiovert microscope 
as described below.
s'-f,::
4.2.3 Insulin reversal experiments.
For analysis of insulin reversal, the following experimental conditions were employed.
After stimulation with insulin for 30 minutes as outlined above, cells were washed once 
with semm-free DMEM at 37°C and then either (i) incubated with anti-insulin 
antibodies in DMEM exactly as outlined in [224], or (ii) washed repeatedly in KRM 
buffer (as KRP except the Hepes was replaced with 20 mM MES at pH 6.0) for the 
times indicated in the figure legends on a hot plate at 37°C prior to microscopic 
examination. In experiments using PI3K inhibitors, cells were washed in serum-free 
DMEM at 37°C then incubated in serum-free DMEM containing either wortmannin (50 
- 250 nM) or LY294002 (10 pM) for the times indicated in a CO2 incubator. In order to 
insure that these conditions effectively reversed insulin action, deGlc transport or Glut4 
plasma membrane lawn assays were performed contemporaneously on parallel plates of 
cells using methods described [100,107].
I4.2.4 Potassium-depletion experiments.Coverslips of cells expressing GFP~Glut4 were washed twice in either KRP or KRP in 
which the potassium chloride was replaced with sodium chloride, then incubated on a 
hot plate in 4 ml of the buffer for 2h prior to image capture, which was performed in the 
same buffer.
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4.2.5 Immunofluorescence analysis o f endogenous Glut4.
Endogenous Glut4 was localised in acetone fixed cells using an antibody against the C- 
terminus of Glut4. Treated cells grown on glass coverslips were washed with ice cold 
PBS and then fixed by incubation in ice cold acetone for 5 minutes. Next, fixed cells 
were washed 3 times with PBS and then washed a further 3 times over a period on 1 
hour with PB S/5 % goat serum, that served to block non-specific binding sites. 
Subsequently, coverslips were turned upside down and incubated on parafilm in 100 pi 
anti-Glut4 antibody diluted 1:200 in PBS/1% goat serum. The cells were then washed 3 
times in PBS\1% BSA before incubation with FlTC-conjugated secondary antibody, 
diluted 1:200 in PBS/2.5% goat serum, for 30 minutes. Finally, the cells were washed 3 
more times with PBS before mounting onto microscope slides with 15 pi Mowiol. The 
mounted slides were left to dry overnight before imaging on the confocal microscope 
using the default FITC settings.
4.2.6 Statistical Analysis
Statistical analysis was performed using StatYiew 4 (Abacus, CA).
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4.3.0 Results
I
4.3.1 Expression o f GFP-Glut4, Glut4-GFP and GEP-GlutI in 3T3-L1 adipocytes by 
microinjection and the effects o f insulin
As described in Chapter 2 we were unsuccessful in our attempts to make a 3T3-L1 
adipocytes cell line that stably expressed our GFP-Glut4 chimera. Therefore, we chose 
to express GFP-Glut4 in 3T3-L1 adipocytes transiently. To this end we employed a 
wide variety of chemical transient transfection strategies. However, each of the methods 
used gave little or no GFP-Glut4 expression. Consequently, we resorted to direct 
nucleus microinjection in order to express GFP-Glut4 in 3T3-L1 adipocytes. Although
more successful than our attempts with transient transiection, the labour-intensive
microinjection approach did somewhat limit the power of our system. As a consequence 
.of the microinjection strategy we were unable to undertake quantitative biochemical 
experiments and were therefore limited to qualitative fluorescent analysis using the 
confocal microscope.
The N-tenninal GFP Glut4 chimera (GFP-Glu4) and the C-terminal GFP Glut4 
chimera (Glut4-GFP) cDNAs were the same as those described in Chapter 3. These
.cDNAs were microinjected in the nuclei of 3T3-L1 adipocytes and imaged by confocal
analysis as described in Materials and Methods. In the absence of insulin, GFP-Glut4
and Glut4»GFP displayed a predominantly intracellular localisation (figure 4.1). Upon
treatment with ljuM insulin, both GFP-Glut4 and Glut4-GFP translocated to the plasma
membrane within a 15 minute time span.
The GFP-tagged Glutl construct (GFP-Glutl) was made and generously supplied by 
.J. Wakefield in our laboratory. When injected into 3T3-L1 adipocytes the distribution of 
Glutl-GFP was noticeably different from the GFP-tagged Glut4 chimeras (figure 4.1).
In the basal state GFP-Glutl was observed at both the plasma membrane and within 
intracellular structures. Upon treatment with insulin, there was little evidence of GFP- 
Glutl translocation to the plasma membrane. Quantification of the extent of insulin- 
stimulated translocation of GFP-Glut4, Glut4-GFP and GFP-Glutl is presented in figure
4.1.
j
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■|I4.3.2 Effects o f nocodazole and chloroquine on GFP-Glut4 distribution in 3T3-L1 
'adipocytes
The microtubule-disrupting drug nocodazole was added directly to the media of Glut4- 
GFP-injected 3T3-L1 adipocytes at a concentration of 10 pg/ml. Following an hour- 
long incubation, nocodazole caused disruption of punctate Glut4-GFP-containing 
vesicles and dispersal of the Glut4-GFP positive perinuclear compartment (figure 4.2). 
In addition, some accumulation of Glut4-GFP at the plasma membrane was observed in 
nocodazole-treated cells. When the acidotrophic agent chloroquine was added to 
injected adipocytes, the intracellular Glut4-GFP vesicles appeared swollen and a portion 
of the Glut4-GFP population was observed to accumulate at the plasma membrane 
(figure 4.2).
4.3.3 Colocalisation o f GFP-Glut4 with Texas Red Transferrin or Lysotracker~Red^
In order to further characterise the Glut4-GFP intracellular compartment we performed 
colocalisation experiments between Glut4-GFP and the early endosomal marker Texas 
Red Transferrin (TRT) or Lysotracker® to identify the late endosomes/lysosomes. 
Glut4-GFP-injected adipocytes were incubated with TRT or Lysotmcker® and analysed 
by confocal microscopy (figure 4.3). In all experiments, only partial overlap between 
Glut4-GFP and the Texas Red Transferrin itinerary was observed. Even less 
colocalisation was evident when the Glut4-GFP pattern of distribution was compared 
with intracellular Lysotracker®.
,4.3.4 FAG-GFP andLAG-GFP exhibit distinct localisation
3T3-L1 adipocytes were microinjected with plasmid DNA encoding either FAG-GFP or 
LAG-GFP and incubated for 24h prior to analysis. Shown are representative cells 
expressing FAG-GFP or LAG-GFP.(figure 4.4.1) The cells shown are representative of 
>10 experiments of this type. In all cells observed, FAG-GFP accumulated at the 
plasma membrane of 3T3-L1 adipocytes. Similarly, in LAG-GFP-injected cells, LAG- 
GFP accumulated at the plasma membrane in adipocytes displaying high levels of GFP 
chimera expression, as judged by the relative intensity of GFP-associated fluorescence. 
In addition, a pronounced LAG-GFP-containing perinuclear compartment was
I
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4.3.5 DAG-GFP and SAG-GFP distribution and the effects o f insulin 
The SAG-GFP and DAG-GFP constructs carry a mutation in the serine 488 
phosphorylation site of Glut4. SAG carries an S488A and DAG a S488D mutation. 
When these chimeras were expressed in 3T3-L1 adipocytes, the pattern of intracellular 
distribution as analysed by confocal microscopy was indistinguishable from wild type 
Glut4-GFP (figure 4.4.1). Furthennore, upon stimulation with insulin at 37^C in a CO2 
incubator, both DAG-GFP and SAG-GFP were observed to translocate to the plasma 
membrane (figure 4.4.2). In each case the proportion of total DAG-GFP/SAG-GFP that 
translocated to the plasma membrane and the time course of movement was very similar 
to Glut4“GFP,
#
4.3.6 Colocalisation o f GFP-tagged FAG, LAG, DAG and SAG with Texas Red 
Transferrin
Analogous to the experiments described with Glut4-GFP, GFP-tagged FAG, LAG,
DAG and SAG were colocalised with Texas Red Transferrin (TRT). The degree of 
colocalisation between FAG-GFP and TRT was considerable (figure 4.5A), and the 
areas of overlap more extensive than between Glut4-GFP and TRT (figure 4.3). In 
contrast, the extent of colocalisation between LAG-GFP and TRT (figure 4.5B) 
appeared much less marked when compared to Glut4-GFP and TRT (figure 4.3), 
especially in the environs of the LAG-GFP perinuclear compartment. When the same 
type of experiment was perfonned using GFP-tagged DAG and SAG chimeras (figure 
4.6), the extent of overlap with the TRT itinerary was indistinguishable from Glut4-GFP
and TRT at tliis level of resolution.
I:Ï:
4.3.7 Reversal o f insulin-stimulated glucose transport and Glut4 translocation in 3T3- 
LÎ adipocytes by low pH  washing or wortmannin treatment
For comparison with Glut4-GFP internalisation following insulin treatment we 
examined the effctes of reversal of insulin-stimulated glucose transport and endogenous 
Glut4 translocation in 3T3-L1 adipocytes. Cells were treated with 100 nM insulin for 30 
minutes and then assayed for glucose transport following a low pH wash or wortmannin 
treatment (figure 4.7). In addition plasma membrane lawn assays were performed under
:similar conditions to measure the extent of Glut4 translocation. As expected both of
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these methods were shown to reverse insulin-stimulated glucose transport and Glut4 
translocation in wild-type 3T3-L1 adipocytes.
4.3.8 GFP-Glut.4 is not internalised after insulin withdrawal
3T3-L1 adipocytes were microinjected with DNA encoding GFP-Glut4 and incubated 
for 24 h. Cells were then incubated in serum-free DMEM for 2h, then insulin was added 
(100 nM) for a further 30 minutes to induce GFP-Glut4 translocation. To test the ability 
of GFP-Glut4 to reintemalise following insulin stimulation we then either (a) 
transferred cells to a hot-plate at 37°C and rapidly washed in KRM buffer, pFI 6 for 0,
30 or 60 min. Or, (b) transferred to a hot plate and washed into KRP buffer ± 50 nM 
wortmannin and incubated for 60 min prior to image analysis (figure 4.8). The results 
show that following a low pH wash or wortmannin treatment, GFP-Glut4 is still not 
reinternalised from the plasma membrane to any significant extent.
4.3.9 Potassium-depletion results in the accumulation o f GFP-Glut4 at the plasma 
membrane.
To examine whether GFP-Glut4 recycles between the intracellular Glut4-storage vesicle 
and the plasma membrane we incubated GFP-Glut4-inj ected adipocytes in K^-depleted 
buffer. 3T3-L1 adipocytes expressing GFP-Glut4 were washed into KRP either with or 
without K"^ . After a 2 hour incubation on a 37°C hot-plate the cells were imaged by 
confocal microscopy. Cells from each of the two conditions are shown in figure 4.9.
Substantial increases in levels of plasma membrane-associated GFP-Glut4 fluorescence 
were observed in cells pre-incubated in the K^-depleted buffer. To ensure that 
endogenous Glut4 also accumulates at the plasma membrane under the same conditions, 
3T3-L1 adipocytes were incubated in K^-depleted buffer and then analysed by whole 
cell imunofluorescence as described in Materials and Methods. Similar to our findings 
in GFP-Glut4 expressing cells, endogenous Glut4 also accumulated at the plasma 
membrane when incubated in a K^-depleted buffer (figure 4.9).
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4.4.0 3~D reconstîmctions and time-lapse movies
3-D reconstructions and time lapse movies of 3T3-L1 adipocytes injected with Glut4- 
GFP cDNAs are available on the accompanying CD-ROM. For a complete index of all 
files on the CD-ROM see the accompanying Word document.
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Figure 4.1 Expression of GFP-GIut4, Glut4-GFP and GFP-Glutl in 3T3-L1 adipocytes and the effcets of insulin
3T3-L1 adipocytes were microinjected with plasmid DNA encoding the GFP-chimera indicated on the figures. After 24 h 
incubation in DMEM containing 10% foetal bovine serum, cells were incubated in serum-fi-ee DMEM for 2h. Insulin or 
vehicle were added directly to the DMEM in a COj incubator for times from 5 to 60 minutes. The microinjected cells were then 
washed into KRP buffer containing 10 mM glucose and imaged by confocal microscopy as described using the 488 nm laser for 
excitation of the GFP. Shown in Figure Panel A are representative cells expressing the different GFP-chimeras incubated 
+\- insulin for 30 min. Quantification of several experiments of this type to determine the fold increase in plasms membrane 
associated GFP-Glut4 is shown in Panel B. In these experiments, the amount of GFP-Glut at the plasma membrane is expressed 
as a percentage of the total cellular GFP-Glut, calculated as outlined in Materials and Methods. The modest increase in plasma 
membrane-associated GFP-Glutl was not statistically significant. For both GFP-Glut4 and Glut4-GFP, in the absence of insulin, 
only ~10% of the total cellular GFP signal was localised to the plasma membrane. In contrast, for GFP-Glutl, -40% of the total 
c e l l u l a r  G F P  s i g n a l  w a s  p l a s m a  m e m b r a n e  l o c a l i s e s  i n  t h e  b a s a l  s t a t e .
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Figure 4.2 Disruption of GFP-Glut4 distribution by chloroquine or nocodazole
G F P - G lu t4 4 n je c te d  3 T 3 -L 1  a d ip o c y te s  w e re  t r e a te d  w ith  e i th e r  2 0 0  pM  o f  th e  a c id o t r o p h ic  
agent Chloroquine (A) or 10 pg/ml o f the microtubule-disrupting drug nocodazole (B) prior to analysis by confocal microscopy.
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Figure 4.3 Colocalisation of GFP-Glut4 with Texas Red Transferrin or Lysotracker
After a 2 h incubation in serum-free DMEM, 3T3-L1 adipocytes expressing GFP-Glut4 were further 
incubated in serum-free DMEM containing either Texas Red Transferrin (20pg/ml) or Lysotracker-Red 
(50 nM) for 30 minutes at 37°C in a CO2 incubator. Thereafter, ceils were gently washed in 
KRP/glucose, transferred to the heat microscope stage at 37°C and images collected using confocal 
microscopy as outlined. (Figure 2) Shown in the left panel is the GFP-Glut4 signal (excitation 488 nm 
laser, filter 505-520 nm band pass), the middle panel is the corresponding signal from the Texas Red 
Transferrin or Lysotracker-Red® (excitation using 545 nm laser, long-pass 590 nm filter). The right 
hand panel is the merged image. The cells shown are representative o f  at least 5 experiments o f  this 
type. Areas o f  the cell where there is pronounced overlap between the GFP and Teaxs Red signals are 
indicated by yellow in the merged images.
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Figure 4.4.1 Distribution of FAG-, LAG-, DAG- and SAG-GFP in 3T3-L1 adipocytes
The GFP-tagged Glut4 cDNA mutants FAG (F5A, panel A), LAG (L489A, L490A, panel B), DAG (S488D, panel C), 
and SAG (S488A, panel D) were microinjected into the nucleus o f  3T3-L1 adipocytes and anaysed 24 hours later by confocal microscopy 
LAG-GFP Hi and LAG-GFP Lo were cells judged to  express high and low levels o f  LAG-GFP protein respectively.
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Figure 4.4.2 DAG-GFP and SAG-GFP tranaslocate to the plasma membrane in response to insulin
DAG-GFP and SAG-GFP were microinjected into 3T3-L1 adipocytes and treated with 100 nM insulin. Cells were then 
analysed by confocal microscopy. Both DAG-GFP and SAG-GFP displayed insulin-induced movement to the plasma 
membrane. This data suggests that Ser 488 is not critical for the translocation process.
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Figure 4.5 FAG-GFP and LAGGFP colocalise with Texas Red Transferrin to different extents
FAG-G FP (A) and LA G -G FP (B) w ere m icroinjected into 3T3-L1 adipocytes and their subcellu lar distributions com pared 
with the early  endosom al m arker Texas Red Transferrin  (TRT). The green left hand panel represents G FP-associated fluorescence, 
while the red centre panel show s the TR T m arker. The m erged right hand panel show s the overlap betw een G FP and TRT in the 
sam e cell. R egions w here the colocalisation  betw een G FP and TRT are greatest show  as yellow  on the m erged image. 
The overlap betw een FA G-G FP and TR T w as considerable, suggesting that FAG-GFP is d istributed to  early  endosom es. However, 
the degree o f  colocalisation betw een LA G -G FP and TRT w as judged  to be even less than betw een G lut4-G FP and TRT.
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Figure 4.6 The degree of colocalisation between DAG- or SAG- GFP and Texas Red Transferrin is the same as between 
Glut4-GFP and TRT
DAG-GFP (A) and SAG-GFP (B) were microinjected into 3T3-L1 adipocytes and their subcellular distributions compared 
with the early endosomal marker Texas Red Transferrin (TRT). The green left hand panel represents GFP-associated fluorescence, 
while the red centre panel shows the TRT marker. The merged right hand panel shows the overlap between GFP and TRT in the 
same cell. Regions where the colocalisation between GFP and TRT are greatest show as yellow on the merged image. 
When compared to the overlap between Glut4-GFP and TRT (Figure 4.3), an equivalent degree of colocalisation 
i s  o b s e r v e d  b e t w e e n  D A G -  or  S A G - G F P  a n d  T R T  i n 3 T 3 - L 1  a d i p o c y t e s .
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Figure 4.7 Reversal of insulin-stimulated glucose transport and Glut4 translocation in 3T3-L1 adipocyte by 
low pH washing or wortmannin treatemnt
3T3-L1 adipocytes were incubated in serum-free DMEM for 2h, then insulin was added (lOOnM) for a further 
30 minutes. After this time, cells were transferred to a hot-plate at 37°C and rapidly washed in KRM buffer, 
pH 6 for the times shown then plasma membrane lawn assays for Glut4 were performed, presented in panel A 
Quantification o f  the data in p anel A is shown in panel B. Cells were assayed for glucose 
uptake {panel C) under similar conditions. In panel D, the effect o f addition o f 50 nM wortmannin for the times 
i n d i c a t e d  o n  b a s a l  a n d  i n s u l i n - s t i m u l a t e d  d e o x y g l u c o s e  t r a n s p o r t  i s  s h o w n .  
( N o t e  that  the wor k  s h o w n  in t hi s  d i agr am w a s  p e r f o r me d  by Dr.  Kat e  P o w e l l ) .
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Figure 4.8 GFP-Glut4 is not internalised after insulin withdrawal.
3T3-L1 adipocytes were micro injected with DNA encoding GFP-Glut4 and incubated for 24 h. Cells 
were then incubated in serum-free DMEM for 2h, then insulin was added (100 nM) for a further 30 
minutes. After this time, cells were either (a) transferred to a hot-plate at 37°C and rapidly washed in 
KRM buffer, pH 6 for 0, 30 or 60 min as indicated on the figures or (b) transferred to a hot plate and 
washed into KRP buffer ± 50 nM wortmannin and incubated for 60 min prior to image analysis. The 
cells shown are representative o f  three (low pH wash) or four (wortmannin) experiments o f  this type, in 
each experiment >10 injected cells were examined. Quantification o f  the fluorescence signal in defined 
areas o f  plasma membrane as a fraction o f  the total cellular fluorescence o f  many experiments o f  this 
type revealed that there was no significant loss o f  GFP-Glut4 fluorescence signal during the 
internalisation experiments (i.e. the plasma membrane/total cellular fluorescence signal was unaffected 
by the experimental manipulations shown).
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Figure 4.9 Potassium-depletion results in the accumulation of GFP-Glut4 at the plasma membrane.
3T3-L1 adipocytes expressing GFP-Glut4 were washed into KRP either with or without K .^ After 2 h 
incubation in this buffer on a hot-plate, cells were imaged by confocal microscopy in the same buffer using 
the 488 nm laser for excitation o f  the GFP (figure 6). Shown in Panel A are representative cells from each 
o f  the two conditions. In the cells incubated in K^-depleted buffer, we observed increased GFP-Glut4 at the 
plasma membrane in 92% o f  the cells examined (n=76 cells in three experiments). Panel B  shows the 
results o f  quantification o f  the level o f  GFP-Glut4 at the plasma membrane after either 1 or 2 h incubation 
in potassium-depleted buffer, expressed as a fold increase over the levels o f  GFP-Glut4 at the plasma 
membrane in control cells incubated in the same buffer with potassium. For comparison, the level o f  GFP- 
Glut4 at the plasma membrane in insulin-stimulated cells is also shown. * indicates a significant increase 
over Control cells (p=0.005), and **p<0.05. Panel C  shows the accumulation o f  endogenous Glut4 at the 
cell surface in 3T3-L1 adipocytes treated exactly as outlined above for GFP-Glut4 injected cells (data from 
a representative experiment, repeated with similar results, is shown).
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4.5.0 Discussion.
Insulin stimulates glucose disposal in peripheral tissues by virtue of the expression of 
the Glut4 glucose transporter isoform [151, 152, 225]. In the absence of insulin, this 
transporter is intracellularly sequestered within the elements of the endosomal system, 
the trans Golgi network and a specialised storage compartment [94, 95, 220, 221]. 
Glut4 is re-distributed from these intracellular locations to the plasma membrane in 
response to insulin [94, 95, 220, 221]. This paradigm of regulated membrane trafficking 
has been investigated using a range of methodologies, including transporter-specific 
photolabels, which have established that Glut4 undergoes continuous recycling between 
the plasma membrane and intracellular locations, even in the presence of insulin [26, 29, 
32, 86, 87, 89, 129]. Upon removal of the insulin signal, Glut4 is effectively sequestered 
within the cell, and leaves the plasma membrane with a half-time of about 6 to 7 min. 
However, the mechanisni(s) of this trafficking event remain poorly understood.
With the aim of addressing this, we have engineered two chimeric species between 
Glut4 and GFP. In the first, GFP is fused in frame at the N-tenninus of Glut4 (termed 
GFP“Glut4) and a second with GFP fused in frame at the C-terminus of the protein 
(termed Glut4-GFP). These cDNAs were expressed in fully differentiated 3T3-L1 
adipocytes by microinjection and exhibited similar patterns of intracellular expression in 
the absence of insulin (figure 4.1). As shown, fluorescence was observed in a 
perinuclear compartment and also in multiple punctate structures throughout the cytosol 
in a pattern reminiscent of native Glut4 identified in these cells. In response to insulin, 
both of these species exhibited extensive redistribution to the plasma membrane 
resulting in a continuous ring of fluorescence around the perimeter of the cell (figure 
4.1). In our hands, translocation of both GFP-Glut4 and Glut4-GFP to the plasma 
membrane in response to insulin was consistently observed after stimulation of cells 
with insulin in a CO2 incubator (figure 4.1). This translocation was rapid, maximal 
redistribution was achieved within 15 minutes of exposure to insulin (data not shown), 
consistent with studies of the endogenous Glut4 protein in these cells [226]. Under these 
conditions, we routinely observed insulin-stimulated translocation in >95% of cells 
expressing GFP-tagged Glut4.
This pattern of intracellular localisation and insulin-dependent re-distribution is 
specific for GFP-tagged Glut4. A chimeric Glutl-GFP species was found to distribute
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between the plasma membrane and intracellular membranes in the absence of insulin, a 
distribution well characterised for this isoform, and did not exhibit extensive 
translocation to the plasma membrane (figure 4.1), consistent with studies of the 
endogenous isoforms in 3T3-L1 adipocytes [226], Quantification of the extent of 
insulin-stimulated translocation of GFP-Glut4, Glut4-GFP and GFP-Glutl is presented 
in figure 4.1. In oui' hands, GFP-Glut4 and Glut4-GFP behave identically. Therefore, in 
all that follows, we show data using GFP-Glut4, but note that all experiments have been 
replicated using Glut4-GFP with identical results. Collectively, this data argues that the 
trafficking signals dictating the specific sorting of Glut4 and Glutl are recognised in the 
context of these chimeras.
Following on from our experiments in 3T3-L1 fibroblasts (Chapter 3) we examined 
the extent of the relationship between Glut4-GFP and microtubules in adipocyes. To 
this end we employed the microtubule depolymerising agent nocodazole (figure 3.6). 
Similar to the results in fibroblasts (Chapter 3, figure 3.7), we found that incubation of 
3T3-L1 adipocytes in media containing 10 pg/ml nocodazole caused dispersion of the 
distinctive Glut4-GFP-containing perinuclear compartment and vesicles throughout the 
cytoplasm (figure 4.2). Furthermore, we saw evidence of increased levels of GFP~Glut4 
at the plasma membrane. This evidence suggests that microtubules play at least some 
part in the basal distribution of Glut4-GFP in both 3T3-L1 adipocytes and fibroblasts. 
Fuilhermore, our data suggests that microtubules may be involved in the basal recycling 
of GFP-Glut4 in adipocytes since noncodazole causes GFP-Glut4 to accumulate at the 
plasma membrane. The involvement of microtubules in Glut4~GFP targeting is 
paralleled by work studying adenosine receptor and transferrin receptor 
distribution. [209, 227]. Saunders et a l observed a relocalisation of the adenosine 
receptor in réponse to nocodazole. Interestingly, Saunders et ai also found that 
adenosine receptor distribution was selective for microtubule-disrupting agents, since 
cytochalasin D, which disrupts actin polymerisation, did not alter adenosine receptor 
targeting. When examining transfemn receptor (TfR) trafficking, Jin et a l noted that 
nocodazole caused a 50% increase in the level of surface TfR, which was due to a 
change in receptor dynamics [209]. The endocytosis rate in treated cells was 20% of 
control, indicating that TfR endocytosis via clathrin-coated vesicles was slowed, 
whereas the recycling of internalised receptors to the cell surface was unaffected. We 
know that Glut4 is also endocytosed via clathrin-coated pits [131, 228] and from our
100
îown data appears to partially colocalise with the TfR. Therefore, if disruption of 
microtubules also slows Glut4-GFP endocytosis in 3T3-L1 adipocytes it would readily 
explain the accumulation of Glut4-GFP at the plasma membrane in response to ' :
nocodazole.
In order to study the effect of endosomal pH. neutralisation on Glut4-GFP 
distribution, cultured 3T3-L1 adipocytes were treated with the acidotrophic agent 
chloroquine (figure 4.2) [204]. Similar to results obtained in 3T3-LI fibroblasts,
(Chapter 3, figure 3.9) we observed that the intracellular Glut-GFP-containing vesicles 
appeared swollen and in the majority of cells a portion of the total Glut4-GFP 
population was displaced to the plasma membrane following chloroquine treatment. -,This further supports the suggestion that at least some of the intracellular Glut4-GFP 
pool resides within acidic endosomes. From studies by Holman et al using a
:bismannose photolabel to elucidate insulin-regulated Glut4 subcellular trafficking
kinetics, we know that Glut4 undergoes continuous recycling between the plasma
Ï
membrane and the cell interior in both the presence and absence of insulin [29].
Therefore, we speculate that Glut4-GFP may accumulate at the cell surface in 
chloroquine treated cells when recycling through the acidic endosomes is compromised.
In an effort to glean further insight into the relationship of the Glut4 storage 
compartment(s) and other membrane compartments, we used a series of fluorescence 
dyes to identify other subcellular compartments in GFP~Glut4 expressing cells.
■Specifically, we employed Texas red-labelled transferrin to identify the TfR itinerary 
and Lysotracker-red to identify acidic compartments (late endosomes/lysosomes). As 
shown in figure 4.3, these compounds are effectively internalised into cells expressing 
GFP-Glut4. Previous research suggests that a significant proportion of the intracellular 
Glut4 resides in a spatially distinct compartment from TfR in both adipocytes and 
muscle [97-99, 151, 220]. The only partial colocalisation of GFP-Glut4 or Glut4-GFP 
with Texas-Red Tf (figure 4.3) provides support for these observations, and further 
suggests that the localisation of the GFP-Glut4 chimeras studied here is accurately 
reflecting the localisation of the endogenous protein. The data of figure 4.3 further 
extends our understanding of Glut4 localisation in that there is no significant overlap 
between either GFP-Glut4 constmct and Lysotracker-Red®, strongly implying that 
Glut4 is not significantly localised within the late endosomal/pre-lysosomal network.
We also studied mutant Glut4 species using this approach (figure 4.4.1) [219, 229,
230]. FAG-GFP was observed to localise predominantly to the plasma membrane, in
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agreement with studies of epitope tagged FAG stably expressed in these cells [229], 
LAG-GFP expression was observed both intracellularly and in part at the plasma 
membrane (figure 4.4.1). In contrast, the DAG-GFP and SAG-GFP mutants primarily 
displayed an intracellular distribution within punctate vesicles similar to the wild type 
Glut4-GFP construct (figure 4.4.1). Furthermore, DAG-GFP and SAG-GFP moved to 
the plasma membrane in response to insulin (figure 4.4.2), indicating that the Glut4 
serine 488 phosphorylation site is not essential to the translocation process. These 
results are in good agreement with a range of studies which have examined the 
subcellular distribution of similar Glut4 mutants [229-231], Collectively, these data 
argue strongly that the intracellular localisation of GFP-Glut4 faithfully replicates the 
distribution of the endogenous protein, and that the targeting signals within Glut4 are 
similarly recognised within the context of the GFP-Glut4 species.
The overlap between the mutant Glut4-GFP species and the TfR itinerary was also 
examined by dual wavelength confocal microscopy (figures 4.5 and 4.6). Reminiscent 
of the findings in 3T3-L1 fibroblasts described in chapter 3 (figure 3.5), the degree of 
overlap between FAG-GFP and Tfi^ was considerable, whereas the overlap between 
LAG-GFP and TfR appeared negligible (figure 4.5). This result is in good agreement 
with work by Melvin et a l [219] using the Transferrin-HRP endosomal ablation 
technique to study FAG and LAG distribution in 3T3-L1 adipocytes. Melvin et a l 
found that in basal adipocytes 40% of Glut4 is ablated following Tf-HRP loading, In 
contrast, they found that in stable cell lines expressing FAG or LAG that almost all or 
virtually none respectively of the mutated Glut4 was localised to the ablated endosomal 
compartment. In the context of this additional biochemical data, our results imply that 
the amino terminal FQQI motif functions in trafficking Glut4 from early endosomes 
whereas the di-leucine motif is involved in sorting Glut4 from a separate intracellular 
compartment such as the TGN.
Colocalisation of DAG or SAG-GFP with TfR. revealed that the extent of 
overlap was very similar to that observed between Glut4-GFP and TfR (figure 4.6). 
Again this is very similar to the observed distribution of SAG and DAG-GFP in 
fibroblasts (Chapter 3, figure 3.4) and largely agrees with another study that has 
characterised SAG in 3T3-L1 adipocytes [230]. In stably transfected adipocytes Marsh 
et a l showed that SAG trafficking was not significantly different from that of Glut4. In 
the basal state SAG displayed an intracellular distribution, translocated to the plasma 
membrane in response to insulin and was only partially ablated when cells were loaded
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with Tf-HRP. All of these results are confirmed in our own studies using SAG-GFP and 
the endosomal marker Texas Red Transferrin. In addition, using immunoelectron 
microscopy. Marsh et al showed that Glut4 is localised to intracellular vesicles 
containing the Golgi-derived g-adaptin subunit of AP-1 [232] and that this localisation
is enhanced when Ser-488 is mutated to alanine. This result would prove difficult to
.corroborate in our own system due to the limits of resolution allowed by GFP and 
confocal microscopy.
Using this system, we have demonstrated insulin-dependent translocation of GFP-
aGlut4 to the plasma membrane when cells were treated with insulin in an incubator prior to image analysis (figure 4.1). We therefore set out to examine the ability of GFP-Glut4 
and Giut4-GFP to re-internalise from the plasma membrane after withdrawal of the 
insulin-stimulus (either by low pH washes, anti-insulin antibodies, or both) or in i
response to addition of inhibitors of PI3K, under similar conditions. In a previous study 
[224], Dobson et a l showed that a chimera similar to GFP-Glut4 did not re-intemalise
from the plasma membrane after removal of the insulin stimulus, but that Glut4-GFP 
did. However, these data were collected using CHO cells which are not a bona-fide
insulin-responsive cell line, and moreover the kinetics of internalisation observed did 
not parallel those reported for endogenous Glut4. Therefore, we decided to revisit these 
observations, this time in a more appropriate cellular context.
In order to remove the insulin signal, we employed either or both of two distinct 
approaches: washing in low pH buffer, or the use of anti-insulin antibodies [29, 33, 
224]. Both of these methods were shown to reverse insulin-stimulated glucose transport 
and Glut4 translocation in wild-type 3T3-L1 adipocytes with the expected half-times
(figure 4.7). Identical conditions were employed for cover-slips of cells expressing 
GFP-Glut4. Strikingly, we were unable to observe internalisation of either GFP~Glut4 
or Glut4“GFP using any of these approaches alone or in combination (figure 4.8); 
quantification of the level of GFP-Glut4 at the plasma membrane of these cells after 
such treatments did not reveal any significant reduction in signal, expressed as a 
percentage of the total cellular GFP-Glut4 level (data not shown). Inhibition of PI3K 
using wortmannin or LY294002 also functions to reverse insulin-stimulated glucose 
transport and Glut4 translocation (see figure 4,7). However, incubation of cells with up 
to 250 nM wortmannin for up to 3 hours did not result in appreciable internalisation of 
GFP-tagged Glut4 from the plasma membrane (figure 4.8). Quantification of this data 
by measurement of GFP-Glut4 fluorescence at the plasma membrane as a percentage of
■I
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the total cellular GFP-Glut4 fluorescence further demonstrated no significant 
internalisation of GFP-Glut4 under any of the conditions employed (data not shown).
These data strongly imply that the internalisation of Glut4 from the cell surface after 
withdrawal of the insulin-stimulus (or by inhibition of PI3K) has been perturbed by the 
presence of the GFP in the cytosolic domain of Glut4, either at the N- or C- terminus.
In order to examine the ability of GFP-Glut4 expressing cells to internalise other 
proteins from the cell sinface, we examined the internalisation of Texas-Red transferrin 
and Lysotracker-Red® into cells expressing GFP-Glut4 in the presence of insulin. These 
ligands were effectively internalised by cells in the presence of insulin (data not shown), 
arguing that these cells do express a functional recycling pathway capable of 
internalising proteins from the plasma membrane to intracellular compartments in the 
presence of insulin.
We next sought to determine whether GFP-tagged GIut4 species were, like 
endogenous Glut4, undergoing recycling between the plasma membrane and 
intracellular compartments. The small number of injected cells on a coverslip precludes 
direct biochemical analysis of this, therefore we adopted a more indirect approach.
Studies have shown that depletion of results in the accumulation of Glut4 at the 
plasma membrane, probably as a consequence of interruption of the recycling pathway 
[132]. We therefore incubated coverslips of cells expressing GFP-Glut4 in potassium- 
depleted buffer or control buffer, and examined the levels of GFP-Glut4 associated with
the plasma membrane under these conditions (figure 4.9). As illustrated, cells incubated
,in potassium-depleted media exhibited consistently increased levels of GFP-Glut4 at the 
plasma membrane than control cells as evidenced by the clear definition of the plasma 
membrane in such cells which is not apparent in control cells. Quantification of the 
accumulation of GFP-Glut4 at the plasma membrane in these cells is shown in figure 
4.9; a statistically significant increase is observed by 2 h of incubation in K*^-depleted 
buffer. Such experiments are suggestive of recycling of GFP-Glut4 in the absence of 
insulin. Using the same experimental conditions, we examined the distribution of 
endogenous Glut4 in 3T3-L1 adipocytes by whole cell immunofluorescence (figure 
4.9). As shown, potassium depletion resulted in the accumulation of endogenous Glut4 
at the cell surface, validating the concept that the morphological assay of GFP-Glut4 
accumulation at the cell surface is reflecting the behaviour of the endogenous protein.
Although we interpret these data to imply that low potassium levels are disrupting 
endosomal recycling, it is possible that these effects arise as a consequence of cellular
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stress induced by changes in membrane potential, sodium-gradients and the activity of 
membrane transporters that utilise the sodium gradient. However, studies in primary rat 
adipocytes have strongly argued that the effect of potassium is to modulate recycling of 
Glut4 through the endosomal system, hence we argue that the responses observed here 
of GFP-Glut4 to potassium-depletion reflect the ability of this protein to recycle in the 
absence of insulin.
It has been shown that Glut4 imdergoes constitutive recycling between the plasma 
membrane and intracellular compartments in the basal state [29, 32, 86]. The partial 
overlap between GFP-Glut4 and TfR positive intracellular membranes (figure 4.3) and 
the obseiwation that iG^-depletion results in the accumulation of GFP-Glut4 at the cell 
surface (figure 4.9) support the notion that GFP-Glut4 is undergoing constitutive 
recycling between the plasma membrane and intracellular membranes in the absence of 
insulin. If the mechanism of GFP-Glut4 internalisation in the basal state were the same 
as that employed to internalise GFP-Glut4 after withdrawal of the insulin signal, then 
the data of figure 4.8 would imply that GFP-Glut4 should accumulate at the plasma 
membrane in the basal state. The data of figure 4.1 (obtained >24 h after microinjection) 
shows that this is not observed. Hence in the absence of insulin GFP-Glut4 appears to 
traffic like the endogenous protein and, also like the endogenous protein, exhibits 
insulin-stimulated translocation to the plasma membrane (figure 4.1). In contrast, after 
insulin withdrawal or inhibition of PI3K, GFP-Glut4 does not exhibit appreciable 
internalisation up to 6 hours after removal of the insulin stimulus, or up to 3 hours after 
addition of wortmannin (figure 4.8). These observations are not a function of laser 
toxicity, as the insulin withdrawal or wortmannin additions were made to cells either in 
a CO2 incubator or on a 3TC  hot-plate, and the cells were not exposed to laser 
illumination until the times indicated in the figures. Nor is this phenomenon restricted to 
GFP appended to the N-terminus of Glut4, as we observe similar phenomena with 
Glut4-GFP (not shown). It has also been suggested that GFP expression may be toxic to 
certain cells [128]. The fact that in all other respects GFP-Glut4 traffics apparantly 
normally and repsonds well to insulin would appear to mitigate against this being an 
issue in this system. Rather we argue that these observations imply distinct mechanisms 
of GFP-Glut4 internalisation in the basal state compared to post-insulin withdrawal.
Such a conclusion pre-supposes that GFP-Glut4/Glut4-GFP are faithfully mimicking 
the trafficking of the endogenous Glut4 protein in the basal state. Clearly, we cannot 
definitively demonstrate this, as we are limited by the very small numbers of cells
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expressing the protein after microinjection. However, we argue that the following data 
support the notion that GFP-Glut4 is a reasonable model for endogenous Glut4 
trafficking: (i) GFP-Glut4 exhibits significant insulin-stimulated translocation to the 
plasma membrane; Others have argued that newly synthesised Glut4 traffics from the 
TGN to the plasma membrane and is then sorted into an insulin-responsive 
compaitment [135]. The fact that GFP-tagged Glut4 is capable of marked insulin- 
stimulated translocation strongly implies that this trafficking is operating correctly for 
the GFP-tagged species, (ii) Glutl-GFP in contrast is differentially distributed between 
the plasma membrane and intracellular membranes; (iii) mutations in the Glut4 primaiy
withdrawal. We suggest that such mechanistic distinctions may also be operating for the
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sequence perturb targeting in a fashion similar to that reported for epitope-tagged Glut4;
:(iv) GFP-Glut4 exhibits partial overlap with the TfR, and almost no overlap with
lysosomal markers; (v) potassium-depletion results in the accumulation of GFP-Glut4 at 
the plasma membrane, suggesting that GFP-Glut4 is recycling in the absence of insulin. 
Furthermore, GFP-Glut4 exhibits extensive overlap with the aminopeptidase, 
vpl65/IRAP [101, 233], also arguing strongly for a close relationship between the 
trafficking of GFP-Glut4 and endogenous Glut4.
We argue that the mechanism of GFP-Glut4 internalisation in the basal state is 
distinct from that employed after insulin withdrawal, as we obseiwe no GFP-Glut4 or 
Glut4-GFP at the plasma membrane in the basal state. Rather, we suggest that our data 
are consistent with a mechanistic distinction between GFP-Glut4 internalisation from 
the plasma membrane in the basal state and GFP-Glut4 internalisation after insulin
endogenous protein, implying that distinct mechanisms for Glut4 internalisation may 
.exist in peripheral tissues. In further support of this hypothesis, we note that the I C 5 0  for
wortmannin inhibition of basal and insulin-stimulated deGlc transport are distinct, and 
also that the inhibition of insulin-stimulated glucose transport observed in response to 
wortmannin does not fall appreciably below the basal rate [31, 89, 234] (see also figure 
4.7). We argue that studies using GFP-tagged Glut4 can reveal hitherto unsuspected 
subtleties of Glut4 trafficking which may be of relevance to endogenous Glut4 cell 
biology.
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Chapter 5
5.0.0 Switching the nucleotide specificity of ARFs 5 and 6 by site directed 
mutagenesis
5,1,0 Introduction
ADP-ribosylation factors (ARFs) represent a family of small molecular weight GTP-
binding proteins that are believed to play a crucial role in the control of membrane
.traffic within the cell [235]. ARFs were originally recognised in the 1980s because of 
their ability to enhance the cholera toxin-catalysed ADP ribosylation of G^a [236]. 
However, under noiinal physiological circumstances, the cellular roles of ARF proteins 
are much different. A whole family of ARF proteins have since been described [237]
that represent critical components of vesicular trafficking pathways and activators of 
specific phospholipase Ds (PLDs) [235]. Similar to other guanine nucleotide binding 
proteins, ARFs with GDP bound are inactive, whereas ARFs with GTP bound are active 
and can associate with membranes [238]. The substitution of GDP with GTP is 
catalysed by guanine nucleotide exchange factors (GEFs) [127, 238]. Conversely, 
GFPase-activating proteins (GAPs) enhance the hydrolysis of bound GTP to inactivate 
ARFs [238, 239]. Therefore ARFs fulfill a critical role within the cell, translating the
Î
effects of upstream signalling proteins into membrane fusion events along the vesicular 
transport pathway.
5.1.1 The ARF protein family
The six ARF proteins are assigned to three classes based on sequence homology: class I,
ARFl, ARF2, and ARF3; class II, ARF4 and ARF5; class III, ARF6 [237]. Hosaka et 
ai transfected HA epitope tagged Arf cDNAs into monkey kidney Vero cells to 
examine the subcellular localisation of each of the six ARF proteins by 
immunofluorescence. In this study the class I ARFs showed a perinuclear distribution 
while the class II and class III ARFs were localised in punctate structures throughout the 
cytoplasm and at the cell periphery. Fluorescence associated with ARFs 3-6 was also 
observed in the cell nucleus.
■Î
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5.1.2 The role o f ARFs in trafficking
The membrane trafficking pathway between the cell interior and the extracellular 
environment ensures that proteins and lipids can move dynamically through the cell as 
required. By this mechanism the cell can maintain the integrity of its membranes and 
synthesise new subcellular organelles [218]. The initial evidence that ARF may be 
involved in the trafficking pathway came from a genetic study in the yeast 
Saccharomyces cerevisiae, where deletion of the ARF gene resulted in a secretory 
defect [240]. Subsequently, ARFl was found to be required for the recruitment of COPI 
to vesicles budding from the endoplasmic reticulum [241]. Since then a number of 
studies have implicated the importance of ARF proteins in eukaryotic cells at distinct 
points along the membrane trafficking pathway [242-245].
5.1.3 ARFs and secretory vesicle formation
The most studied of the ARF proteins, ARFl, is localised to the Golgi complex and 
recruits the coat proteins COP I and APl-clathrin complex to Golgi membranes prior to 
vesicle budding and transport along the secretory pathway [235]. The mechanism by 
which active GTP-bound ARF gains the specificity to dock with the correct membrane 
site prior to vesicle formation is unclear. However, Galas et al. found evidence of ARF 
binding to the py subunits of heterotrimeric G proteins [243], an interaction that could 
provide a degree of specificity to ARF function at target membranes.
Xu et al. established a permeabilised cell system that supports prohormone 
processing and secretory vesicle formation from rat anterior pituitary growth hormone 
and prolactin secreting GHg cells [246]. Using this cell system, Chen et al. 1996 
reported that recombinant human ARF-1 stimulates the release of nascent secretory 
vesicles from the TGN [247]. In contrast, mutant forms of ARF imable to exchange 
GDP for GTP or missing a portion of their N-terminal domain were unable to stimulate 
secretory vesicle fomiation. The binding of ARF to Golgi membranes and the foiination rViof coatamer-coated vesicles is also associated with PLD activation [245]. The role of 
ARF-activated PLD in secretory vesicle release was examined by Chen et al. 1997 
[248] Again using the permeabilised GFÎ3 cell system, they showed that the addition of 
recombinant PLD also stimulates secretory vesicle budding from the TGN. 
Furthermore, Chen et a l 1997 also showed that the addition of ARF-1 polypeptide, but 
not mutant ARF-1 unable to exchange GDP for GTP, increases PLD activity under the 'i
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ARF 6 displays a different cellular distribution to ARF 1 [237] and therefore may be 
expected to fulfill a slightly different role in membrane trafficking. In CHO cells, ARF6
same conditions where ARF-1 enhances vesicle budding from the TGN [247, 248].
These data demonstrate a clear link between ARF-1 and PLD activity leading to vesicle 
budding in the secretory pathway
Inhibition of PLD-derived phosphatidic acid (PA) formation using ethanol 
prevents coated vesicle formation budding from the Golgi membranes [245]. This result 
implies that PA is involved in the fonnation of secretoiy vesicles. However, whether PA 
accumulation itself or metabolites of PA, for example DAG, enhanced vesicle release 
remained unknown imtil the question was addressed by Siddhanta et al. [249]. Using the 
permeabilised GH3 cell system, Siddlianta et al added phospholipid-hydrolysing 
enzymes to generate either DAG or PA independently of PLD activity and then 
analysed their effects on the budding of nascent secretory vesicles. They found that the 
addition of a combination of enzymes expected to generate significant levels of PA 
rather than DAG gave the most significant increase in secretory vesicle budding from 
the TGN.
.The stimulatory effect of PA may be a consequence of signalling events 
downstream of PA formation or a result of its effects as a fusogenic lipid [250]. In 
support of the latter hypotheses Ktistakis et a l observed that the P-COP subunit of the 
coatamer complex binds more effectively to PA-containing liposomes [245]. In 
addition, the transient, localised accumulation of negatively charged PA in the TGN 
membrane could promote changes in the lipid bilayer curvature, further contributing to 
vesicle formation.
■■■;Evidence that GTP-binding proteins may also be involved in the formation of 
neuroendocrine synaptic vesicles (SV) came form the observation that the non- 
hydrolysable GTP analogue GTPyS inhibited the production of properly sized SVs in 
PC 12 cell extracts [251]. In the same cell type a peptide conesponding to ARFl was 
shown to inhibit the formation of SVs, an effect that could be rescued by the addition of 
recombinant myristoylated native ARFl [244]. Thus, in addition to a general house­
keeping role in membrane transport, ARF proteins are also intimately tied to the 
formation of specialised vesicles.
■
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exhibits a peripheral distribution localising mainly to the plasma membrane and some 
internal pimctate structures [242]. Furthermore, ARF6 colocalises with endosomal 
transferrin receptors and cellubrevin [242], an endosomal v-SNARE [252].
This characteristic distribution suggests that ARF6 may be involved in 
membrane transport in recycling endosomes in CHO cells, D’Souza-Schorey et al 
1995, transiently expressed ARF6 in CHO cells that overexpressed the human 
transferrin receptor [253]. In these cells the researchers monitored receptor-mediated 
endocytosis by following transfeiTin receptor (TfR) recycling. Overexpression of ARF6 
resulted in a significant increase in binding of Tfn when compared to control cells. 
Similarly, the mutant ARF6(Q67L) that is defective in GTP hydrolysis, and is therefore 
locked in the activated state, also increased cell surface-bound Tfn. In contrast, cells that 
overexpressed then mutant ARF6(T27N) that is defective in GTP binding, and therefore 
inactivated, showed a 70% decrease in cell surface-bound Tfn. This data suggests that 
these changes in Tfn binding probably reflect a redistribution of the TfR. The 
redistribution of TfR from punctate vesicles to the plasma membrane when ARF6 or 
ARF6(Q67L) is expressed was confirmed by confocal microscopy. In contrast, cells that 
overexpressed ARF6(T27N) showed little TfR at the plasma membrane but prominent 
fluorescent staining of intracellular compartments. Double labeling experiments 
revealed that ARF6(Q67L)) colocalised with TfR at the plasma membrane, while 
ARF6(T27N) colocalised with TfR in intracellular compartments.
The kinetics of Tfn internalisation and release was also examined in CHO cells 
overexpressing ARF6 or the ARF6 mutants. Tfn release was decreased by the 
overexpression of ARF6, ARF6(Q67L) and ARF6(T27N). Tfn internalisation was 
reduced in cells that expressed ARF6(Q67L), whereas the Tfn recycling rate was 
dramatically reduced in cells that expressed ARF6(T27N) and as a consequence 
internalised Tfn was trapped within the cells. Taken together, these data suggest 
overexpression of ARF6 results in significant changes in endocytic traffic in CHO cells. 
The colocalisation of the ARF6 mutants with TfR also suggests that the nucleotide 
status of ARF6 plays an important role in TfR progression through the recycling 
endosomes.
ARF6 has also been implicated in the exocytotic pathway in cultured chromaffin 
cells due to the inhibition of calcium-evoked catecholamine secretion by a 
myristoylated ARF6 peptide [243]. Therefore the involvement of ARF proteins in 
glucose transporter trafficking remains an intriguing possibility.
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5.1.5 GEFs and GAPs
Under physiological conditions the release of GDP from ARF and GDP/GTP exchange 
is very slow but is greatly enhanced by the presence of guanine nucleotide exchange 
proteins (GEFs) [238] (figure 5.1). Similarly, the inactivation of ARF by the removal of 
GTP is very inefficient in the absence of GTPase activating proteins (GAPs) [238] (Fig 
5.1).Clearly this added level of complexity provides mechanisms whereby extracellular 
factors could stimulate cell signalling pathways that have GEFs and GAPs as 
downstream targets, thus modulating the rates of membrane fusion events.
GDP/GTP 
Exchange protein(Inactive) (Active)
GTPase-activating 
protein
(Cytosolic) (Membrane-associated I
Figure 5.1 The relationship between ARFs GEFs and GAPs
Guanine Nucleotide ExchangePactors (GEFs) catalyse the exchange o f  GDP for GTP to activate ARF 
proteins, whereas GTPase Activating Proteins (GAPs) enhance the hydrolysis o f  ARF-bound GTP to 
GDP rendering the ARF inactive.
ARNO (ARF nucleotide binding site opener) is a GEF for ARF6 [127]. ARNO 
also catalyses the exchange of GDP for GTP on ARFl [254]. However, based on 
subcellular fractionation and immunolocalisation experiments the distribution of ARNO 
more closely resembles that of ARF6 than ARF I [127]. Therefore, it is more likely that 
ARNO affects vesicular trafficking by modulating the activity of ARF6. Whereas 
ARNO is ubiquitously expressed, the GEF cytohesin-1 is present in relatively few cells
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[128], The closely related cytohesin-3 (GRP-1) was isolated from a mouse adipocyte 
expression libraiy in a search for proteins that bind S'-phosphoinositides [255]. 
Therefore, cytohesin-3 provides an attractive theoretical means by which insulin 
induced PI3K activity could be translated into ARF activation, increased membrane 
fusion events and Glut4 movement to the plasma membrane in adipocytes.
To date more ARF GEFs than ARF GAPs have been discovered and 
characterised [238]. Ding et al. characterised an ARF GAP purified from rat spleen 
cytosol [239]. The purified GAP accelerated the hydrolysis of GTP bound to 
recombinant ARFl, ARF3, ARF5 and ARF6. This broad substrate specificity may 
indeed represent a less specialised function of ARF GAP. However, a more detailed 
study may reveal that the subcellular distribution of ARF GAP is tightly controlled and 
therefore inaccessible to ARF proteins of different classes.
5.1.6 ARFs and Glut4
Given the wide variety of cell types in which ARF proteins are expressed, their pivotal
role in vesicular transport, and their involvement in the fonnation of specialised
organelles, it is reasonable to hypothesise that ARF proteins may play a part Glut4 
,tiufficking. This hypothesis was tested by Miliar et al. in 3T3-L1 adipocytes [56]. This 
study found that 3T3-L1 adipocytes express ARF5 and ARF6 protein and that the 
former relocates to the plasma membrane in response to insulin. Permeabilised cells 
were then treated with myristoylated ARF5 and ARF6 peptides to investigate the 
function of these proteins. The ARF6 peptide caused an approximately 50% reduction 
in Glut4 translocation in response to insulin, whereas ARF5 and ARFl peptides were 
without effect. Both, the ARF5 and ARF6 peptides inhibited cell surface levels of Glutl 
and transferrin receptor (TfR) in response to insulin. However, the ARF6 peptide did 
not inhibit the fold increase in Glutl and TfR at the plasma membrane in response to 
insulin. In light of this data, Millar et al. suggested that in 3T3-L1 adipocytes ARF5 
controls membrane protein transport through the recycling endosomes where Glutl and 
TfR are primarily located. In addition there is growing evidence the Glut4 populates two 
distinct intracellular compartments in 3T3-L1 adipocytes [98] whereas Glutl is located 
within the endosomal system and the plasma membrane. One of the Glut4 intracellular 
compartments corresponds to the recycling endosomal system, the other a specialised 
Glut4 storage vesicle. The mechanism whereby ARF6 peptides reduce the degree of
Glut4 translocation by 50% and the cell surface levels of endosomaly derived Glutl is 
unclear. Millar/Powell et a l speculate that ARF6 peptides may inliibit translocation 
from one of the two proposed Glut4 pools in 3T3-L1 adipocytes. Alternatively, ARF6 
may fimction in constitutive membrane protein recycling hence causing the observed 
decrease in surface levels of Glutl in the basal and insulin-stimulated state. In this 
model ARF6 peptides could also decrease cell surface Glut4 levels following insulin 
stimulation since Glut4 is known to recycle with intracellular compartments even in the 
presence of insulin [86]. Whether ARF6 is involved in the exocytosis of Glut4 storage 
vesicles in insulin-responsive cells, analogous to ARF6 function in the secretory 
granules of chromaffin cells [243], or plays a part in the recycling endosomal system as 
suggested by D'Souza-Schorey et al, remains to be firmly established. The contribution 
of GEFs and GAPs to the control of Glut4 ti anslocation remains unexplored.
In an effort to more clearly define the mechanism of Glut4 translocation we sought to 
make ARF5 and ARF6 XTPase mutants. A conserved NKXD motif is found in the 
GTP-binding site of the GTPase superfamily. It has been shown that the hydrogen bond 
formed with the aspartate residue belonging this motif determines the specificity of 
guanine nucleotide binding [256]. GTP-binding proteins carrying an aspartate to 
asparagine mutation at this position are characteristically regulated by xanthine 
nucleotides rather than guanine nucleotides [257-261]. Furthermore, Zhong et al 
showed that GAP also accelerates the hydrolysis of XTP bound to a mutant Ras G 
protein. Examination of the amino acid sequence of ARF5 and ARF6 reveals that both 
proteins contain an NKXD motif towards the carboxyl tenninus.
Aspartate to asparagine mutations were made within the NKXD motifs of ARF5 and 
ARF6 by site directed mutagenesis. Using PGR we subcloned the Arf cDNAs into a 
eukaryotic expression vector and added a FLAG epitope tag to the C-teiininus of the 
ARF proteins. The addition of a FLAG epitope tag would allow for the efficient 
purification and immunolocalisation of wild type and mutant ARF proteins, Prior to any 
future experiments we must first verify the phenotype of the ARF5 and 6 XTPases. 
Subsequently we plan to make 3T3-L1 adipocyte cell lines that stably express both wild 
type and XTPase mutant ARF5 and 6. These stable cell lines will then be used to assay 
the contribution of ARF to Glut4 translocation in Glut4-GFP injected 3T3-L1 
ARF5/6XTPase stable cell lines. Any effect detrimental to the action of insulin in such
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cell lines should in theoiy be rescued by the addition of XTP to permeabilised cells. In 
this chapter we describe the molecular biological approach to the generation of ARF5 
and ARF6 XTPases. s
I
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5.2.0 Materials and Methods
5.2.1.0 Site directed mutagenesis of ArfSFLAG/pBluescript
In order to change the nucleotide specificity of the ARF5 GTPase to an XTPase, we 
needed to make an aspartate to asparigine mutation at position 129 within an NKXD 
motif towards the C-terminus of ARF5. This D129N mutation was achieved using the 
Clontech Transformer^'^ Site-Directed Mutagenesis Kit. Arf5 cDNA subcloned into the 
Not I-Xba I site of the pBluescript II KS(+) vector was kindly supplied by Dr Kazuhisa 
Nakayama. The strategy for generating specific base changes using the Transformer 
Site-Directed Mutagenesis Kit is outlined below: 4
:,.:4
-I
■I
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Unique 
restriction
1. Denature dsDNA
2. Anneal Primers
ArfSFLAG
pCR3.1
ArfSFLAG gene
Selection \  
Primer
3. Synthesise second strand with T4 DNA 
polymerse and seal gaps with T4 DNA 
ligase; primary digestion with restriction 
enzyme.
4, Transform mutS E. coli, 
first transfonnation
5. Isolate DNA from transformant 
pool
6. Secondary digestion with 
selection enzyme
+
Mutagenic
Primer
Parental
plasmid
M utated
plasmid
7. Transform E. coli
second (final) transformation
8. Isolate DNA from individual transformants 
to confirm presence of desired mutation
Figure 5.2 Diagramatical outline of site directed mutagenesis strategy
M utated
plasmid
M utated
plasmid
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5.2.1.1 Denaturing o f plasmid DNA and annealing o f primers to the DNA template ":STwo primers were required for the mutagenesis reactions. The first primer, ARF5MUT, 
was designed to introduce the aspartate to asparagine mutation at position 129 of the 
ARF5 primary amino acid sequence. The second primer, XHOIMUTX, was designed to
introduce a mutation into a unique Xho I restriction site within the ArfS/pBluescript
■-Ivector. feÏSequence o f Arf5 site-directed mutagenesis oligonucleotide primers
Mutagen ic Primer ARF5MUT
The oligonucleotide sequence is shown, with the corresponding ARFS amino acid 
sequence written below. A red star highlights the G to A nucleotide mutation 
introduced, which alters the coding sequence such that an aspartate to asparagine 
substitution within the amino acid sequence of ARFS results. Both the mutagenic and 
selection primers were S' phosphorylated so that they could be ligated to the 3' end of 
the newly synthsised strand. The primers were purified by polyacrylamide gel 
electrophoresis (PAGE). S' Phosphorylation and PAGE purification of the primers was 
carried out by Genosys prior to delivery.
IARF5MUT sequence '%
Selection Primer XHOIMUTX
The Clontech Transformer™ Site-Directed Mutagenesis Kit requires that one unique 
restriction site within the gene/vector DNA sequence is also mutated in order to select 
for mutant plasmids. Therefore, unique restriction sites within the ArfS/pBluescript 
DNA sequence were identified. We chose to mutate a unique Xho I restriction site 
within the multiple cloning region of the pBluescript backbone. Sequence analysis using 
Gene Jockey software showed that there were no Xho I sites within the cDNA sequence
;
of Arf5. Hence a selection primer carrying a mutation in the Xho I site was designed. A |
H2O 12.0 ql
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red star highlights the A to G nucleotide mutation introduced.
☆
5 ' P - A C C G T C G A C C T C G G G G G G G G G C C C 3 '< ^Xho I
restriction site
5.2.1.2 Dénaturation o f plasmid DNA and annealing o f primers to the DNA template 
The following reagents were pipetted into a 0.5 ml Eppendorf tube:
-
ÎI.'J;1 Ox Annealing buffer 2.0 pi
Plasmid DNA (0.05 ng/^1) 2.0 ^1
Selection primer (XHOIMUTX) (0.05 pg/pl) 2.0 pi
- Ï ÎMutagenic primer (ARF5MUT) (0.05 pg/pl) 2.0 pi
Ï
I
The DNA was denatured by incubating the tube at lOO^C for 3 minutes. Immediately 
thereafter, the sample was chilled in an ice water bath (0°C) for 5 minutes to anneal the 
primers to the ArfS/pBluescript template DNA.
Î5.2.1.3 Synthesis o f mutant DNA strand
The following reagents were added to the primer/plasmid annealing reaction described 
above:
lOx Synthesis buffer 3,0 pi
T4 DNA polymerase (2 units/pl) 1.0 pi
T4 DNA ligase (4 imits/pl) 1,0 pi
H2O 5.0 pi
The sample was incubated at 37°C for 2 houis and then the reaction stopped by heating 
the mixture at 70*^ 0 for 5 minutes to inactivate the enzymes.
i
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5.2.1.4 Primary selection by restriction digestion
The purpose of the primary restriction digestion is to selectively linearise the parental 
DNA. This step renders the paiental DNA incapable of transforming the repair-deficient 
E. coli., thus greatly increasing the proportion of mutant plasmids present in the 
bacterial culture from the first transformation. The reagents for the restriction digestion 
were added to a 0.5 ml Eppendorf tube;
30 pi synthesis/ligation mix
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3.25 pi lOx restriction enzyme buffer (added to optimise NaCl concentration)
1.5 pi Xho I
5.25 plHzO
pi ho I restriction enzyme
lOx restriction buffer was added to the reaction in order to optimise the NaCl 
concentration for digestion by Xho I. The sample was incubated at 37°C for 2 hours and 
then at 70°C for 5 minutes to inactivate the restriction enzyme.
5.2.1.5 First transformation
The purpose of the first transformation is to amplify the mutated, Xho I-resistant strand 
of Arf5/pBiusescript into competent mutS (repair-deficient) E. coli. Repair-deficient 
bacteria are used so that any lineaiised parental Arf5/pBluescript DNA that is taken up 
by the mutS E. coli is not repaired and amplified by the bacterial cells. 10 pi of the 
plasmid/primer DNA solution from the previous step was added to 100 pi of competent 
BMH 71-18 mutS cells in a 15 ml Falcon tube and incubated on ice for 20 minutes. The 
cells were then heat shocked in a 42°C water bath for 1 minute. 1 ml of LB media was 
added to the tube and the sample placed in an incubator at 37°C for 1 hour with shaking 
at 225 r.p.m. Following the recovery step, 4 ml of LB containing 50 pg/ml ampicillin 
selection antibiotic was added to the mix. The culture was then incubated overnight at
37°C with shaking at 225 r.p.m. to amplify the transfomiants carrying the mutated 
Arf5/pBluescript plasmid. The following morning the mixed plasmid pool was isolated 
from 1.5 ml culture volume using the alkaline-lysis mini-prep method outlined in 
Chapter 2.
I
5.2.1.6 Selection o f the mutant plasmid
The purpose of this second digestion is to select for the mutant Arf5/pBluescript 
plasmid by complete digestion of the parental umnutated plasmids. 5 pi of the purified 
mixed plasmid DNA from the previous step was digested with 10 units of Xho I as 
previously described and incubated at 37°C for 2 hours. Next, another 10 units of Xho I 
was added to the mix and the incubation continued for 1 hour to ensure that as much of 
the umnutated parental DNA plasmid as possible was linearised. As a control 100 ng of 
unmutated ArfS/pBluescript maxi-prep DNA was also digested with Xho I prior to the 
final transformation.
I5,2.1.7 Final transformation and analysis o f putative ArfSXTPase/pBluescript clones
5 pi of the digested plasmid DNA (approximately 25 ng) and 5 pi of the digested
parental control DNA were transformed into Invitrogen One-Shot Topi OF' competent
cells as previously described in Chapter 3. Transformed cells at concentrations of Ix,
O.lx and O.Olx were then plated out onto agar plates containing 50 pg/ml ampicillin. 
.Following an overnight incubation at 37°C there were approximately 10 fold more 
ampicillin-resistant colonies on the plates containing cells transformed with the mutated
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#Arf5/pBluescript than on the control plates. Colonies were then picked from the plate containing mutant ArfS/Bluescript transfonned cells and grown overnight in LB plus 50 
pg/ml ampicillin. DNA was extracted from the overnight cultures using the alkaline- 
lysis mini-prep protocol as outlined before. 5 pi of the putative Arf5XTPase/pBluescript 
DNAs were then digested with Xho I and analysed by TBB agarose gel electrophoresis 
as previosly described. Mutant Arf5/pBluescript plasmids should be resistant to Xho I 
digestion and therefore migrate at a different rate from linearised parental DNA when 
analysed by agarose gel electrophoresis (figure 5.3).
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Figure 5.3 TBE agarose gel electrophoresis analysis o f putative ArfSXTPase/pBluescript DNA  
clones
Putative ArfSXTPase/pBluescript DNA clones (lanes 4-12 and 16-18) were digested with Xho I and 
analysed by TBE agarose gel electrophoresis. A DNA molecular weight marker (lanes 1 and 13), uncut 
parental ArfS/pBluescript DNA (lanes 2 and 14) and parental ArfS/pBluescript DNA digested with Xho I 
were also run through the gel. The Successfully mutated ArfSXTPase/pBluescript clones were resistant to 
Xho I digestion and therefore migrated through the agarose gel at the same rate as the uncut parental 
ArfS/pB luescript DNA
Figure 5.3 shows that the DNA from the putative Arf5XTPase/pBIuescript clones 1-11 
is resistant to Xho I digestion and migrates at a different rate from the linearised 
parental DNA. Therefore we would expect that the putative ArfSXTPase/pBluescript 
DNAs carry the desired mutations in the unique Xho I restriction site and in the codon 
encoding the aspartate residue at position 129. Automated sequencing confirmed that 
Arf5XTPase/pBluescript Clone 1 did indeed contain the desired G to A nucleotide i
mutation within the codon encoding aspartate 129. Thus ArfSXTPase/pBluescript Clone |
1 contained an aspartate to asparagine mutation at position 129 of the amino acid 
sequence, a mutation hypothesised to change the nucleotide specificty of ArfS from 
GTP to XTP.
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5.2.2 Addition o f a FLAG epitope tag to the C-terminus o f wild-type ARF 5 and 
ARFSXTPase byPCR
To allow for the efficient immunodetection or purification of wild type ARF 5 and
ARF5XTPase we wanted to tag the ARF5 proteins with a FLAG epitope that has the
amino acid sequence DYKDDDDK. The wild type and mutant ARF5s were tagged with
the FLAG epitope by PCR. Two oligonucleotide PCR primers (ARFFLAGA and
ARFFLAGC) were designed corresponding to the 5' and 3' ends of the ArfS cDNA. The
ARFFLAGC primer was designed to introduce a FLAG epitope to the C-terminus of
.ArfS. Furthermore a unique Sal I restriction site was added to the extreme 3' end of the 
ARFFLAGC primer to allow for the positive identification of cDNA clones at a later 
date. Primers were synthesised and supplied by Genosys.
ÎÎ
Sense primer ARFFLAGA
5 ' G G C C C C G C C A T G G G C C T C A C G 3 '
4---------------- --►<---------- - -----——-——
V ector ArfS coding
.sequence sequence
"
IAnti-sense primer ARFFLAGC
5 ' G T C G A C C T A C T T G T C G T C G T C G T C C T T A T A G T C C G C G  
C G C T T T G A C A G C T C G T G G G A C 3 '
5 ' G T C C C A G G A G C T G T C A A A G C G C G C G G A C T A T A A G G A      -------------
ArfS coding FLA G  epitope
sequence
S a i l
STOP restriction 
site
Î
The wild type Aif5 cDNA was then amplified by PCR using the ARFFLAGA and 
ARFFLAGC primers. The mutant ArfSXTPase cDNA was amplified and epitope 
tagged in exactly the same way described for the wild type Arf5 cDNA.
PCR Protocol
1.0 pi Arf5/pBluescript template DNA (100 ng/pl)
LO pi ARFFLAGA primer (50 pM)
1.0 pi ARFFLAGC primer (50 pM)
5.0 pi 1 Ox PCR buffer, Mg '^^-free 
2.0pl25mM MgCl2
0.5 pi lOOmMdNTPs
38.5 of sterile H2O
1.0 pi Taq DNA polymerase
PCR cycle parameters
10 minutes 94®C 
1 minute 95 °C —^
1 minute 78°C 25 cycles
7 minutes 72°C-^
10 minutes 72°C
Following completion of the PCR reactions, the resultant DNA was purified using the 
Promega Wizard PCR clean-up kit, and the size of the DNA product checked by 
agarose gel electrophoresis as described in Chapter 2. The Taq-amplified DNA PCR 
product was then quantified by measuring its absorbance at 260 mn and then A-tail 
ligated into the Invitrogen pCR3.1 expression vector as described in Chapter 2. Ligation 
reactions were carried out overnight at 14°C, the ligated DNA transformed into One 
Shof^“ TOPI OF' competent cells and DNA extracted from bacterial cultures, again as 
described in Chapter 2. Each of the putative ArfSFLAG cDNA clones was then 
restriction digested with Eco RI. The multiple cloning region (MCR) of the pCR3.1 
vector contains two Eco RI restriction sites either side of the A-tailed PCR fragment
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insertion point. Therefore, digestion with Eco RI would yield a DNA fragment 
approximately 600 base pairs in length indicating that the ArfSFLAG cDNA had been 
successfully subcloned into pCR3.1. Figure 5.4 shows that of the 18 putative 
Arf5FLAG/pCR3.1 clones, all but one yielded a DNA fragment of the expected size.
6 7 8 9 10 11 12 13 14 15 16DNA size (bpl
DNA size (bp)
17 18 19 20 21 22 23 24
Figure 5.4 Putative Arf5FLAG/pCR3.1 DNA clones analysed by TBE agarose gel electrophoresis
18 Putative Arf5FLAG/pCR3.1 DNA clones (lanes 4-16 and 20-24) were digested with EcoR 1 and 
analysed by TBE agarose gel electrophoresis. Clones that contained the correct ArfSFLAG insert yielded 
a 600 base pair fragment (lanes 4-16 and 21-24). For comparison, a DNA molecular weight marker was 
included in lanes 1 and 17, uncut pCR3 1 plasmid DNA in lanes 2 and 18, and pCR3 1 plasmid DNA  
digested with EcoR I in Lanes 3 and 19.
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The orientation of the ArfSFLAG cDNA inserts in the pCR3.1 vector was then checked 
using the Bam HI restriction enzyme;
Correct orientation
Bam HI Bam HI
Wfl ArfSFLAG PCR Product A
Figure 5.5 Relative position of Bam HI restriction sites within ArfSFLAG and pCR3.1
As well as a Bam HI site in the upstream MCR of pCR3.1, there is also a Bam HI site at 
position 105 of the ArfSFLAG PCR product (figure 5.5). Therefore, if the ArfSFLAG 
cDNA is inserted into the pCR3.1 vector in the correct orientation, a restriction digest 
with Bam HI will yield only a very small DNA fragment of about 140 base pairs. 
However, if ArfSFLAG is inserted in the anti sense orientation, a restriction digest with 
Bam HI will yield a larger DNA fragment about 500 base pairs in length.
Following a Bam HI digest, putative Arf5FLAG/pCR3.1 cDNA clones were analysed 
by electrophoresis on a 1% agarose TBE gel. Four of the ten putative 
Arf5FLAG/pCR3.1 clones contained the ArfSFLAG cDNA inserted into the vector in 
the correct orientation. The DNA sequence of these four DNA clones was then verified 
by automated sequencing, and the corresponding clonal bacterial cultures made into 
frozen glycerol stocks as described.
5.2.3.0 Addition o f a FLAG epitope tag to the C-terminus o f ARF6G2A by PCR
Arfô cDNA carrying a glycine to alanine mutation at position 2 and inserted into a pXS 
vector (Takebe et al., 1988, MCB 8; 466-472) was kindly supplied by Dr. J. Donaldson, 
NIH, Bethesda, Maryland. Therefore, two oligonucleotide primers were designed, 
ARF6FLAGA and ARF6FLAGB. These primers encoded the addition of a FLAG 
epitope tag to the C-terminus of ARF6 and mutate the glycine residue at position 2 back 
to alanine.
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ARF6FLAGA cmdARFFLAGB oligonucleotide sequences 
Sense primer ARF6FLAGA
5 ' G G A A G C T T A T G G G G A A G G T G C T A T C C A A A A T C T T C G
<-------------M--------------------------------------------------------------------------------
Hind III Arf6 coding sequence
G G A A C 3 ' I
Alanine to  glycine mutation codon 
Antisense primer ARF6FLAGB
5 ' G G C T C G A G C T A C T T G T C G T C G T C G T C C T T G T A G T C C
G C A G A T T T G T A G T T A G A G G T C A A C 3 '
ARF6FLAGB sense
5.2.3.1 ArfSFLAG PCR and sub-cloning protocol
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5 ' G T T G A C C T C T A A C T A C A A A T C T G C G G A C T A C A A G G A  --------------------------------------------------------------- H  M-------------------------------------Arf6 coding sequence FLAG sequence
C G A C G A C G A C A A G T A G C T C G A G C C 3 '
- —   ►Stop Xho I
restriction 
sits^  = Stop codon to alanine mutation
.J::
.Arf6FLAG was amplified by PCR and subcloned into the pCR3.1 expression vector in 
exactly the same way described for ArfSFLAG. Orientation of the ArfSFLAG cDNA 
fragment in the pCR3.1 vector was established by restriction digestion at a unique Bam 
HI site 44 base pairs downstream of the ArfS start codon. Purified DNA stocks of
1i
Arf6FLAG/pCR3.1 were then made using the Qiagen Maxi-Prep kit. The predicted 
DNA sequence of Arf6FLAG/pCR3.1 was confirmed by automated sequencing.
5.2.4 Mutagenesis o f wild-type ARF6FLAG to ARFôXTPaseFLAG 
To change the nucleotide specificity of the wild type ARF6FLAG GTPase to an XTPase 
we wanted to make an aspartate to asparagine mutation within the NKXD motif of 
ARF6, analogous to the D129N mutation described for the ARF5XTPase. The required 
mutation was achieved using the Clontech Transformer’^ '^  Site-Directed Mutagenesis Kit 
exactly as described previously when making the same mutation in ARF5. Two 
Arf6FLAG/pCR3.1-specific primers were designed to make the required aspartate to 
asaparagine mutation. The selection primer ARF6KPNMUT introduced a G to A 
mutation into a unique Kpn I restriction site within the mutiple cloning region of 
pCR3.1. The mutagenic primer ARF6XTP introduced a G to A mutation into the first 
position of the codon encoding aspartate 125 thus introducing the required D to N 
substitution.
ARF6XTP mutagenic primer sequence
☆
5 ' P - C A A C A A G C A G A A C C T G C C C G A T 3 '
N K Q N L P D
ARF6KPNMUT selection primer sequence
☆
5 ' P - C T T A A G C T T G A T A C C G A G C T C G G 3 '
■4--------- —'—k"
Kpn I site
Both the ARF6XTP and ARF6KPNMUT primers were PAGE purified and 5' 
phosphorylated by Genosys prior to delivery. Red stars denote the mutation points.
5.2.5 Transfection o f HEK293 cells with wild-type Arf5FLAG/pCR3.1 and
HEK293 cells were maintained in DMEM containing 10% calf sermn and 1% 
penicillin/streptomycin antibiotic. Cells were trypsinised into 10 cm plates and grown to
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50% confluency prior to transfection. The HEK293s were transfected with 10 pg of 
DNA mixed with 60 pi of Superfectin reagent per 10 cm plate as described in the 
Qiagen Superfect protocol.
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5.2.6 Lysis o f transfected HEK 293 cells
4x Lvsis Buffer Recipe 
1.9 ml 2M Tris pH 6.8 
4 ml 20% SDS 
4 ml glycerol 
0.2 ml 0.2MEDTA 
0.1 ml Bromphenol Blue "I
Transfected cell were washed twice in cold PBS. 2 ml of Ix lysis buffer supplemented 
.with 1:1000 dilutions of the proteases Aproptinin, Pepstatin A and DTP was added to 
each 10 cm plate and the cells scraped from the surface of the tissue culture dish.
Nuclear DNA was sheered by passing the lysate through progiessively smaller syringe
needles. The lysates were then divided into 400 pi aliquots and snap frozen in liquid 
nitrogen prior to storage at ~80°C.
T
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5.2.7 SDS-PAGE and immunoblotting o f transfected HEK293 cell lysates with an anti- 
FLAG antibody
Proteins within the transfected HEK293 cell lysates were separated by SDS-PAGE on a 
15% acrylamide gel.
Stacking gel recipe 
l.dmlHzO
0.33 ml 30% aciylamide mix 
0.25 ml 0.5 M Tris pH 6.8 
0.02 ml 10% SDS 
0.02 ml 10% APS 
0.02 ml TEMED
Resolving gel recipe for mini-gel
1.1 ml HzO
2.5 ml 30% acrylamide mix
1.3 ml 1.5M Tris pH 8.8 
0.05 ml 10% SDS 
0.05 ml 10% APS 
0.02 ml TEMED
SDS-PAGE running buffer recipe 
14.43 g glycine 
3 g Tris 
1 g SDS
Made up to 1 L with H2O
20 pi of lysate per lane was loaded onto the gel and polyacrylamide gel electrophoresis 
and transfer of lysate proteins onto nitrocellulose membranes carried out as described by 
Sambrook et al. 1989. The nitocellulose membrane was then incubated overnight at 4°C 
in a solution of TEST (150 mM NaCl, 150 inM Tris, 0.02% Tween 20, pH. 7.4) 
supplemented with 5% Marvel to block any non-specific interactions when 
immunoblotting with the anti-FLAG antibody. The following day the membrane was 
twice washed in room temperature TEST for 2 minutes. The membrane was then 
incubated in room temperature TEST containing 10 pg/ml anti-FLAG M2 (Sigma) 
primary antibody for 30 minutes in a heat-sealed plastic bag. Next the membrane was 
washed 3x for 2 minutes in TEST and then incubated with anti-mouse IgG peroxidase 
conjugated secondary antibody diluted 1:1000 for 30 minutes in a sealed bag. The 
membrane was then washed 3x in TEST with 15 minutes per wash. Finally, the
is;l
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.membrane was treated with ECL reagent and exposed for 5 seconds onto Kodak X- 
OMAT film.
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5.3.0 Results
5.3.1 Immunoblot o f HEK293 cells transfected with wild-type ArfSFLAG and
m
: ' e, -y::;
K
IIn order to verify that the wild type ArfSFLAG and ArfSXTPaseFLAG constructs were 
correctly expressed in eukaryotic cells and that the FLAG epitope-tagged proteins could 
be detected by the anti-FLAG M2 antibody we transfected HEK 293 cells with |
Arf5FLAG/pCR3.1 or Arf5XTPaseFLAG/pCR3 DNA. The HEK 293 fibroblast cell
■':'Fline was chosen because HEK 293 cells have high transfection efficiency and are easily |
grown in culture. Lysates from control and ArfSFLAG -transfected cells were analysed f
by SDS-PAGE and immunoblotted with the anti-FLAG M2 antibody (figure 5.6). |
i
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Molecular Mass
25 kDa
-21 kDa
Figure 5.6 SDS-PAGE verification of ARFFLAG expression in Hek 293 cells
Lysates from transfected Hek 293 cells were analysed by SDS-PAGE and the gel loaded as described in 
the table below. Proteins were then transferred to a nitrocellulose membrane and immunoblotted with an 
anti-FLAG primary antibody. Following treatment with an HRP-conjugated anti-mouse secondary 
antibody, addition o f  ECL reagent and exposure to X-OMAT film, bands corresponding to FL AG-tagged 
ARF5 proteins were visible at the predicted molecular mass o f  21 kDa
Lane A Lysate from untransfected Hek 293 cells
Lane B Lysate from Hek 293 cells transfected with GIut4-GFP cDNA
Lane C Lysate from Hek 293 cells transfected with wild type ARFSFLAG cDNA
Lane D Lysate from Hek 293 cells transfected with ARFSXTPaseFLAG cDNA
The above figure shows that in cells transfected with the wild-type and mutant 
ArfSFLAG constructs there is a band corresponding to the predicted molecular mass of 
ArfSFLAG, approximately 21 kDa. This band is not found in the lysate from mock- 
transfected cells or HEK293s transfected with Glut4-GFP. Therefore we suggest that 
this band represents FLAG epitope-tagged wild type and XTPase mutant ARFS and that 
the cDNA constructs are correctly expressed by eukaryotic cells.
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5.4.0 Discussion
Using molecular biological techniques we successfully epitope tagged wild type Aif5 
and Arf6 cDNA. Then by site directed mutagenesis we made an aspartate to asparagine 
mutation in the GTP-binding KKXD motif of both proteins. Automated sequencing 
showed that the ArfSXTPaseFLAG cDNA contained no mutations other than the 
desired G to A substitution within the aspartate codon of the NKXD motif. However, 
we were not so fortunate in the generation of the Arf6XTPaseFLAG mutant. The 
sequence of the mutated cDNA did not match with the known sequence of the wild 
type Arf6 cDNA. This suggests that during the site directed mutagenesis protocol either 
one or both of the selection and mutagenic oligonucleotides did not anneal correctly to 
the template DNA. Therefore, replication of the parental DNA strand by DNA 
polymerase was misprimed. In an attempt to circumvent this problem a variety of 
selection primers were designed corresponding to different unique restriction sites 
within the Aif6FLAG/pCR3.1 vector DNA. Unfortunately, regardless of selection 
primer used, very few mutant colonies were obtained. Furthermore, the cDNA retrieved 
from these colonies did not match the sequence of Arf6. This suggests that the problem 
may lie within the crucial mutagenic primer. The sequence of the mutagenic primer is 
evidently defined by the DNA sequence surrounding the desired mutation point. 
Therefore, if the mutagenic primer misprimes due to secondary structures within the 
oligonucleotide itself or within the template plasmid DNA there is little we can do to 
rectify this problem other than adopt a different site-directed mutagenesis protocol.
Upon completion of site directed mutagenesis and the addition of an epitope tag and 
DNA sequencing, wild type and mutant Arf5FLAG/pCR3.1 were transfected into 
HEK293 cells. Western blot analysis of transfected cell lysates gave a clear band at 20 
kDa, not present in the control cells, that conesponds to the predicted molecular mass of 
ARFSFLAG (figure 5.6). This result suggests that the ARFSFLAG protein is correctly 
expressed in a eukaryotic cell background. Once the phenotype of the ARFSXTPase has 
been verified we will endeavour to make 3T3-L1 cell lines that stably express wild type 
or mutant ARFSFLAG. Our success in generating stable cell lines may depend upon 
how critical ARFS is for normal cell function. Studies have already demonstrated the 
importance of ARFs 5 [56] and 6 [56, 243, 253] in endosomal transport. Hosaka et al 
found mRNA corresponding to each of the ARF family members in all mouse tissues
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examined [237], In addition Millar et al. showed that ARFs 5 and 6 are expressed in 
mouse 3T3-L1 adipocytes [56]. Assuming that ARFs 5 and 6 do play a critical a role in 
3T3-L1 cells, then the generation of stable transfectants carrying ARF5/6XTPase 
mutations may prove difficult since cells carrying a mutation in such a critical 
component of the endosomal system may not prove viable. If this is the case, then the 
effect of a mutation in ARF5 or ARF6 on Glut4 trafficking could be examined by the 
coinjection of Arf5/6XTPase and Glut4-GFP cDNA into adipocytes. The effects of an 
ARF5 GTP-binding site mutation on Glut4 translocation could then be examined by 
confocal microscopy and any detrimental effects rescued by the addition of XTP.
Whatever the outcome, the continued study of ARF proteins in relation to Glut4 :trafficking is important. ARFs may hold the crucial key to unlocking Glut4 
translocation in response to insulin-induced signalling pathways. Under such 
circumstances, ARF proteins may provide a future target for the development of 
antidiabetic therapeutic agents.
.1
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Chapter 6
6.0.0 An investigation of nitric oxide signalling and Gliit4 trafficking in L6 cells
6.1.0 Introduction
• . ,> r
Î
a
Skeletal muscle is the principal tissue of glucose utilisation by the body during 
exercise and of insulin-stimulated post-prandial glucose disposal. Therefore control of 
glucose transport into muscle is vital for glucose homeostasis. Two distinct mechanism 
mediate glucose uptake into skeletal muscle, the insulin-stimulated and the contraction- 
dependent signalling cascades [262, 263]. Whereas insulin stimulates increased glucose 
transport into skeletal muscle through a Phosphatidylinositol-3-Kinase (PI3K)- 
dependent pathway [189], there is growing evidence that contraction-stimulated glucose 
uptake is Nitric Oxide (NO)-dependent [75]. It is established that NO synthase (NOS) is 
expressed in skeletal muscle and NO is released from incubated skeletal muscle 
preparations [72, 264]. The downstream result of both the insulin and exercise-mediated 
signalling pathways is the recruitment of glucose transporter 4 (Glut4) from an 
intracellular location to the plasma membrane in a process called Translocation’ [262, 
263] and hence increase glucose transport into the cell. Once the key components of the 
signalling pathways leading to translocation are identified, novel therapeutic agents 
could be designed as possible anti-diabetic compounds.
In the absence of a contraction stimulus a NO-donor alone can stimulate glucose 
transport and metabolism in rat skeletal muscle [74]. However, there is conflicting 
evidence regarding the effect of NO on insulin-stimulated glucose transport. Work by 
Balon et a l [264] shows that the effects of the NO-donor sodium nitroprusside (SNP) 
and insulin on 2-deoxyglucose transport are additive in skeletal muscle, whereas Kapur 
et a/. [265] suggest that the NO-donor, GEA5024, blunts insulin-stimulated glucose 
transport. It is of some importance that this ambiguity be resolved since there is 
evidence that altered sensitivity of the NO/cGMP signalling cascade contributes to 
skeletal muscle insulin resistance [266] and therefore may play a part in non-insulin- 
dependent diabetes mellitus [267].
NO interacts with the haem group bound to a soluble form of guanylate cyclase 
expressed in a variety of tissues [73]. This interaction catalyses the formation of the 
intracellular signal molecule cGMP from GTP by guanylate cyclase. The NO-donor
I
SNP causes a rise in both cGMP concentrations and 2-deoxyglucose transport in rat yi;skeletal muscle, increases that are diminished by the guanylate cyclase inhibitor LY- S
83583 [74]. However, the downstream intracellular target of cGMP in muscle cells that 
leads to increased glucose utilisation has not yet been identified. It is now recognised 
that cGMP targets in a variety of cell types include the Protein Kinase G family 
(PKG’s), the cGMP-stimulated/cGMP-inhibited phosphodiesterases and cGMP-gated 
cation channels [268]. Young et al. have demonstrated that Zaprinast, considered to be a 
selective inhibitor of cGMP-specific PDE’s [269], increases cGMP levels and glucose 
oxidation in incubated soleus muscle from rats [74].
The link between exercise and skeletal muscle Glut4 translocation is well 
established [262, 263]. Furthermore, the nitric oxide synthase inhibitor L-NAME 
inhibits both exercise-stimulated glucose transport in rats and Glut4 translocation [264].
This data therefore suggests that exercise-induced Glut4 translocation is mediated by 
NO. GFP-tagged Glut4 provides an attractive means by which to test this hypothesis. |
L6 is a skeletal muscle cell line that has been used to investigate the effects of insulin |
and serotonin [270,271]. L6 cells also provide a suitable method to study NO-signalling 
pathways in cultured muscle cells, without the added complication of diffusion of NO 
gas into cells of the muscle tissue vasculature, which can lead to difficulty in data 
interpretation. L6 cells have no detectable endogenous NOS activity in the resting state, 
but express inducible NOS (iNOS) upon exposure to cytokines and endotoxin [272]. i;y=;
Therefore, L6 myotubes can be used as a model to investigate the action of NO on 
glucose uptake in muscle cells.
In this study we used cultured L6 muscle cells to investigate the effect of NO-donors 
on both basal and insulin-stimulated 2-deoxyglucose transport. We hypothesised that ysi
the effects of NO-donors on glucose transport in L6 cells were mediated by cGMP and 
therefore, we measured cGMP levels in cells exposed to the NO-donor SNP. We also 
investigated whether manipulation of endogenous cGMP levels within the cell by 
inhibitors of soluble guanylate cyclase (ODQ) or cGMP-specific PDE’s (Zaprinast) 
could affect a change in 2-deoxyglucose uptake. Finally, we microinjected L6 myotubes 
with GFP-tagged Glut4 cDNA to examine the effect of NO and insulin on Giut4-GFP 
translocation. A clearly demonstrated link between NO, cGMP, Glut4-GFP 
translocation and glucose transport within muscle cells would present a range of targets 
for future therapeutic intervention and treatment of diabetes.
fl
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6.2.0 Materials and Methods
studies.
Î
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6.2.1 L6 cell culture
Monolayers of L6 muscle cells were grown to the stage of myotubes in a-minimum 
essential medium containing ribonucleosides, 2% foetal calf serum and 1%
antimicotic/antibiotic solution at 37° C in an atmosphere of 5% CO2 , 95% air. Muscle 
cells were grown in 6-well plates for transport measurements and cGMP concentration
6.2.2 2-Deoxyglucose uptake assay
All uptake assays were performed in triplicate on fully differentiated L6 myotubes
grown in 6-well tissue culture plates. Cells were assayed 5-10 days post confluency.
Following drug treatment, cells were washed once with 2 ml of Krebs Ringer Phosphate
.(KRP) buffer pH.7.4, then incubated for 20 minutes in radioactive 50 pM2-
deoxyglucose (14C 2-deoxyglucose 0.1 pCi/ml). Uptake was stopped by three washes 
.with ice cold phosphate buffered saline (PBS) pH, 7.4 and the plates left to air dry. 
Thereafter, cells were lysed by a 20 minute incubation in 1% Triton X-100 on an orbital 
shaker and the radioactivity associated with the cells detennined by scintillation 
counting. Non-carrier-mediated uptake was checked by incubation in the presence of 5 
pM-cytochalasin B and it amoimted to no more than ~1% of the total uptake.
.6.2.3.0 Cyclic GMP Assay
i
i6.2.3.1 Sample preparation
All cGMP assays were performed on fully differentiated L6 myotubes grown in 6-well 
tissue culture plates. Cells were assayed 5-10 days post confluency. Following the 
appropriate drug treatment cells were washed once in ice cold PBS and placed on ice. 
The PBS was then aspirated away and 1 ml of 12.5% acetic acid added to the first well 
on the 6-well plate. The cells in this well were then scraped in the 12.5% acetic acid and 
transferred into the second well and scraped again. This process was repeated until the 
cells in each of the wells were combined into 1ml of 12.5% acetic acid, which was then 
transferred into a 1.5 ml Eppendorf tube. Next, cells sonicated briefly to brake down 
cell membranes and the cell lysates centrifuged for 15 minutes at 4°C. The supernatant
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was then transferred to a fresh tube spun down over night in a ‘speed-vac’. The dried- 
out samples were then resuspended in 250 pi phosphate buffer
6.2.3.2 Cyclic GMP assay protocol
The cyclic GMP assay was then performed as described in the Cayman Chemical Cyclic 
GMP Enzyme Immunoassay Kit protocol. Briefly, the assay is based on the competition 
between the free cGMP in a particular sample and a cGMP tracer linked to an 
acetylcholinesterase molecule, for a limited number of anti-cGMP binding sites on a 
cGMP-specific rabbit antisermn. As the concentration of tracer cGMP is constant, the 
amount of cGMP tracer able to bind the specific antiserum is inversely proportional to 
the amount of free cGMP in a particular sample. This competition for binding sites 
occurs in the individual wells of a 96-well plate pre-coated with a mouse anti-rabbit 
monoclonal antibody. The plate is washed to remove any unbound reagents and then 
Ellman’s Reagent (which contains the substrate to acetylcholinesterase) is added to the 
well. The product of the enzymatic reaction catalysed by acetylcholinesterase absorbs at 
412 mn. Therefore, the intensity of this yellow colour determined 
spectrophotometrically is inversely proportional to the amount of free cGMP present in 
the well.
6.2.3.3 Acétylation o f cGMP samples
The cGMP enzyme immunoassay is able to detect lower concentrations of cGMP if the 
samples are first acetylated. In these cGMP assays all samples and standards were 
acetylated prior to performing the assay. To acetylate 150 pi of each sample, 30 pi of 4 
M KOH and 25 pi Acetic Anhydride were added in quick succession. The sample was 
then vortexed for 15 seconds, 7.5 pi 4 M KOH added and then vortexed again. This 
process was repeated for all samples and standards.
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6.2.3.4 Performing the assay
Each sample was assayed in duplicate at two dilutions (undiluted and a 1:10 dilution) 
Plate design
Partial Plate Format
1 2 3 4
* o # •B O # •c O # •D O # •
# # •
F # # •
G # # •
H # # •
Blank (B), no additions
O Non-Specific Binding (NSB); buffer and tracer only.Maximum Binding (B„); buffer, 
tracer and cGMP antiserum.
•  Standards 1-8 (S1-S8) 3 - 0.023 pmol/ml in buffer, tracer and cGMP antiserum.Total Activity (TA), tracer only
Sample in buffer, tracer and cGMP antiserum
Figure 6.1.1 Plate design for cGMP assay
Immediately prior to use the plate was rinsed once with wash buffer. The samples and 
reagents were then pipetted into the wells and incubated for 18 hours at room 
temperature. Next all wells were emptied and rinsed 5 times with wash buffer, before 
adding 200 pi Ellman’s Reagent to each well and 5 pi tracer to the total activity wells. 
The plate was then covered and developed in the dark for 90 minutes.
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6.2.3,5 Calculating the results
The results were calculated as follows on a Macintosh computer using SOFTmax®PRO
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software.
-Absorbance readings averaged from the NSB wells.
-Absorbance readings averaged from the Bo wells.
-NSB average subti'acted from the Bo average. This is the corrected Bq.
"%B/Bo calculated for the remaining wells, i.e. average NSB absorbance subtracted 
from the average SI absorbance and divided by the corrected Bo. The result is then 
multiplied by 100 to obtain %B/Bo. This is repeated for S2-S8 and all sample wells.
6.2.3.6 Standard curve 
%B/Bo for standards S1-S8 was plotted versus cGMP concentration (pmol/ml) on semi­
log paper (figure 6.1.2)
■6.2.3.7 Determination o f sample concentration
The concentration of each sample was found by identifying its %B/Bo on the standard 
curve and reading the corresponding cGMP concentration values on the x-axis.
6.2.4 L6 microinjection and confocal analysis 
L6 myotubes were grown on collagen-coated coverslips and microinjected with Glut4- 
GFP cDNA exactly as described in Chapter 2. Insulin- or NO-treated cells were than 
analysed by confocal microscopy, again as described in Chapter 2.
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Figure 6.1.2 cGMP assay standard curve
The standard curve was prepared as described in materials and methods, section 6.2.3.6
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6.3.0 Results
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6.3.1 Nitric Oxide donors stimulate 2-deoxyglucose uptake in L6 cells 
The nitric oxide donor sodium nitroprusside (SNP) was effective at stimulating uptake 
of the non-metabolisable glucose analogue 2-deoxyglucose into L6 myotubes. When 
added directly into the cell culture media for a period of 90 minutes, SNP at J
concentrations of 10 raM and above significantly increased 2-deoxyglucose uptake 
approximately 1.4 fold relative to basal (figure 6.2.1) in a time dependent mamier.
Similarly, SNP-stimulated 2-deoxyglucose uptake into L6 cells dose-dependently 
(figure 6.2.2). In response to both 1 and 10 mM SNP, 2-deoxyglucosse uptake was 
significantly elevated after a 90 minute incubation (figure 6.2.1). ' -4To ensure that the increase in 2-deoxyglucose uptake seen in L6 cells in response to 
SNP was not an effect peculiar to the NO-donor SNP, two further NO-donors were 
tested, S-Nitroso-N-acetyl-D, L-penicillamine (SNAP) and [1,2,3,4-Oxatriazolium, 5- 
amino-3-(3-chloro-2-methylphenyl)-,chloride] (GEA5024) (Figure 6.2.3). SNAP caused 
a significant increase in 2-deoxyglucose uptake in L6 cells at concentrations of 100 pM 
and above. However, GEA5024 did not enhance 2-deoxyglucose uptake into L6 cells 
and proved toxic to the cells at concentrations over 100 pM.
%
6.3.2 Effects o f NO-donors and insulin on 2-deoxyglucose uptake %
Next the effect of insulin in combination with NO upon 2-deoxyglucose uptake was 
examined. When insulin alone at concentrations of 100 nM or 1 pM was added to L6 
cells for 15 minutes, a 20-30 % increase in 2-deoxyglucose uptake was observed.
However, when 1 pM insulin was added in the last fifteen minutes of a 90 minute 
incubation with SNP, no additional increase in 2-deoxyglucose uptake was found 
(figure 6.3.1). Similarly, insulin had no further effect upon 2-deoxyglucose uptake when 
combined with 100 pM SNAP (figure 6.3.2). Conversely, the effect of 1 pM insulin 
upon transport levels in cells preincubated with GEA5024 was additive, and GEA5024 
at concentrations over 10 pM appeared to inhibit insulin-stimulated 2-deoxyglucose 
transport (figure 6.3.2). However, we propose that the inhibitory effect of GEA5024 on 
insulin stimulated transport is merely an artifact of GEA5024 toxicity at concentrations 
over 10 pM.
s
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6.3.3 Treatment with SNP causes cGMP levels to rise within the cell 
We hypothesised that the increase seen in 2-deoxyglucose uptake in response to NO- 
donors may be a cGMP-mediated effect. Therefore, we measured cGMP concentrations 
in L6 cells following a 90 minute incubation with 10 or 50 mM SNP or 1 pM insulin. 10 
inM SNP produced a small yet significant increase (approximately 1.5 fold above basal) 
in cGMP concentrations within the L6 cells, while 50 mM SNP gave a roughly 5 fold 
increase in cGMP levels (figure 6.4.1). As expected, insulin produced no change in 
cGMP levels within the cell, probably as insulin acts via PI3K to increase glucose 
transport. :S
5:6.3.4 77ze guanylate cyclase inhibitor ODQ inhibits the NO-induced increase in 2- 
deoxyglucose uptake and cGMP levels
To further test the hypothesis that NO-stimulated 2-deoxyglucose uptake in L6 cells is a 
cGMP-mediated effect we used the potent and specific guanylate cyclase inhibitor IH- 
[l,2,4]oxadiazolo[4,3,-a]quinoxaliii-l-one, (ODQ). L6 cells treated with 200 pM ODQ
:for 90 minutes showed a small decrease in intracellular cGMP levels, as did cells 
coincubated with 10 mM SNP and 200 pM ODQ relative to 10 mM SNP only (figure
6.5.1). We therefore assayed whether an ODQ-induced decrease in endogenous cGMP 
levels within the cell also mediated a decrease in the rate of 2-deoxyglucose uptake 
(figure 6.5.2). ODQ alone had no significant effect on basal 2-deoxyglucose transport, 
however at concentrations over 100 pM, ODQ caused a decrease in NO-stimulated 2- 
deoxyglucose uptake into L6 cells,
6.3.5 The phosphodiesterase inhibitor Zaprinast enhances the effects o f SNP 
Free cGMP within the cell is broken down by cGMP -specific phosphodiesterases 
(PDE’s), e.g. PDEV. Therefore, we treated L6 cells both in the presence and absence of 
10 mM SNP with Zaprinast, a PDEV-specific inhibitor, with the hypothesis that by 
manipulating endogenous cGMP levels within the cell at the PDE level we could alter 
the rate of 2-deoxyglucose uptake (Figure 6.6.1). At the concentrations tested, Zaprinast 
had no stimulatory effect upon 2-deoxyglucose uptake into L6 cells and appeared 
somewhat toxic at concentrations much over 50 pM. However, 50 pM Zaprinast further 
enhanced NO-stimulated 2-deoxyglucose uptake, approximately 2-fold above SNP only.
50 pM Zaprinast also caused a concomitant rise in cGMP levels within L6 cells (Figure
6.6.2). A 90 minute incubation with 50 pM Zaprinast or 10 mM SNP alone caused a 
small increase in cGMP levels, whereas 50 pM Zaprinast in combination with 10 mM 
SNP caused a much larger increase in cGMP levels within L6 cells.
6.3.6 cGMP analogues do not mimic the effects o f SNP on 2-deoxyglucose transport 
Although manipulation of endogenous cGMP levels within L6 cells appeared to affect 
2-deoxyglucose uptake levels, this effect was not replicated by incubation with 
exogenous cGMP analogues. Transport assays showed that following a 90 minute 
incubation with the cGMP analogue dibutyryl-cGMP (dbcGMP), no increase in 2- 
deoxyglucose transport was observed in L6 cells (Figure 6.7.1). Neither did the cGMP 
analogues 8-bromo-cGMP and 8-pCPT-cGMP cause any increase in 2-deoxyglucose 
transport (data not shown). However, the cAMP analogue dibutyryl-cAMP (dbcAMP) 
that was used as a control, consistently elevated 2-deoxyglucose uptake levels at 
concentiations of 100 pM and above (Figure 6.7.1). This suggests that the failure of db­
cGMP to induce any increase in 2-deoxyglucose uptake is not a consequence of cell 
impermeability to this analogue (see discussion).
6.3.7 Inhibition ofprotein kinase G does not block the effects o f SNP
We conjectured that any increase in endogenous intracellular cGMP levels that leads to 
a change in sugar transport levels may be mediated by protein kinase G (PKG). PKG is 
activated by cGMP and the cGMP analogue Rp-8-pCPT-cGMPS is known to be a 
specific inhibitor of PKG activity. Therefore, the ability of Rp-8-pCPT-cGMPS to 
inhibit NO-stimulated 2-deoxyglucose uptake was tested on L6 cells (Figure 6.8.1). Rp- 
8-pCPT-cGMPS failed to inhibit NO-stimulated 2-deoxyglucose transport at any of the 
concentrations tested. This result suggests that the increase in 2-deoxyglucose transport 
seen in cultured L6 cells is not mediated by PKG.
6.3.8 Insulin but not a NO-donor stimulates Glut4-GFP translocation in L6 cells
The effects of insulin and NO on Glut4 translocation were investigated using the GFP- 
Glut4 chimera (figure 6.9.1). L6 myotubes grown on glass coverslips were 
microinjected with GFP-Glut4 cDNA. The following day the injected cell were 
incubated in serum-free media for 2 hours, then treated with 1 pM insulin for 15 
minutes (figure 6.9. IB) or 100 pM SNAP for 90 minutes (figure 6.9.1C). Basal cells
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(figure 6.9.1 A) are shown for comparison. Stimulation with 1 pM insulin caused 
significant translocation of GFP-Glut4, indicated by increased GFP-associated 
fluorescence at the plasma membrane. However, microinjected L6 cells treated with the 
NO-donor SNAP showed no evidence of GFP-Glut4 translocation.
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Figure 6.2.1 SNP stimulates 2-deoxglucose uptake into L6 cells in a time-dependent manner
L6 myotubes were grown in 6-well plates until fully differentiated. Prior to the assay, cells were 
incubated in serum-ffee a-Medium for 2 hours and then treated with either 1 mM or 10 mM SNP 
diluted in serum-ffee media for the times indicated at 37°C and 5% COj. The 2-deoxyglucose 
transport assay was performed as described in materials and methods The graph shown is 
representative o f  a number o f  experiments. Results are expressed as mean values +/- standard errors 
o f the mean.
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Figure 6.2.2 2-deoxyglucose uptake inreases in L6 myotubes in réponse to inreasing 
doses of SNP
Prior to the assay, cells were incubated in serum-free a-medium for 2 hours and then treated 
with 10 mM SNP diluted in serum-free media for 90 miutes at 37°C and 5% CO; The 2- 
deoxyglucose transport assay was performed as described in materials and methods. The 
graph shown is representative o f  a number o f  experiments. Results are expressed as mean 
values +/- standard errors o f  the mean.
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Figure 6.2.3 2-deoxyglucose uptake in L6 myotubes increases in réponse to inreasing doses 
of the nitric oxide donor SNAP but not GEA5024
Prior to the assay, cells were incubated in serum-free a-medium for 2 hours and then treated with 
SNAP or GEA5024 diluted in serum-free media for 60 miutes at 37 °C and 5% CO; The 2- 
deoxyglucose transport assay was performed as described in materials and methods. The graph 
shown is representative o f  a number o f  experiments. Results are expressed as mean values +/- 
standard errors o f  the mean.
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Figure 6.3.1 The effects of insulin and SNP on 2-deoxyglucose uptake in L6 cells are not 
additive
Prior to the assay, cells were incubated in serum-free a-medium for 2 hours and then treated with 10 
mM SNP diluted in serum-free media for 90 miutes at 37®C and 5% CO; or insulin for 15 minutes. 
During the last 15 minutes o f  the SNP incubation 100 nM or 1 |iM insulin was added to the media 
The 2-deoxyglucose transport assay was performed as described in materials and methods. The graph 
shown is representative o f  a number o f  experiments. Results are expressed as mean values +/- 
standard errors o f  the mean
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Figure 6.3.2 EfTect of the NO-donors SNAP and GEA5024 on insulin-stimulated 2- 
deoxyglucose uptake
Prior to the assay, cells were incubated in serum-free a-medium for 2 hours and then treated for 90 
minutes with SNAP or GEA5024 diluted in serum-free media to the concentations indicated at 37®C 
and 5% CO;. During the last 15 minutes o f  the SNAP/GEA5024 incubation, I pM insulin was added 
to the media o f  the appropriate wells. The 2-deoxyglucose transport assay was performed as 
described in materials and methods. The graph shown is representative o f  a number o f  experiments. 
Results are expressed as mean values +/- standard errors o f  the mean.
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Figure 6.4.1 SNP but not insulin causes cGMP concentrations to rise in L6 cells
Effect o f  insulin or SNP on cGMP concentration in L6 cells. Prior to assay cells were serum starved in a- 
medium for 2 hours. Next, cells were treated with either insulin for 15 minutes or SNP for 90 minutes 
diluted to the appropriate concentration in a-medium at 37°C and 5% CO; The cGMPassay was then 
carried out exactly as described in the materials and methods. Results are presented in duplicate and the 
graph shown is typical o f  a number o f  like experiments.
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Figure 6.5.1 ODQ decreases the cGMP content of L6 cells
Effect o f  SNP and the guanylyl synthase inhibitor ODQ on cGMP concentration in L6 cells. Prior to assay 
cells were serum starved in a-medium for 2 hours. Next, cells were treated with either SNP, ODQ or SNP 
+ ODQ for 90 minutes diluted to the appropriate concentration in a-medium at 37°C and 5% CO; The 
cGMP assay was then carried out exactly as described in the materials and methods. Results are presented 
in duplicate and the graph shown is typical o f  a number o f  like experiments.
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Figure 6.5.2 The guanylyl cyclase inhibitor ODQ decreases NO-stimulated 2-deoxyglucose 
uptake in L6 cells
Prior to the assay, cells were incubated in serum-free a-medium for 2 hours. Then cells were treated 
with 10 mM SNP +/- ODQ or vehicle (DMSO) diluted in serum-free media for 90 miutes at 37®C 
and 5% CO2 The 2-deoxyglucose transport assay was performed as described in materials and 
methods. The graph shown is representative o f  a number o f  experiments. Results are expressed as 
mean values +/- standard errors o f  the mean.
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Figure 6.6.1 The PDE V inhibitor Zaprinast enhances SNP-stimulated 2-deoxyglucose uptake 
into L6 myotubes
Prior to the assay, cells were incubated in serum-free a-medium for 2 hours. Then cells were treated 
with 10 mM SNP +/- Zaprinast diluted in serum-free media for 90 miutes at 37°C and 5% COg. The 
2-deoxyglucose transport assay was performed as described in materials and methods The graph 
shown is representative o f  a number o f  experiments. Results are expressed as mean values +/- 
standard errors o f  the mean.
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Figure 6.6.2 SNP and the PDE V inhibitor Zaprinast bave an additive efTect on cGMP concentration 
in L6 cells
Prior to assay cells were serum starved in a-medium for 2 hours. Next, cells were treated with SNPor 
Zaprinast or SNP + Zaprinas for 90 minutes diluted to the appropriate concentration in a-medium at 37°C 
and 5% CO; The cGMPassay was then carried out exactly as described in the materials and methods 
Results are presented in duplicate and the graph shown is typical o f  a number o f  like experiments.
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Figure 6.7.1 The cyclic nucleotide analogue dbcAMP but not dbcGMP increases 2- 
deoxyglucose uptake in L6 cells
Prior to the assay, cells were incubated in serum-free a-medium for 2 hours. Then cells were treated 
with cAMP or cGMP diluted in serum-free media for 90 miutes at 37°C and 5% CO; The 2- 
deoxyglucose transport assay was performed as described in materials and methods. The graph 
shown is representative o f  a number o f  experiments. Results are expressed as mean values +/- 
standard errors o f  the mean.
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Figure 6.8.1 The PKG inhibitor Rp-8pCPT-cGMPs does not inhibit NO-stimulated 2- 
deoxyglucose uptake in L6 cells
2-deoxyglucose uptake in L6 myotubes in réponse to 50 mM SNP +/- the PKG inhibitor Rp-8pCPT- 
cGMPS. Prior to the assay, cells were incubated in serum-free a-medium for 2 hours Then cells 
were treated with 10 mM SNP +/- Rp-8pCPT-cGMPS diluted in serum-free media for 90 miutes at 
37°C and 5% CO] The 2-deoxyglucose transport assay was performed as described in materials and 
methods. The graph shown is representative o f  a number o f  experiments. Results are expressed as 
mean values +/- standard errors o f  the mean.
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Fi gure 6.9.1 Insul in but not  SNAP i nduces  GFP- Gl ut 4  t rans l oca t i on  in L6 cel l s
L6 cells were grown on collagen-coated coverslips and once fully differentiated injected with GFP-Glut4 cDNA 
as described in the materials and methods section of Chapter 3. The next day the injected cells were serum starved 
in DMEM for 2 hours and then treated with 1 pM insulin for 15 minutes (B), 100 pM SNAP for 90 minutes (C) or left 
untreated (A). The cells were then analysed by confocal microscopy, again as described in Chpater 3. Insulin was observed 
to c a u s e  an i n c r e a s e  in G F P - G l u t 4  l e v e l s  at the p l a s ms a  me mb r a n e ,  s e e  arr ows .
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6,4.0 Discussion
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Previous work has shown that NO-donors can stimulate glucose transport in 
skeletal muscle tissue [72, 74]. In the present studies we show that NO~donors cause a 
similar increase in glucose transport in cultured L6 myotubes (figures 6.2.1, 6.2.2, 6.2.3) 
and that this increase is concomitant with a rise in cGMP levels within the cell (Fig
6.4.1).
We found no additive effect on glucose transport using NO-donors, either SNP 
or SNAP, in combination with maximal doses of insulin (figures 6.3.1, 6.3.2). Similarly, 
Baton et a l [264] showed that in rat skeletal muscle, when using a maximal stimulating 
concentration of insulin, SNP has no additional effect on the stimulation of 2- 
deoxyglucose transport. Although L6 cells in our hands yielded only small increase in 
glucose transport, about 30%, in response to maximal doses of insulin, these values are 
in line with those found by other groups using the same cell type [73, 270]. The lack of 
any additive effect upon glucose transport between NO-donors and maximal doses of 
insulin may suggest that the downstream signalling cascades triggered by each stimuli 
utilise the same pool of glucose transporters, at least in this cell system.
In agreement with the work of Balon et a l [264] in skeletal muscle tissue but in 
contrast with results obtained by Kapur et al [265] in both skeletal muscle and L6 cells 
we found that NO-donors have no inhibitory effect on 2-deoxyglucose uptake in L6 
cells. However, we found that the NO-donor GEA5024 used in some experiments by 
Kapur et a l was toxic to L6 cells at concentrations of 50-100 pM. Therefore, we
I
Ïsuggest that the inhibitory effects of GEA5024 on insulin-stimulated glucose uptake are 
likely due to the toxic effects caused by this particular NO-donor.
We hypothesised that the messenger molecule cGMP affected the increase in 
glucose transport seen in response to NO-donors. Therefore, we investigated glucose 
transport rates and cGMP levels using inhibitors of soluble guanylate cyclase or cGMP- 
specific phosphodiesterases. ODQ is a potent and specific inhibitor of guanylate cyclase 
[273] and as such has been used in a number of studies to investigate the function of the 
cGMP pathway in NO signal transduction [274-276]. In Figures 6.5.1 and 6.5.2 we 
show that incubation of L6 cells with ODQ decreases cGMP levels within the cell and
■ ■ f
that this decrease in cGMP levels is reflected in a decreased rate of NO-stimulated 2- ■. ■ ■I 
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deoxyglucose transport. This result suggests that guanylate cyclase is involved in 
mediating the effect of NO-donors on L6 cells.
Using RT-PCR v^ e know that L6 myotubes express PDEV (results not shown). 
Zaprinast is a known inhibitor of cGMP-specific PDE’s [70, 269]. Therefore we tested 
the ability of Zaprinast to elevate endogenous cGMP levels within L6 cells and to alter 
glucose transport. We show that incubation of L6 cells with 50 pM Zaprinast increases 
the cGMP content of L6 cells in both the basal and NO-stimulated states (figure 6.6.2). 
Furthermore, 50 pM Zaprinast caused a significant increase in NO-stimulated glucose 
transport (figure 6.6.1). This evidence gives further weight to the hypothesis that cGMP 
levels and rates of glucose transport are intimately linked in L6 cells and is in agreement 
with work published by Young et al. in rat skeletal muscle [74].
Although protein kinase G (PKG) mediates many of the downstream effects of 
cGMP in other cell types [268, 277], it is also known that skeletal muscle expresses 
little if any PKG [71]. That PKG is not the mediator of cGMP-induced increases in 
glucose uptake in L6 muscle cells is supported by the finding that the specific PKG 
inhibitor Rp-8-pCPT-cGMPS [278] has no effect on NO-stimulated glucose uptake 
(figure 6.8.1). The cGMP analogue dbcGMP is a known activator of PKG, whereas 8- 
bromo-cGMP and 8-pCPT-cGMP are more potent activators of the enzyme than the 
native nucleotide [279]. Nevertheless, neither dbcGMP (figure 6.7.1), 8-bromo-cGMP 
nor 8-pCPT-cGMP (data not shown) caused any increase in 2-deoxyglucose uptake in 
L6 cells. However, the cyclic AMP analogue dbcAMP consistently stimulated glucose 
uptake in L6 cells (figure 6.7.1).
This paradox between the apparent abihty of endogenous cGMP and cAMP 
analogues, but not cGMP analogues, to cause an increase in glucose uptake may be 
explained in terms of the PDE’s expressed in L6 cells. PDE3, often referred to as the 
cGMP-inhibited PDE, is expressed in a number of tissues [70]. Inhibition of PDE3, 
which results in increased cAMP and activation of cAMP-dependent protein kinase 
[70], may mediate some of the biological effects of endogenous cGMP. For example, in 
rat thymocytes NO-donors increased cAMP, and thereby cell proliferation, at least in 
part by increasing cGMP which inhibits PDE3 [280]. Furthermore, Marcoz et al. 
showed that 8-bromo-cGMP had only weak inhibitory effects on PDE3.
We tested the hypothesis that NO can increase Glut4 translocation by 
microinjecting L6 myotubes with GFP-Glut4 cDNA and then incubating the cells with
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the NO donor SNAP. It is well established that insulin causes an increase in glucose
transport in L6 cells from our own studies and the work of others [270, 271]. Research
by Hajduch et a l suggests that this insulin-induced increase in glucose transport is at
least partly mediated by Glut4 [271]. This finding is supported by our own experiments
that show GFP-Glut4 translocation in L6 cells in response to insulin.
Exercise also induces Glut4 translocation in rat skeletal muscle [75, 262, 281].
In light of the proposed links between exercise, NO generation, and glucose uptake [72,
.75, 264], we may also expect that like insulin, NO induces Glut4 translocation. 
However, figure 6.9.1 shows no evidence of GFP-Glut4 translocation in L6 cells in 
response to treatment with 100 pM SNAP, a concentration shown to increase glucose 
transport (figure 6.2.3). GFP-Glut4 translocation was also absent in cells treated with 
200 pM SNAP (data not shown). The implication of this finding is that the increase in
glucose transport in response to the NO donor SNAP is not mediated by Glut4 and 
instead may be attributable to translocation by Glutl or GlutS, glucose transporters that 
are also expressed in L6 cells [271]. Induction of glucose transport and GFP-Glut4 
translocation by insulin is rapid, around 15 minutes. However, appreciable increases in 
glucose transport by NO-donors in both skeletal muscle and L6 cells are much slower, 
usually 60 minutes or more [74, 264]. This difference in time course of action between 
insulin and NO may reflect the utilisation of different glucose transporters in response 
to these two stimuli. For example, while insulin-stimulated glucose uptake is mediated 
by Glut4, Glutl or GlutS may mediate NO stimulated glucose uptake. Alternatively, the 
increase in glucose transport seen in L6 cells in response to NO may not be due to Glut 
translocation, but instead reflects an increase in the intrinsic transporter activity of Gluts 
already present at the plasma membrane. Such an increase in the intrinsic catalytic 
activity Glutl is proposed to mediate noradrenaline-induced glucose transport in brown 
adipocytes [82]. Regarding the results of Roberts et al, we suggest that signalling 
events upstream of NO generation must contribute to nitric oxide dependent exercise 
stimulated glucose transport and Glut4 translocation in rat skeletal muscle, since in our 
hands, NO alone is not sufficient to stimulate GFP-Glut4 translocation in L6 cells.
This study clearly demonstrates that by manipulation of the NO-signalling 
pathway it is possible to enhance glucose uptake into muscle cells. Furthermore, we 
show that this increase in glucose transport is mediated by cGMP. The mechanism by 
which NO and cGMP induce an increase in glucose transport in L6 cells requires further
investigation. Nevertheless, we propose that components of the NO-signalling pathway 
in skeletal muscle present potential targets for therapeutic intervention in the treatment 
of diabetes. The precise mechanism by which cGMP mediates an increase in glucose 
transport remains an important challenge for future studies.
,s
i
ia:-îâ;
I
I
I
:ïî|'
Î
162
s. ...
:7.0.0 Conclusion :à:
To date, the majority of research investigating Glut4 distribution and trafficking has 
used immunofluorescence or electron microscope-based techniques [96, 101, 193].
These strategies involve a fixation process prior to image analysis, and are therefore 
unsuitable methods for examining Glut4 trafficking in live cells in real time. To 
circumvent the shortcomings of conventional imaging methods we tagged Glut4 with .1
I
It
GFP. The native fluorescence of Glut4-GFP allowed us to monitor Glut4-GFP 
trafficking in real time by confocal microscopy when expressed in a variety of cell 
types.
When expressed in 3T3-L1 fibroblasts we found that Glut4-GFP exhibited an 
intracellular distribution principally within a distinct perinuclear compartment and 
discrete punctate vesicles throughout the cytoplasm (figure 3.2.2). Glut4-GFP displayed 
a very similar distribution when expressed in 3T3-L1 adipocytes (figure 4.1) and L6 
cells (figure 6.9.1), suggesting that the Glut4-GFP intracellular compartment is a feature 
of a variety of cell types [193]. In order to further characterise this compartment we 
compared the distribution of Glut4-GFP with established markers of the early 
endosomes (figures 3.3, 4.3) and late endosomes (lysotracker) (figure 4.3). We found 
that Glut4“GFP only partially overlaps with Texas Red Transferrin and displays very 
little colocalisation with Lysotracker in 3T3-L1 adipocytes, in good agreement with 
endosomal ablation studies [97, 98]. We also present evidence that the organisation of 
the Glut4-GFP-containing compartment is defined by elements of the cytoskeleton. 
Nocodazole, an inhibitor of microtubule formation, was found to disrupt the perinuclear 
distribution of Glut4-GFP when added to Glut4-GFP-expressing 3T3-L1 fibroblasts 
(figure 3.7) or adipocytes (figure 4.2)
Glut4 contains known targeting motifs with its N- and C-termini [198, 199, 231] tliat 
contribute to the intracellular localisation of Glut4. To further study these targeting 
motifs we made mutant Glut4-GFP constructs canying a mutation in the N-terminus 
tyrosine motif (FAG) and double mutation in the C-tenninus dileucine motif (LAG). In 
both 3T3-L1 fibroblasts and adipocytes, FAG-GFP accumulated at the plasma 
membrane and witliin an endosomal compartment as defined by TRT (figures 3.2.2, 
4.4.1, 3.5A, 4.5A) LAG-GFP also accumulated at the plasma membrane when 
expressed at high levels (figures 3.2.2, 4.4.1). In addition, LAG-GFP accumulated 
witliin an enlarged perinuclear compartment, distinct from the TRT endosomal marker
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(figures 3.5B,4.5B). Again these results are in good agreement with ablation analysis of 
FAG and LAG Glut4 mutants [219]. Together, these data suggest that the phenylalanine 
5 residue is required for the efficient intracellular sequestration of Glut4 and targeting to 
a non-endosomal cellular compartment. Conversely, the Glut4 C-tenninus dileucine 
motif may play a role in sorting Glut4 from a post-Golgi compartment into the recycling 
endosomes.
Multi-planar confocal analysis allows us to construct 3-dimensional representations of
Glut4-GFP expressing cells in computer memory (see accompanying CD-ROM). Using
this technique we examined the 3-D distribution of Glut4-GFP in a living adipocyte (z-
section). These 3-D reconstructions give a more detailed picture of the Glut4-GFP
containing compartments in relation to the other cellular compartments. In addition, we
used time lapse confocal microscopy to investigate Glut4-GFP trafficking in basal 3T3-
L1 fibroblasts and adipocytes (see accompanying CD-ROM). These time-lapse movies
give us a new appreciation of the dynamics of Glut4-GFP movement in the context of
.the cell. Interactions between Glut4-GFP-containing vesicles, structural elements of the 
cell and other vesicles are clearly visible (movie).
From the outset we fully intended to make time-lapse movies of Glut4-GFP 
translocation in real time. However, we were unsuccessful in our attempts to induce 
Glut4“GFP translocation on the confocal microscope stage. This failure may be due to 
inappropriate buffer conditions or poor temperature management. Alternatively, 
elements within the translocation machinery may be sensitive to ultra-violet or laser 
light illumination, thus rendering Glut4-GFP translocation impossible. Nevertheless, 
Glut4-GFP expressed in 3T3-L1 adipocytes or L6 cells did translocate to the plasma 
membrane when placed in a CO2 incubator following insulin addition to the media 
(figure 4.1). This suggests that Glut4-GFP is distributed to the correct insulin-sensitive 
compartment and is a functional protein in the context of translocation. Therefore, our 
inability to promote real time translocation of Glut4-GFF is more likely due to technical 
limitations within our system rather than the GFP tag disrupting the translocation 
machinery.
Although the exocytotic arm of Glut4-GFP translocation appears nonnal in our 
system, perhaps the most significant finding of this study is the observation that Glut4- 
GFP endocytosis following insulin stimulation is defective. Endogenous Glut4 is known 
to recycle in both the basal and insulin-stimulated states [26, 29, 86]. Glut4-GFP also 
appears to recycle normally in the basal state as evidenced by the basal time lapse
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:movies (CD-ROM) and Glut4-GFP accumulation at the plasma membrane when 
incubated in K"*" depleted media (figure 4.9) [132]. However, subsequent to insulin |
withdrawl, Glut4-GFP is not effectively endocytosed (figure 4.8), suggesting that the 
GFP tag may interfere with a unique rapid reinternalisation mechanism following 
insulin-induced Glut4 translocation. This hypothesis makes physiological sense since it 
would be undesirable to continue to have a large number of Glut4 glucose transporters 
at the plasma membrane in the absence of insulin, as such a situation would lead to 
hypoglycaemia.
We also briefly examined Glut4-GFP translocation in L6 cells in the context of nitric 
oxide (NO) signalling. Using inhibitors of the NO signalling pathway we established 
that the increase in glucose uptake seen in L6 muscle cells in response to NO-donors is 
likely mediated by gaunylyl cyclase and cGMP (figures 6.4.1, 6.5.1, 6.5.2). Although 
unable to identify the downstream target of cGMP in the NO signalling pathway, it is
■unlikely protein kinase G plays a role in NO-induced glucose uptake (figure 6.8.1).Although Glut4-GFP moved to the plasma membrane in L6 cells in response to insulin, 
we were unable to replicate Glut4-GFP translocation using a NO donor. This î
observation suggests that NO-induced glucose uptake is mediated by a glucose I
transporter isoform other than Glut4 in L6 cells. Whereas insulin-induced glucose 
uptake is rapid [151], reflecting Glut4 translocation, appreciable NO- donor-induced 
glucose uptake occurs more slowly (figure 6.2.1) [74, 264]. This further suggests that a 
glucose transporter other than Glut4 mediates NO donor-induced glucose transport in 
L6 cells.
Given more time we would address the question of the glucose transporter isoform 
that mediates NO-induced glucose uptake in L6 cells firstly by using a Glutl-GFP I
chimera. The downstream target of cGMP in the NO signalling pathway may be a 
phosphodiesterase. Therefore a more detailed analysis of the phosphodiesterase a-isoforms expressed in L6 cells is also desirable. NO-donors yield a pronounced increase ,ï;in glucose uptake in muscle cells (figure 6.2.2) and tissue [74]. Therefore it is of some "S'importance that the components of the NO-signalling pathway are resolved. This |
knowledge would enable the screening of small molecule inliibitors that could mimic 
the effects of NO donors on glucose uptake and would therefore hold potential as anti- 
diabetic agents.
Recent evidence suggests that ARF proteins play a crucial role in insulin-stimulated 
Glut4 translocation [56]. In Chapter 5 we describe the molecular biological steps
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performed to create ARF5 and ARF6 XTPases. By mutating the ARF GTPase we hope
to change the nucleotide specificity of ARF5 and ARF6 from GTP to XTP. Such a
mutation would allow us to inliibit and then rescue ARF5 or ARF6 fimction by the
addition of XTP to penneabilised cells, thus establishing the contribution of ARF5 and
ARF6 to insulin stimulated Glut4 translocation. Now that the ARF5XTPase cDNA 
.constructs is made, efforts are continuing within our laboratory to confirm its 
nucleotide-binding characteristics. Once the ARFXTPases are fully characterised their 
contribution to Glut4 trafficking will be analysed by establishing stable 3T3-L1 cell 
lines that overexpress ARFXTPase, or by ARFXTPase/Glut4-GFP cDNA coinjection 
into adipocytes, or by the addition of ARFXTPase protein directly to penneabilised 
cells.
In the final analysis, our inability to promote Glut4-GFP translocation in real time on 
the microscope stage was a disappointment. Furthermore, the labour intensive process 
of nuclear microinjection required to express the Glut4-GFP constructs in 3T3-L1 cells 
limited both the power of the system and our ability to perfonn a comprehensive 
biochemical analysis. Nevertheless, our studies with wild-type and mutant Glut4-GFP 
chimeras gave us a greater understanding of the intracellular Glut4 compartment in the 
basal state. The problems associated with the real time translocation of Glut4-GFP are 
most likely technical in nature. Perhaps a confocal microscope with more powerful 
optics, thus allovGng us to decrease the intensity of the laser, would prove more 
amenable to the delicate translocation process. Even so, we have highlighted an 
inconsistency in Glut4-GFP trafficking as evidence for a novel Glut4 reinternalisation 
mechanism following insulin-induced tianslocation. Therefore a question remains over 
the continued use of Green Fluorescent Protein as an entirely valid method to study 
Glut4 trafficking.
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